---
document_datetime: 2025-11-27 08:57:03
document_pages: 96
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/cejemly-vr-0000261157-epar-assessment-report_en.pdf
document_name: cejemly-vr-0000261157-epar-assessment-report_en.pdf
version: success
processing_time: 169.355064
conversion_datetime: 2025-12-27 17:12:31.278332
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

EMADOC-1700519818-2465582 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Cejemly

International non-proprietary name: Sugemalimab

Procedure No. EMA/VR/0000261157

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| Background information on the procedure ..............................................6                                                                                                         |                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| 1.1. Type II variation............................................................................................6                                                                             |                                                                                                    |
| 1.2. Steps taken for the assessment of the product...................................................6                                                                                          |                                                                                                    |
| 2. Scientific discussion                                                                                                                                                                        | ............................................................................7                      |
| 2.1. Introduction..................................................................................................7                                                                            |                                                                                                    |
| 2.1.1. Problem statement......................................................................................7                                                                                 |                                                                                                    |
| 2.1.2. About the product                                                                                                                                                                        | .......................................................................................8           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                                                                                       | advice...8                                                                                         |
| 2.1.4. General comments on compliance with GCP....................................................8                                                                                             |                                                                                                    |
| 2.2. Non-clinical aspects........................................................................................8                                                                              |                                                                                                    |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                                                                                                | .....................................................8                                             |
| 2.2.2. Conclusion on the non-clinical aspects............................................................8                                                                                      |                                                                                                    |
| 2.3. Clinical aspects..............................................................................................9                                                                            |                                                                                                    |
| 2.3.1. Introduction                                                                                                                                                                             | ...............................................................................................9   |
| 2.3.2. Pharmacokinetics ......................................................................................                                                                                  | 10                                                                                                 |
| 2.3.3. Pharmacodynamics ...................................................................................                                                                                     | 16                                                                                                 |
| 2.3.4. PK/PD modelling .......................................................................................                                                                                  | 17                                                                                                 |
| 2.3.5. Discussion on clinical pharmacology.............................................................                                                                                         | 19                                                                                                 |
| 2.3.6. Conclusions on clinical pharmacology...........................................................                                                                                          | 20                                                                                                 |
| 2.4. Clinical efficacy............................................................................................                                                                              | 20                                                                                                 |
| 2.4.1. Main study(ies).........................................................................................                                                                                 | 20                                                                                                 |
| 2.4.2. Discussion on clinical efficacy......................................................................                                                                                    | 54                                                                                                 |
| 2.4.3. Conclusions on the clinical efficacy...............................................................                                                                                      | 58                                                                                                 |
| 2.5. Clinical safety..............................................................................................                                                                              | 58                                                                                                 |
| 2.5.1. Discussion on clinical safety........................................................................                                                                                    | 85                                                                                                 |
| 2.5.2. Conclusions on clinical safety ......................................................................                                                                                    | 88                                                                                                 |
| 2.5.3. PSUR cycle...............................................................................................                                                                                | 88                                                                                                 |
| 2.6. Risk management plan .................................................................................                                                                                     | 89                                                                                                 |
| 2.7. Update of the Product information.................................................................. ...................................................................................... | 90                                                                                                 |
| 2.7.1. User consultation                                                                                                                                                                        | 90                                                                                                 |
| 3. Benefit-Risk Balance                                                                                                                                                                         | .........................................................................90                        |
| 3.1. Therapeutic Context.....................................................................................                                                                                   | 90                                                                                                 |
| 3.1.1. Disease or condition ..................................................................................                                                                                  | 90                                                                                                 |
| 3.1.2. Available therapies and unmet medical need.................................................                                                                                              | 90                                                                                                 |
| 3.1.3. Main clinical studies...................................................................................                                                                                 | 91                                                                                                 |
| 3.2. Favourable effects........................................................................................                                                                                 | 91                                                                                                 |
| 3.3. Uncertainties and limitations about favourable effects                                                                                                                                     | ....................................... 91                                                         |
| 3.4. Unfavourable effects                                                                                                                                                                       | .................................................................................... 91            |
| 3.5. Uncertainties and limitations about unfavourable effects....................................                                                                                               | 92                                                                                                 |
| 3.6. Effects Table                                                                                                                                                                              | ............................................................................................... 93 |
| 3.7. Benefit-risk assessment and discussion...........................................................                                                                                          | 94                                                                                                 |
| 3.7.1. Importance of favourable and unfavourable effects                                                                                                                                        | ........................................ 94                                                        |
| 3.7.2. Balance of benefits and risks                                                                                                                                                            | ...................................................................... 94                          |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

3.8. Conclusions  ................................................................................................. 94

## 4. Recommendations .............................................................................  95

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                             |
|----------------|------------------------------------------------------------------------|
| ADA            | antidrug antibody                                                      |
| ADR            | adverse drug reaction                                                  |
| AE             | adverse event                                                          |
| AESI           | adverse event of special interest                                      |
| ALK            | anaplastic lymphoma kinase                                             |
| ALT            | alanine aminotransferase                                               |
| AST            | aspartate aminotransferase                                             |
| AUC            | area under the serum concentration-time curve                          |
| AUC 0- ∞       | area under the serum concentration-time curve extrapolated to infinity |
| BICR           | blinded independent central review                                     |
| CHO            | Chinese hamster ovary                                                  |
| CL             | clearance                                                              |
| C max (CV)     | maximum serum concentration                                            |
| C trough       | trough serum concentration                                             |
| C trough,C1    | trough serum concentration in Cycle 1                                  |
| CSCO           | Chinese Society of Clinical Oncology                                   |
| CSR            | clinical study report                                                  |
| CR             | complete response                                                      |
| CTCAE          | Common Terminology Criteria for Adverse Events                         |
| DCO            | data cutoff                                                            |
| DCO1           | data cutoff 1 = 08 Mar 2021                                            |
| DCO2           | data cutoff 2 = 01 Mar 2022                                            |
| DCO3           | data cut off 3 = 03 Apr 2023                                           |
| DoR            | duration of response                                                   |
| ECIS           | European Cancer Information System                                     |
| ECOG           | Eastern Cooperative Oncology Group                                     |
| EGFR           | epidermal growth factor receptor                                       |
| EMA            | European Medicines Agency                                              |
| ENKTL          | extranodal natural killer/T-cell lymphoma                              |
| E-R            | exposure/response                                                      |
| ESCC           | oesophageal squamous cell carcinoma                                    |
| ESMO           | European Society for Medical Oncology                                  |
| EU             | European Union                                                         |
| FDA            | Food and Drug Administration                                           |
| GEJ            | gastro-oesophageal junction                                            |
| GC             | gastric adenocarcinoma                                                 |
| GMR            | geometric mean ratios                                                  |
| HCC            | hepatocellular carcinoma                                               |
| HR             | hazard ratio                                                           |
| IFN- γ         | interferon- γ                                                          |
| IgG4           | immunoglobulin G4                                                      |
| IL             | interleukin                                                            |
| irAE           | immune-related adverse event                                           |
| ITT            | intention-to-treat                                                     |
| IV             | intravenous                                                            |
| IxRS           | interactive voice response system/interactive web response system      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                                       |
|----------------|------------------------------------------------------------------|
| MAA            | Marketing Authorisation Application                              |
| mAb            | monoclonal antibody                                              |
| MedDRA         | Medical Dictionary for Regulatory Activities                     |
| MHRA           | Medicines and Healthcare Products Regulatory Agency              |
| MTD            | maximum tolerated dose                                           |
| NAb            | neutralizing antibodies                                          |
| NCCN           | National Comprehensive Cancer Network                            |
| NCI            | (U.S.) National Cancer Institute                                 |
| NDA            | New Drug Application                                             |
| NE             | Not estimable or not evaluable                                   |
| NICE           | National Institute for Health and Care Excellence                |
| NMPA           | National Medical Products Administration                         |
| NSCLC          | non-small cell lung cancer                                       |
| ORR            | overall response rate                                            |
| OS             | overall survival                                                 |
| PD             | progressive disease                                              |
| PD-1           | programmed cell death-1                                          |
| PD-L1          | programmed cell death-ligand-1                                   |
| PFS            | progression-free survival                                        |
| PK             | pharmacokinetic(s)                                               |
| PopPK          | population pharmacokinetics                                      |
| PR             | partial response                                                 |
| PS             | performance status                                               |
| PT             | preferred term                                                   |
| Q3W            | once every 3 weeks                                               |
| RECIST         | response evaluation criteria in solid tumours                    |
| RET            | rearranged during transfection                                   |
| ROS1           | ROS proto-oncogene 1, receptor tyrosine kinase                   |
| RP2D           | recommended Phase 2 dose                                         |
| R/R cHL        | relapsed or refractory classical Hodgkin lymphoma                |
| R/R ENKTL      | relapsed or refractory extranodal natural killer/T-cell lymphoma |
| SAE            | serious adverse event                                            |
| SAP            | Statistical Analysis Plan                                        |
| SCS            | Summary of Clinical Safety                                       |
| SD             | standard deviation                                               |
| SOC            | standard of care                                                 |
| SOC            | system organ class                                               |
| TEAE           | treatment-emergent adverse event                                 |
| UK             | United Kingdom                                                   |
| US             | United States                                                    |
| V ss           | volume of distribution of sugemalimab at steady-state            |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Cstone Pharmaceuticals Ireland limited submitted to the European Medicines Agency on 13/03/2025 an application for a variations.

The following variation was requested:

| Variation(s) requested   | Variation(s) requested                                                              | Type              |
|--------------------------|-------------------------------------------------------------------------------------|-------------------|
| C.I.6.a                  | C.I.6.a Addition of a new therapeutic indication or modification of an approved one | Variation type II |

Extension of indication to include the treatment of unresectable stage III non -small -cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy for CEJEMLY, based on final results from study CS1001-301; this is a Phase III, multicentre, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of sugemalimab as consolidation therapy versus placebo in participants with locally advanced or unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0194/2022 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and PRAC Rapporteur appointed by the CHMP were:

Rapporteur:

Filip Josephson

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                | Actual dates      |
|------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                          | 13 March 2025     |
| Start of procedure:                                                                      | 26 April 2025     |
| CHMP Rapporteur's preliminary assessment report circulated on:                           | 20 June 2025      |
| PRAC Rapporteur's preliminary assessment report circulated on:                           | 26 June 2025      |
| PRAC outcome                                                                             | 10 July 2025      |
| Joint Rapporteur's updated assessment report circulated on:                              | 17 July 2025      |
| Request for supplementary information and extension of timetable adopted by the CHMP on: | 24 July 2025      |
| MAH's responses submitted to the CHMP on:                                                | 14 August 2025    |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on:    | 16 September 2025 |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on:    | 17 September 2025 |
| Joint Rapporteur's updated assessment report on the MAH's responses circulated on:       | 9 October 2025    |
| CHMP opinion:                                                                            | 16 October 2025   |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

## State the claimed therapeutic indication

The claimed therapeutic indication is: 'Cejemly as monotherapy is indicated for the treatment of unresectable stage III NSCLC with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.

## Epidemiology

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death across the globe. About 30% of patients diagnosed with NSCLC present with tumour stages IIIA to IIIC, the majority of which are unresectable. Across the EU-27, lung cancer is the leading cause of death among all cancers for men (22.9%) and the second-leading cause for women (15.3%) behind breast cancer (16.7%) with an estimated about 253,000 deaths in 2022.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Management

Platinum-based chemotherapy concurrent with radiotherapy is standard of care for patients with unresectable stage III NSCLC. If concurrent chemoradiotherapy is not possible for any reason, sequential approaches of induction chemotherapy followed by definitive radiotherapy represent a valid and effective alternative. In this treatment niche, durvalumab is approved as maintenance for patients whose disease did not progress after chemoradiotherapy and whose tumours express PDL1 on ≥ 1% of tumour cells. Moreover, for patients expressing relevant EGFR driver mutations, osimertinib is approved.

## 2.1.2. About the product

Sugemalimab is a fully human immunoglobulin G4 monoclonal antibody. It specifically binds to programmed cell death ligand 1 (PD-L1), thus blocking its ligation with PD-1. PD-L1, when expressed on tumour cells and tumour-infiltrating immune cells, can contribute to the inhibition of an anti-tumour immune response. Binding of PD-L1 to the PD-1 and CD80 (B7.1) receptors found on T-cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses without inducing antibody dependent cell-mediated cytotoxicity (ADCC).

Currently approved indication:

'Cejemly in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small -cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations.'

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The applicant did not seek Scientific advice from the CHMP.

## 2.1.4. General comments on compliance with GCP

The applicant claims that Study CS1001-301 was performed according to GCP.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application.

## 2.2.1. Ecotoxicity/environmental risk assessment

Sugemalimab is a natural substance (monoclonal antibody), the use of which will not alter the concentration or distribution of the substance in the environment. As a result no Phase I environmental risk assessment is necessary according to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00). Sugemalimab is not expected to pose a risk to the environment.

## 2.2.2. Conclusion on the non-clinical aspects

No new non-clinical data have been submitted in this application, which is acceptable.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

## Table 1: Listing of All Clinical Studies

| Phase/Stu dy Identifier; Country(ie s)                                                            | Objective( s) of the Study (Key Endpoints )                                                       | Study Design and Type of Control                                                                  | Diagnosis of Participant s                                                                                      | No. of Participa nts per Cohort                                                                   | Test Product(s); Dosage Regimen; Route of Administration                                                                                                 | Duratio n of Treatme nt per Protocol a                                                            | Study Status b ; Type of Report; DCO/LPLV                                                         |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports               | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports                                                        | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports | Reports of Human Pharmacokinetic (PK) Studies - Patient PK and Initial Tolerability Study Reports |
| Phase 1; CS1001-101 1a; NCT033128 42; China                                                       | Safety and tolerability, MTD, and RP2D                                                            | Open-label, dose- exploration, not controlled                                                     | Participants with metastatic or locally advanced unresectabl e solid tumours or lymphoma with at least 1 lesion | Sugemali mab: 29                                                                                  | Sugemalimab; 3, 10, 20, and 40 mg/kg or 1200 mg single dose every 3 weeks; IV                                                                            | Up to 2 years                                                                                     | Completed; Full CSR; LPLV: 30 Nov 2018                                                            |
| Phase 1; CS1001-101 1b; NCT033128 42; China                                                       | Preliminary efficacy (ORR, DCR, DoR, PFS, OS, and Epstein- Barr virus DNA levels)                 | Open-label, dose- expansion, not controlled                                                       | Participants with metastatic or locally advanced unresectabl e solid tumours or NKTL                            | Sugemali mab: 217 c                                                                               | Sugemalimab as a monotherapy or in combination with chemotherapy drugs, radiation therapy, or targeted therapy; 1200 mg single dose every 3 weeks d ; IV | Up to 2 years                                                                                     | Ongoing; Full CSR; DCO: 16 Aug 2021                                                               |
| Phase 1; CS1001- 102; NCT037444 03; US                                                            | Safety, tolerability, and RP2D                                                                    | Open-label, dose- escalation, not controlled                                                      | Participants with metastatic or locally advanced unresectabl e solid tumours                                    | Sugemali mab: 24                                                                                  | Sugemalimab; 10 mg/kg or 1200 mg single dose every 3 weeks; IV                                                                                           | Up to 2 years                                                                                     | Completed; Full CSR; LPLV: 19 Oct 2020                                                            |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

| the Claimed Indication                                       | the Claimed Indication                                       | the Claimed Indication                                       | the Claimed Indication                                              | the Claimed Indication                                       | the Claimed Indication                                                                             | the Claimed Indication                                       | the Claimed Indication                                       |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Phase 3; CS1001-302; NCT0378960 4; China                     | Efficacy (PFS and OS)                                        | Randomised, double-blind, placebo- controlled                | Participants with metastatic (Stage IV) NSCLC                       | Sugemalim ab: 320 Placebo: 159                               | Sugemalimab in combination with platinum-based chemotherapy; 1200 mg single dose every 3 weeks; IV | Up to 2 years                                                | Ongoing; Full CSR; DCO: 22 Nov 2021                          |
| Phase 3; CS1001-301; NCT0372855 6; China                     | Efficacy (PFS, OS)                                           | Randomised, double-blind, placebo- controlled                | Participants with locally advanced unresectabl e Stage III NSCLC    | Sugemalim ab: 255 Placebo: 126                               | Sugemalimab as a consolidation therapy; 1200 mg single dose every 3 weeks; IV                      | Up to 2 years                                                | Completed; Full CSR; LPLV: 03 Apr 2023                       |
| Reports of Efficacy and Safety Studies - Other Study Reports | Reports of Efficacy and Safety Studies - Other Study Reports | Reports of Efficacy and Safety Studies - Other Study Reports | Reports of Efficacy and Safety Studies - Other Study Reports        | Reports of Efficacy and Safety Studies - Other Study Reports | Reports of Efficacy and Safety Studies - Other Study Reports                                       | Reports of Efficacy and Safety Studies - Other Study Reports | Reports of Efficacy and Safety Studies - Other Study Reports |
| Phase 2; CS1001-201; NCT0359565 7; China, US e               | Efficacy (ORR)                                               | Open-label, not controlled                                   | Participants with relapsed or refractory extranodal NKTL            | Sugemalim ab: 80                                             | Sugemalimab; 1200 mg single dose every 3 weeks; IV                                                 | Up to 2 years                                                | Ongoing; Full CSR; DCO: 10 Nov 2021                          |
| Phase 2; CS1001-202; NCT0350599 6; China                     | Efficacy (ORR)                                               | Open-label, not controlled                                   | Participants with relapsed or refractory classical Hodgkin lymphoma | Sugemalim ab: 81                                             | Sugemalimab; 1200 mg single dose every 3 weeks; IV                                                 | Up to 2 years                                                | Ongoing; Full CSR; DCO: 19 Feb 2020                          |
| Phase 3; CS1001-301; NCT0372855 6; China                     | Efficacy (PFS, OS)                                           | Randomised, double-blind, placebo- controlled                | Participants with locally advanced unresectabl e Stage III NSCLC    | Sugemalim ab: 255 Placebo: 126                               | Sugemalimab as a consolidation therapy; 1200 mg single dose every 3 weeks; IV                      | Up to 2 years                                                | Ongoing; Full CSR; DCO: 08 Mar 2021                          |

a  Participants who had completed 2 years of study treatment, after consultation with the Investigator and the Sponsor, may have continued treatment until the participant experienced an intolerable adverse reaction, progressive disease, withdrawal of ICF, lost to follow-up, death, or study termination, whichever occurred first.

b  As of the data cutoff date for each included study.

c  There were 217 participants enrolled into Cohort 1 to Cohort 9 and Cohort 11. No participant was enrolled into Cohort 10. The data for Cohort 12 and Cohort 13 were not included in the CSR.

d  Data from Cohort 12 (1800 mg every 4 weeks) were not included in the CSR.

e  No US participants were enrolled.

CS1001 = sugemalimab; CSR = clinical study report; DCO = data cutoff date (for ongoing studies); DCR = disease control rate; DNA = deoxyribonucleic acid; DoR = duration of response; ICF=informed consent form; IV = intravenous; LPLV = last participant last visit (for completed studies); MTD = maximum tolerated dose; NKTL = natural killer/T-cell lymphoma; No. = number; NSCLC = nonsmall cell lung cancer; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PK=pharmacokinetic(s); RP2D = recommended Phase 2 dose; US = United States.

## 2.3.2. Pharmacokinetics

## Bioanalytical methods

Human serum samples were analyzed for sugemalimab concentrations using a fully validated specific enzyme-linked immunosorbent assay (ELISA) (Analysis method No. 17BASM127) by WuXi AppTec (Shanghai) Co., Ltd.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Human serum samples were analyzed for anti-sugemalimab antibodies (ADA) using a fully validated electrochemiluminescence (ECL) three-step method (Method No.: 19BASM036) by WuXi AppTec (Shang hai) Co., Ltd.

Human serum samples were analyzed for anti-sugemalimab neutralizing antibodies using a fully validated ECL method (Method No.: ICSH 19-118) by Labcorp Pharmaceutical Research and Development (Shanghai) Co., Ltd.

## Distribution

The empirical Bayes estimates of pharmacokinetic parameters in Stage III NSCLC patients (CS1001-301) showed that the geometric mean (inter subject CV%) for the volume of distribution at steady state (Vss) was 4.74 L (20%).

## Elimination

The empirical Bayes estimates of pharmacokinetic parameters in Stage III NSCLC patients (CS1001-301) showed that the geometric mean (inter subject CV%) for the total clearance (CL) at the end of Cycle 1 was 0.214 L/day (23.8%), and the elimination half-life (t 1/2) was 16.6 days (20.8%).

## Target population

A PopPK analysis was provided to describe PK in the target population and for performing PK simulations to support the proposed posology. An updated population pharmacokinetic model including patients in the target population (Stage III NSCLC patients) was submitted, compared to the original PopPK model in the initial submission (EMEA/H/C/006088/0000).

As of Apr 3, 2023, a total of 255 participants had received sugemalimab 1200 mg IV Q3W in study CS1001-301. After multiple doses of sugemalimab at 1200 mg IV Q3W, the geometric mean Ctrough,C4 and Cmax ,C4 were 130.5 and 546.7 μg/mL, respectively .

Comparisons of the observed Ctrough and Cmax at Cycle 1 between Stage III patients (Study CS1001301) and Stage IV patients (Study CS1001-301) is included in Figure 1.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 1: Box plot of Ctrough,c1 and Cmax,c1 for Studies 301 and 302.

<!-- image -->

Study

Study

The solid horizontal lines and box heights represent the median, and 25th to 75th percentiles, respectively. The circles are single observed values. Number in each box specifies the number of patients per group.

The baseline demographics/covariates that were identified in the final PopPK model were weight, albumin and sex. The median albumin levels at baseline were comparable between Stage III and IV patients in Phase 3 treated with sugemalimab (Stage III: 42.7 g/L; Stage IV: 40.9 g/L). The median body weights at baseline were comparable between Stage III and IV patients in Phase 3 treated with sugemalimab (Stage III: 62.0 kg, Stage IV: 61.0 kg). The proportions of males/females were comparable between Stage III and IV patients in Phase 3 treated with sugemalimab (Stage III: 92.5% male patients; Stage IV: 79.4% male patients).

## PopPK model

The updated sugemalimab PopPK structural model was a two-compartment model with a timedependent component of clearance (Table 2). The PopPK model identified body weight, sex, albumin, time-varying ADA titre, and disease status as statistically significant covariates; however, the magnitude of these covariate effects on predicted steady-state sugemalimab exposure metrics were generally &lt; 20% and not considered clinically meaningful. Stage III and Stage IV NSCLC disease stage was included as covariates on CL0 and Vc as a sensitivity analysis despite the limited magnitude of these covariate effects (&lt;20%).

Table 2: Parameter estimates of the Updated PopPK model

|                          | Updated Model OFV=61797   | Updated Model OFV=61797   |
|--------------------------|---------------------------|---------------------------|
| Parameter                | Estimates                 | 95% CI                    |
| CL0 (L/day)              | 0.146                     | [0.141, 0.152]            |
| Effect of Sex on CL0     | 0.902                     | [0.861, 0.943]            |
| Effect of Weight on CL0  | 0.741                     | [0.637, 0.845]            |
| Effect of Albumin on CL0 | -0.852                    | [-1.01, -0.697]           |
| Effect of NSCLC3 on CL0  | 1.02                      | [0.964, 1.08]             |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                                   | Updated Model OFV=61797   | Updated Model OFV=61797   |
|---------------------------------------------------|---------------------------|---------------------------|
| Parameter                                         | Estimates                 | 95% CI                    |
| Effect of NSCLC4 on CL0                           | 1.05                      | [1, 1.1]                  |
| CLT (L/day)                                       | 0.109                     | [0.101, 0.117]            |
| Effect of Sex on CLT                              | 0.722                     | [0.642, 0.803]            |
| Effect of Time-varying ADA Titer on CLT           | 0.0856                    | [0.0649, 0.106]           |
| K des (1/day)                                     | 0.0214                    | [0.0189, 0.0239]          |
| Effect of Lymphoma Disease on K des               | 0.0426                    | [0.0322, 0.053]           |
| Central Volume of Distribution (Vc, L)            | 3.47                      | [3.36, 3.58]              |
| Effect of Sex on Vc                               | 0.844                     | [0.813, 0.874]            |
| Effect of Weight on Vc                            | 0.445                     | [0.369, 0.522]            |
| Effect of Albumin on Vc                           | -0.252                    | [-0.364, -0.14]           |
| Effect of Lymphoma on Vc                          | 0.894                     | [0.858, 0.93]             |
| Effect of NSCLC3 on Vc                            | 0.918                     | [0.881, 0.955]            |
| Effect of NSCLC4 on Vc                            | 1.05                      | [1.01, 1.09]              |
| Inter-compartmental Clearance (Q, L/day)          | 0.362                     | [0.314, 0.411]            |
| Peripheral Volume of Distribution (Vp, L)         | 0.751                     | [0.451, 1.05]             |
| Effect of Albumin on Vp                           | -1.95                     | [-2.57, -1.33]            |
| Effect of NSCLC Disease on Vp                     | 2.15                      | [1.31, 2.99]              |
| Between Subject Variability for CL0               | 23.9                      | [22.3, 25.5]              |
| Between Subject Variability for Vc                | 17.8                      | [16.8, 18.9]              |
| Between Subject Variability for Vp                | 63.4                      | [55.9, 70.9]              |
| Between Subject Variability for CLT               | 36.7                      | [31.7, 41.6]              |
| Between Subject Variability for K des             | 93.7                      | [82.7, 105]               |
| Correlation Between CL0 and Vc                    | 0.431                     | [0.35, 0.512]             |
| Correlation Between CLT and Vc                    | 0.691                     | [0.59, 0.791]             |
| Correlation Between CLT and K des                 | -0.0705                   | [-0.28, 0.139]            |
| Proportional Residual Unexplained Variability (%) | 17                        | [16.8, 17.3]              |

The effect of sex is showing the change in parameter for females relative to males.

The ability of the model to describe PK data in the is shown in a pcVPC (Figure 2).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 2: Prediction Variability corrected VPC for the updated PopPK model.

<!-- image -->

Open circles = individual observed, dashed blue lines = observed 10th &amp; 90th percentiles of the observed data, solid blue line = observed median concentration, shaded red/blue areas = 95% prediction interval around the model predicted 10th, 50th, &amp; 90th percentiles.

In the initial submission, 7054 concentrations from 1002 subjects collected prior to March 8, 2021, were included in the PopPK model. After this date, 312 additional PK samples of CS1001-301 have been collected, consisting of 4 samples from Cycle 4 (from 2 new subjects) and 308 trough concentrations from Cycle 8 and later cycles (from 167 subjects). These additional samples account for less than 5% of the total PopPK dataset.

## PopPK simulations

The proposed therapeutic dose of sugemalimab for Stage III NSCLC consolidation treatment is 1200 mg Q3W for patients weighing ≤ 115 kg and 1500 mg Q3W for those &gt;115 kg. This dosing recommendation is supported by PK simulations for high-body-weight patients.

This dosing approach follows the same modelling &amp; simulation methodology used for the approved indication for stage IV NSCLC indication (EMEA/H/C/006088/0000), which established a regimen of 1200 mg Q3W for patients weighing 115 kg or less and 1500 mg Q3W for those over 115 kg.

A simulation of exposure metrics across an extended weight range of 80-150 kg following dosages of 1200 mg Q3W and 1500 mg Q3W was conducted, based on the updated PopPK model. The predicted exposure metrics for Cycle 1 of the CS1001-301 study, which serves as the reference for the following analysis, were estimated from individual concentration-time profiles simulated based on individual empirical Bayes estimates (EBE) in the final PopPK model. Simulated body weight values for all 1002 patients included in the PopPK analysis were randomly drawn from a uniform distribution for each 5 kg stratum in the range of 80-150 kg while maintaining the effects of other covariates unchanged.

The predicted sugemalimab exposure metrics at cycle 1 versus body weight for a flat dose of 1200 mg from the final population PK model are shown in Figure 3. The simulations for Ctrough, C1 by dose and body weight strata and for study CS1001-301 are shown in Table 3 and identifies that 1500 mg Q3W in patients with body weights above 115 kg provides exposures comparable with the observed exposure.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Corresponding simulations for AUC and Cmax were provided (data not shown) which also demonstrated comparable PK exposures between the proposed posology and the observed PK exposures in Study 301.

Corresponding PK simulations were provided for Stage IV patients where the simulated Ctrough during Cycle 1 for the already approved posology were compared with the observed Ctrough during Cycle 1 in Study 302. The simulation-based exposure comparisons for Stage IV patients demonstrated that the simulated median and 90% prediction interval of Ctrough during Cycle 1 overlapped with the observed median and 90% prediction interval, to a similar degree as the simulations for Stage III patients. The geometric mean ratios (GMR) between the simulated and observed Ctrough during Cycle 1 were 0.74 or higher for the already posology for Stage IV patients across the entire simulated weight range which is similar to the simulations for Stage III patients.

Figure 3: Simulated exposure (Ctrough,C1) following 1200 mg Q3W for high body weight and reference range from study CS1001-301 with proposed target lower limit (from observed data).

<!-- image -->

Predicted Ctrough,C1 based on the updated population PK model for weight &gt; 80kg population (black circles: individual predictions). The blue and red solid lines are the median and 90% PIs for predicted Ctrough,C1. The blue shaded area encompasses 90% of the simulated patients in each weight stratum (5kg intervals). The grey band encompasses 90% range from Study CS1001-301. The red dotted line represents the 5th percentile of observed Ctrough, C1 in Study CS1001301 (52.1 μg/mL).

Table 3: Ctrough,C1 (μg/mL) by dose and body weight strata and for Study CS1001 -301

| Weight (kg)                                | N                                          | GeoMean                                    | Median(5 th -95 th )                       | %of C trough,C1 > 52.1 μg/ mL a            | GMR b (90% CI)                             |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| From model prediction for study CS1001-301 | From model prediction for study CS1001-301 | From model prediction for study CS1001-301 | From model prediction for study CS1001-301 | From model prediction for study CS1001-301 | From model prediction for study CS1001-301 |
| 43-98                                      | 252                                        | 80.5                                       | 79(54.9-119.9)                             | 97.2                                       | -                                          |
| From simulated patients dosed 1200mg       | From simulated patients dosed 1200mg       | From simulated patients dosed 1200mg       | From simulated patients dosed 1200mg       | From simulated patients dosed 1200mg       | From simulated patients dosed 1200mg       |
| 80-85                                      | 252                                        | 70.6                                       | 69(50.3-100.4)                             | 92.9                                       | 0.877(0.848-0.907)                         |
| 85-90                                      | 252                                        | 68.4                                       | 67(49.1-97.2)                              | 89.7                                       | 0.850(0.822-0.879)                         |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Weight (kg)                          | N                                    | GeoMean                              | Median(5 th -95 th )                 | %of C trough,C1 > 52.1 μg/ mL a      | GMR b (90% CI)                       |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| 90-95                                | 252                                  | 66.5                                 | 66(47.9-95.8)                        | 87.7                                 | 0.825(0.798-0.853)                   |
| 95-100                               | 252                                  | 64.6                                 | 63.5(46.5-92.4)                      | 84.9                                 | 0.802(0.775-0.829)                   |
| 100-105                              | 252                                  | 62.8                                 | 62(45.5-90.3)                        | 81.3                                 | 0.780(0.755-0.807)                   |
| 105-110                              | 252                                  | 61.1                                 | 60(44.1-87.6)                        | 77.8                                 | 0.759(0.734-0.785)                   |
| 110-115                              | 252                                  | 59.6                                 | 58(43.0-85.6)                        | 74.6                                 | 0.740(0.716-0.765)                   |
| 115-120                              | 252                                  | 58.2                                 | 57(42.1-83.2)                        | 68.7                                 | 0.722(0.698-0.747)                   |
| 120-125                              | 252                                  | 56.7                                 | 56(41.2-81.6)                        | 63.9                                 | 0.704(0.681-0.728)                   |
| 125-130                              | 252                                  | 55.4                                 | 55(40.2-79.7)                        | 59.1                                 | 0.688(0.665-0.711)                   |
| 130-135                              | 252                                  | 54.2                                 | 53.5(39.4-78.2)                      | 55.6                                 | 0.672(0.650-0.695)                   |
| 135-140                              | 252                                  | 53.0                                 | 52.5(38.6-76.3)                      | 50.4                                 | 0.658(0.636-0.680)                   |
| 140-145                              | 252                                  | 51.8                                 | 51(37.8-75.0)                        | 46.8                                 | 0.643(0.622-0.665)                   |
| 145-150                              | 252                                  | 50.7                                 | 50(37.1-73.4)                        | 42.9                                 | 0.629(0.609-0.651)                   |
| From simulated patients dosed 1500mg | From simulated patients dosed 1500mg | From simulated patients dosed 1500mg | From simulated patients dosed 1500mg | From simulated patients dosed 1500mg | From simulated patients dosed 1500mg |
| 80-85                                | 252                                  | 88.3                                 | 87(62.9-125.6)                       | 99.6                                 | 1.096(1.06-1.13)                     |
| 85-90                                | 252                                  | 85.6                                 | 84(61.4-121.5)                       | 99.2                                 | 1.062(1.03-1.10)                     |
| 90-95                                | 252                                  | 83.1                                 | 82(59.9-119.8)                       | 98.8                                 | 1.032(0.998-1.07)                    |
| 95-100                               | 252                                  | 80.7                                 | 79(58.2-115.5)                       | 98.4                                 | 1.002(0.969-1.04)                    |
| 100-105                              | 252                                  | 78.6                                 | 77(56.8-112.9)                       | 98.0                                 | 0.976(0.944-1.01)                    |
| 105-110                              | 252                                  | 76.5                                 | 75(55.1-109.5)                       | 97.2                                 | 0.949(0.918-0.981)                   |
| 110-115                              | 252                                  | 74.6                                 | 73(53.7-107)                         | 96.8                                 | 0.926(0.895-0.957)                   |
| 115-120                              | 252                                  | 72.7                                 | 71.5(52.6-104.1)                     | 96.0                                 | 0.903(0.873-0.934)                   |
| 120-125                              | 252                                  | 70.9                                 | 70(51.6-102)                         | 92.5                                 | 0.880(0.852-0.910)                   |
| 125-130                              | 252                                  | 69.3                                 | 68(50.3-99.6)                        | 90.5                                 | 0.860(0.832-0.889)                   |
| 130-135                              | 252                                  | 67.7                                 | 67(49.3-97.8)                        | 89.3                                 | 0.841(0.813-0.869)                   |
| 135-140                              | 252                                  | 66.2                                 | 65.5(48.3-95.4)                      | 88.1                                 | 0.822(0.795-0.850)                   |
| 140-145                              | 252                                  | 64.8                                 | 64(47.3-93.8)                        | 84.1                                 | 0.805(0.778-0.832)                   |
| 145-150                              | 252                                  | 63.4                                 | 63(46.3-91.8)                        | 81.3                                 | 0.787(0.761-0.814)                   |

a: 52.1 µg/mL is the 5 th  percent of observed Ctrough in Study 301 at cycle 1 within time window of 21±3 days.

b: GeoMean: Geometric Mean;*GMR: the ratio of from two-sample t-test for log-transformed exposure from &gt;80kg and Study CS1001-301 group.

## Dose proportionality and time dependencies

No new data regarding dose proportionality was presented.

Regarding time dependencies, in the phase 3 stage III NSCLC study, among 255 patients in the sugemalimab group, the prevalence of anti-drug antibodies (ADA) was 10.6% (27 patients), with 5.9% (15 patients) as treatment-emergent ADA. The total positive rate of NAb was 2.0% (5 patients).

No evidence was observed that ADA had an impact on pharmacokinetics, efficacy or safety, however data are still limited.

## 2.3.3. Pharmacodynamics

Sugemalimab is a fully human immunoglobulin G4 monoclonal antibody. It specifically binds to programmed cell death ligand 1 (PD L1), thus blocking its ligation with PD 1. PD L1, when expressed on tumour cells and tumour-infiltrating immune cells, can contribute to the inhibition of

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

an anti-tumour immune response. Binding of PD L1 to the PD 1 and CD80 (B7.1) receptors found on T cells and antigen presenting cells suppresses cytotoxic T cell activity, T cell proliferation, and cytokine production.

## 2.3.4. PK/PD modelling

New efficacy PKPD analyses in the target population were provided and efficacy simulations were performed to support the proposed posology.

A safety PKPD analysis including patients in the target population (Stage III NSCLC patients) was previously submitted in the initial submission (EMEA/H/C/006088/0000) and is not included in the current assessment report.

## Exposure-efficacy analysis

Exposure metrics taken during Cycle 1 were used in the analysis. Using data from the Phase 3 study, CS1001-301 in participants with Stage III NSCLC, the exposure-efficacy relationship of sugemalimab was explored following a dose of 1200 mg IV Q3W for PFS and OS.

The E-R relationships including PFS and OS were explored by Kaplan-Meier plots and time to events (TTEs) models.

Graphical analysis for PFS indicated a possible relationship between Ctrough,C1 and PFS, as assessed by both BICR and the Investigator (Kaplan-Meier curves by quartiles of Ctrough,C1,Figure 4).

Figure 4: Progression-free Survival by Quartiles of Ctrough,C1.

<!-- image -->

Time (months)

Note: Solid lines represent Kaplan-Meier curves, shaded areas represent 95% CI, and P value is derived from a log-rank test. BICR = blinded independent central review; CI = confidence interval; Ctrough,C1 = trough serum concentration in Cycle 1.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The TTE model for PFS as assessed by BICR showed an estimated 7.9% reduction in the hazard of disease progression or death per increase in Ctrough,C1 of 10 μg/mL, indicating an improvement in PFS with increasing sugemalimab Cycle 1 trough concentration.

The graphical analysis using Kaplan-Meier plots for OS indicated no significant relationship present between sugemalimab exposure (Ctrough,C1) and OS (p&gt;0.05) (Figure 5).

Figure 5: Overall Survival by Quartiles of Ctrough,C1.

<!-- image -->

Time (months)

Note: Solid lines represent Kaplan-Meier curves, shaded areas represent 95% CI, and P value is derived from a log-rank test. CI = confidence interval; Ctrough,C1 = trough serum concentration in Cycle 1.

## Exposure-efficacy simulations

Since all participants with stage III NSCLC were of Asian race, simulations based upon developed exposure-response analysis were carried out to understand expected exposure-response relationships for different patient characteristics to help support dose selection in the high body weight demographic. Specifically, these simulations accounted for differences in PK due to patient characteristics to allow for prediction of outcomes in NSCLC patients with demographics representative of the high body weight population under the 1200 mg and 1500mg dose IV Q3W regimen.

The final PopPK model was used to simulate exposure metrics AUCC1, Ctrough,C1, and Cmax,C1 for virtual patients under both 1200 mg IV Q3W and 1500mg IV Q3W. These exposure metrics were then incorporated into the exposure-efficacy models to compute the cumulative expected probability of PFS every 3 months up to 24 months.

Simulations of the probability of PFS, stratified by body weight, examined differences in PFS between participants with high body weights in the range of 90 to 120 kg receiving a 1200 mg and higher dose 1500 mg compared to Asian participants with body weights in the range of 43 to 98 kg (Figure 6).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 6: Exposure-response Simulations: Progression-free Survival.

<!-- image -->

Note: Solid lines represent median., shaded area = 90% PI , red: high body weight population (90 to 120 kg) at 1200 mg; green: high body weight population (90 to 120 kg) at 1500 mg; blue: Asian at 1200 mg.

## 2.3.5. Discussion on clinical pharmacology

PK information in the target population was collected in Study CS1001-301. The PK data in Study CS1001-301 were included in the initial submission (EMEA/H/C/006088/0000) as supportive evidence. The PK data was also used to support dosing recommendations in patients with high body weight using a PopPK-based PK-bridge.

The bioanalytical methods used in this study are acceptable. The bioanalysis methods as well as the methods for detecting anti-sugemalimab antibodies and anti-sugemalimab neutralizing antibodies were already assessed and found acceptable in the initial submission (EMEA/H/C/006088/0000).

Information on the PK parameters (distribution and elimination) in Stage III patients have been included in section 5.2 of the SmPC which is acceptable.

An updated PopPK model was included compared to the initial submission (EMEA/H/C/006088/0000). The updated PopPK model included NSCLC disease stage (Stage III vs Stage IV) as a new covariate on CL and Vc. The updated PopPK model predicted similar CL between Stage III and Stage IV patients whereas the Vc was slightly lower (~10-15%) for Stage III patients compared to Stage IV patients.

A weight cutoff of 115 kg (1200 mg Q3W ≤115 kg and 1500 mg Q3W &gt;115 kg) was proposed for both Stage III and Stage IV patients which is acceptable. There is a numerical difference in the observed PK exposure between Studies 301 (Stage III) and 302 (Stage IV) (Figure 1) but the difference is not clinically relevant. Furthermore, there is no biological rationale that the dosage of sugemalimab should differ between these patient groups.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The proposed posology weight cut-off was further supported by updated PopPK simulations. The updated simulations for Stage III patients demonstrated that the simulated Ctrough during Cycle 1 following the proposed posology (1200 mg Q3W ≤ 115 kg and 1500 mg Q3W &gt;115 kg) are comparable to the corresponding observed Ctrough during Cycle 1 in Study 301. The simulated median and 90% prediction interval for Ctrough during Cycle 1 for the proposed posology overlapped with the observed median and 90% prediction interval for Ctrough during Cycle 1 in study 301. A geometric mean ratio (GMR) was also calculated between the simulated and observed Ctrough during Cycle 1 which were 0.74 or higher for the proposed posology across the entire simulated weight range which is adequate.

The PK comparisons focused on Ctrough during Cycle 1 which is acceptable since it is the most relevant exposure metric from an efficacy perspective for a checkpoint inhibitor. Corresponding simulations for AUC and Cmax (data not shown) also demonstrated comparable PK exposures between the proposed posology and the observed PK exposures in Study 301.

Corresponding PK simulations were provided for Stage IV patients where the simulated Ctrough during Cycle 1 for the already approved posology were compared with the observed Ctrough during Cycle 1 in Study 302. The simulation-based exposure comparisons for Stage IV patients demonstrated that the simulated median and 90% prediction interval of Ctrough during Cycle 1 overlapped with the observed median and 90% prediction interval, to a similar degree as the simulations for Stage III patients. The GMR between the simulated and observed Ctrough during Cycle 1 were 0.74 or higher for the already posology for Stage IV patients across the entire simulated weight range which is similar to the simulations for Stage III patients. Regarding immunogenicity, there are no clinically relevant differences between Stage III and Stage IV patients which is acceptable. The SmPC section 5.1 has been adequately updated with the ADA results from Study CS1001-301.

The exposure-efficacy analyses and corresponding simulations were only considered supportive evidence with limited impact on the overall benefit-risk. The exposure-efficacy analyses were based on PKPD data from Study CS1001-301 which only included one dose level (1200 mg Q3W). This is a significant limitation of the exposure-efficacy analyses since a single dose level gives a too narrow exposure range to adequately characterise the true exposure-response relationship. This issue is not pursued since the PopPK analysis and PK simulations are considered sufficient to support the proposed posology.

A safety PKPD analysis including patients in the target population (Stage III NSCLC patients) was previously submitted in the initial marketing authorisation application (EMEA/H/C/006088/0000) and is not included in the current assessment report which is acceptable.

## 2.3.6. Conclusions on clinical pharmacology

Overall, the clinical pharmacology package suffices to support the proposed use.

## 2.4. Clinical efficacy

## 2.4.1. Main study(ies)

## Study CS1001-301

Study CS1001-301 (GEMSTONE-301): a randomised, double-blind, placebo-controlled, multicentre Phase III study conducted in China, to evaluate the efficacy and safety of sugemalimab as

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

consolidation therapy versus placebo in participants with locally advanced or unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy.

The results from the first interim analysis for PFS (DCO 08 March 2021) from Study CS1001-301 were claimed as supportive in the initial MAA and were described briefly in the EPAR of procedure EMEA/H/C/006088/0000.

The study has been terminated.

## Methods

## Figure 7:  Study flow chart

| Pre-screening Period                                                                                                                        | Screening Period                                                                                                                    | Randomisation                                                                                                                                 | Treatment Period                                                                                                                                                                                                                                                               | Follow-up Period                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pre-screening is optional. After entering the pre- screening process, the participant should sign the pre- screening informed consent form. | Screening should be completed within 42 days （including 42 days) after the end of concurrent or sequential chemoradiotherapy. After | Participants should try to receive the the first dose of study drug on the day of randomisation, no later than 1 day after the randomisation. | First drug administration; Treatment duration was up to 24 months; The first dose should be administered within 42 days (including 42 days) after completion of concurrent or sequential chemoradiotherapy (with at least 2 cycles ofplatinum-based chemotherapy). Sugemalimab | The safety follow-up period was 90 days after the last dose of study drug or until the initiation of new anti-tumour therapy, whichever occurred earlier; Survival follow- up was performed every 12 weeks. |

## Study participants

## Inclusion criteria

1. Willing to participate in this trial; fully understand and get informed of this trial and have signed the master informed consent form (ICF).
2. ≥ 18 years of age on the day of signing ICF.
3. Have histologically or cytologically confirmed locally advanced, unresectable stage III non-small cell lung cancer (staged according to the International Association for the Study of Lung Cancer [IASLC] classification, version 8; refer to section 14.8).
4.  Non-squamous-cell cancer:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- -About epidermal growth factor receptor (EGFR) mutation status: subjects with known EGFR mutation must be excluded (testing method and results are acceptable as evaluated by the site  and  sponsor;  methods  described  in  NCCN  or  CSCO  guidelines  are  recommended). Subjects with unknown EGFR mutation status must receive tests which method must be acceptable as evaluated by site or sponsor; subjects with confirmed EGFR mutation will be excluded.
- -About anaplastic lymphoma kinase (ALK) translocation and c-ros pro-oncogene 1-receptor tyrosine kinase (ROS1) translocation: subjects with known ALK or ROS1 translocation will be  excluded;  subjects  with  unknown  ALK  and  ROS1  translocation  may  directly  undergo screening without having translocation tests.
-  Squamous-cell cancer:
- Subjects with known EGFR mutation, ALK translocation or ROS1 translocation will be excluded; subjects with unknown EGFR, ALK or ROS1 status may directly undergo screening without having tests for these factors.
4. The  first  dose  of  CS1001  will  be  administered  within  1  -  42  days  (including  42  days)  after concurrent/sequential  chemoradiotherapy  (including  at  least  2  cycles  of  platinum-containing chemotherapy) is completed.

Note: Concurrent chemoradiotherapy is required to be at least 2 cycles of platinum-based chemotherapy concurrent with radiotherapy.

Note: If a subject was receiving weekly chemotherapy regimen, platinum-based chemotherapy of at least 4 weeks should be completed.

Note: Screening of subjects within 14 days after concurrent / sequential chemoradiotherapy is recommended.

5. Platinum-containing chemotherapy: Platinum must be one of cisplatin, carboplatin or nedaplatin. Chemotherapy  must  contain  at  least  one  of  the  following  drugs:  etoposide,  vinorelbine, vinblastine, pemetrexed,  taxanes  (e.g., paclitaxel, docetaxel, albumin-bound  paclitaxel, paclitaxel  liposome)  or  gemcitabine  (gemcitabine  must  not  be  used  as  chemotherapy  in  the chemoradiotherapy).

Note: Chemotherapy shall follow instructions in the Chinese Society of Clinical Oncology (CSCO) Guideline for Diagnosis and Treatment of Primary Lung Cancer 2017 V1.

6. The last chemotherapy must be administered no later than the last radiotherapy. Consolidation chemotherapy is not allowed after radiotherapy; but induction chemotherapy before concurrent chemoradiotherapy is allowed.

Note: Interval between the end of chemotherapy cycle and beginning of radiotherapy must not exceed 35 days for sequential chemoradiotherapy.

7. Total dose of radiotherapy is 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is three-dimensional conformal radiotherapy (3D-CRT) with CT planning.

Note: Study RTOG 0617 proved that total dose of radiotherapy increased to 74 Gy would not improve efficacy.

Note: Dose received by organs is recommended to be as close to the following principles as possible:

-  Average dose in lungs ≤ 20 Gy and/or V20 ≤ 35%

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

-  Average dose in esophagus ≤ 34 Gy
-  Average dose in heart ≤ 20 Gy or V50 ≤ 25%
8. Absence of progression after concurrent/sequential chemoradiotherapy (responses should be complete response [CR], partial response [PR] and stable disease [SD]).
9. ECOG PS of 0 or 1.
10. Life expectancy ≥ 12 weeks.
11. Provide  unstained  tumor  tissue  sections  for  TMB  assay  and  provide  the  relevant  pathology report. Subjects with no available archived tumor tissue samples should be willing to receive tumor lesion biopsy for obtaining tumor sample before receiving any study treatment (number of  samples will be determined according to the biopsy status). If due to medical reasons, a subject is unable to receive tumor lesion biopsy, the investigator should discuss with the Sponsor to determine the eligibility of the subject.
12. Subject  with  prior  anti-cancer  treatment  can  only  be  enrolled  when  all  toxicities  except  for hearing loss, alopecia and fatigue, of prior anticancer treatment has recovered to baseline or ≤ Grade 1 (according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v4.03).

Note: Subjects with &gt; Grade 1 irreversible toxicity that is not expected to get worse after the initiation of study treatment may be eligible after consultation with the Sponsor.

13. Subjects  must  have  adequate  organ  function  as  assessed  in  the  following  laboratory  tests (subjects  must  not  receive  any  blood  transfusion,  erythropoietin  (EPO),  granulocyte  colonystimulating  factor  (G-CSF)  or  other  medical  supportive  treatment  within  7  days  prior  to  the investigational product administration):

| Systems                                                                           | Laboratory Tests                                                                                                                                                |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hematology                                                                        |                                                                                                                                                                 |
| Absolute neutrophil count (ANC)                                                   | ≥ 1.5 X 109/L                                                                                                                                                   |
| Platelets                                                                         | ≥ 100 X 109/L                                                                                                                                                   |
| Hemoglobin                                                                        | ≥ 90 g/L or ≥ 5.6 mmol/L                                                                                                                                        |
| Kidney                                                                            |                                                                                                                                                                 |
| Serum creatinine or serum creatinine clearance                                    | < 1.5 X ULN ≥ 40 mL/min (according to Cockcroft-Gault equation; refer to Section 14.9; creatinine clearance is only calculated if serum creatinine > 1.5 X ULN) |
| Liver                                                                             |                                                                                                                                                                 |
| Total bilirubin                                                                   | ≤ 1.5 X ULN (not applicable for subjects with Gilbert's Syndrome, whose eligibility will be determined after consultation with sponsor).                        |
| Aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) | ≤ 3 X ULN                                                                                                                                                       |
| Coagulation                                                                       | Coagulation                                                                                                                                                     |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| International normalized ratio (INR) or prothrombin time (PT)   | ≤ 1.5 X ULN   |
|-----------------------------------------------------------------|---------------|

14. Women of childbearing potential or fertile men must agree to use an effective contraceptive method from signing the master ICF until 180 days after the last dose of investigational product. Women  of  childbearing  potential  include  premenopausal  women  and  women  who  became menopausal  less  than  2  years  ago.  Women  of  childbearing  potential  must  have  a  negative pregnancy test ≤7 days prior to the first dose of investigational product.

## Exclusion criteria

1. Histologically identified to have mixed small cell lung cancer component.
2. Disease progression after concurrent/sequential chemoradiotherapy.
3. Major surgical procedure (as determined by investigators) within 28 days prior to the first dose of investigational product.
4. Has received a live vaccine within 28 days prior to the first dose of investigational product.
5. Any use of traditional Chinese medicine or herbal preparations with anti-tumor indications within 14 days prior to the first dose of investigational product.
6. Current participation in another clinical study or use of any investigational drug within 28 days prior to the first dose of investigational product in this trial. (Participation in the overall survival follow-up of a study is allowed.)
7. Any  prior  treatment  of  antibody/drug  that  targets  at  T-cell  coregulatory  proteins  (immune checkpoints, including PD-1, PD-L1, CTLA4, TIM3 and LAG3, etc.).
8. Subjects with squamous cell lung cancer who had prior treatment of antiangiogenic drugs.
9. Subjects with current active autoimmune disease or prior history of autoimmune disease that probably  will  relapse  (for  example,  systemic  lupus  erythematosus,  rheumatoid  arthritis, inflammatory bowel disease, autoimmune thyroid conditions, vasculitis, psoriasis, etc.) or at risk of  having  these  conditions  (for  example  having  received  organ  transplantation  or  immune suppressant treatment). Subjects with the following conditions are allowed to be screened: type I  diabetes  mellitus,  hypothyroidsm  that  can  be  managed  with  thyroxine  replacement  only, dermatological  condition  that  doesn't  require  systemic  treatment  (for  example  leukoderma, psoriasis or alopecia) or the condition is expected not to relapse without external trigger.
10. Immune deficient disease or currently under systemic corticosteroid treatment (equivalent to &gt; 10 mg/day prednisone) or any other form of immune suppressing treatment within 7 days prior to the first dose of investigational product.

Note: Subjects with no active autoimmune disease is allowed to use corticosteroid equivalent to ≤ 10 mg/day prednisone as adrenal replacement treatment. Topical, ophthalmic, intra -articular, nasal or inhaled corticosteroid (with very low systemic absorption) is allowed. Short -term corticosteroid for prevention (for example for contrast allergy) or treating non -autoimmune conditions (for example delayed hypersensitivity caused by contrast allergy).

11. A known additional malignancy within 5 years prior to the first dose of investigational product. Subjects with locally curable malignancies (including basal cell carcinoma of skin, squamous cell carcinoma of skin, breast cancer in situ or cervical cancer in situ) that have undergone curative therapy are permitted to enroll.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

12. Pneumonitis ≥ grade 2 caused by chemoradiotherapy (Subjects with Grade 2 pneumonitis not treated  with  systemic  corticosteroid  which  has  recovered  to  ≤  Grade  1  within  14  days  and without risk of recurrence as per investigator's judgment can be screened).
13. Symptomatic interstitial  lung  disease;  subjects  with  past  history  of  lung  disease  that  in  the investigator's judgment may interfere with judgment of treatment of drug-related lung toxicity will also be excluded.
14. Active pulmonary tuberculosis in 1 year prior to first dose of investigational product. Subjects whose active pulmonary tuberculosis occurred at least 1 year ago, who have no evidence of active pulmonary tuberculosis as determined by the investigators are permitted to enroll.
15. History  of  inflammatory  bowel  disease  or  active  inflammatory  bowel  disease  (for  example Crohn's disease or ulcerative colitis).
16. Known  history  of  human  immunodeficiency  virus  (HIV)  infection  and/or  acquired  immune deficiency syndrome.
17. Subjects at  active  phase  of  chronic  hepatitis  B  or  with  active  hepatitis  C.  Subjects  who  are hepatitis  B  surface  antigen  (HBsAg)  positive  or  hepatitis  C  virus  (HCV)  antibody  positive  at screening  must  receive  hepatitis  B  virus  (HBV)  DNA  quantitative  test  (excluded  if  &gt;  2500 copies/mL  or  500  IU/mL)  and  HCV  RNA  test  (excluded  if  &gt;  lower  limit  of  detection)  for confirmation. The subjects can only be enrolled when presence of active hepatitis B or C that requires treatment is ruled out, respectively. Subjects that carry hepatitis B virus, with stable hepatitis B (HBV DNA titer ≤ 2500 copies/mL or 500 IU/mL) after medical treatment or with cured hepatitis C are permitted to enroll.

Note: If the lower detection limit of HBV DNA test performed locally at the Site is higher than 2500 cps/mL or 500 IU/mL, the subject in that site is eligible as long as the HBV DNA quantitative test result is lower than the lower detection limit.

18. Active infection that necessitates systemic treatment within 14 days prior to the first dose of investigational product.
19. History of organ transplantation.
20. Subjects with known history of alcoholism or drugs abuse.
21. Severe allergic reaction (&gt; grade 3 according to CTCAE v4.03) to other monoclonal antibodies.
22. Uncontrollable  concomitant  diseases  which  include  but  may  not  be  limited  to:  symptomatic congestive  heart  failure,  uncontrollable  hypertension,  arrhythmia,  active  peptic  ulcer  or hemorrhagic disease.
23. QTc interval &gt; 480 msec on the screening electrocardiogram (ECG) (as calculated by Fridericia formula).
24. Subjects  with  other  conditions  that  in  the  investigator's  opinion  may  influence  subject's compliance or make subjects not suitable for participating in this trial.

## Treatments

The investigational treatment regimen was CS1001, 1200 mg, i.v. infusion every 3 weeks. For the placebo group, corresponding placebo was used.

Treatment was to be continued until disease progression or unacceptable toxicity.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Dose increase or reduction of investigational product was not permitted in this trial.

## Objectives

## Primary objective

To compare the efficacy of sugemalimab vs. placebo in terms of PFS evaluated by BICR according to RECIST v1.1.

## Secondary objectives

To compare efficacy of sugemalimab vs. placebo in terms of OS, PFS by INV according to RECIST v1.1, ORR, DoR and time to death/distant metastasis (TTDM) by BICR and INV according to RECIST v1.1.

## Outcomes/endpoints

## Primary endpoint

Study CS1001-301 had one primary efficacy endpoint, PFS evaluated by BICR according to RECIST v1.1.

PFS was defined as the time from randomization to the first recorded progression or all-cause death, whichever occurred first.

The date of disease progression was the date of the subject's first disease progression whether or not that disease progression is confirmed. Subjects without event (no disease progression or death) will be censored at the date of 'last tumour assessment'. Subjects without tumour assessment after baseline was censored at the date of randomization. Subjects with two or more missed tumour evaluations and subjects who initiated a new therapy before progression were not censored.

## Secondary endpoints

OS (key secondary endpoint):

Overall survival was defined as the time interval between the date of randomization to the date of all-cause death.

ORR:

The number and percentage of subjects who achieve objective tumour response (CR or PR). A subject who failed to receive any tumour assessment after baseline was considered as a nonresponder.

DoR:

Duration of response for responders (CR or PR) was defined as the time interval between the date of the earliest qualified response and the date of PD or all-cause death, whichever occurred first. For subjects who were alive without progression following the qualified response, duration of response was censored on the date of last evaluable tumour assessment or last follow up for progression of disease. If no tumour assessment was performed after the first occurrence of CR or PR, duration of response (DoR) was censored at the date when CR or PR first occurs. Subjects with two or more missed tumour evaluations and subjects who initiated a new therapy before progression were not censored.

## TTDM:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

TTDM was defined as the time from the date of randomization to distant metastasis or death, whichever occurred first. Distant metastasis was defined as new lesion outside the radiation field (as evaluated according to RECIST v1.1 or tissue biopsy). Subjects without event (no distant metastasis or death) were censored at the date of 'last tumour assessment'. Subjects without tumour assessment after baseline were censored at the date of randomization.

Imaging assessments:

During the first year of the treatment period, imaging assessments were performed every 9 weeks; after 1 year: imaging assessments were performed every 12 weeks until disease progression, loss to follow-up, death, or end of study, whichever occurred first.

## Sample size

Sample size and number of events of the study were estimated based upon the following assumptions:

- PFS tested in a two-sided log-rank test at a significance level of 5%
- A power of 97.6% to detect a PFS hazard ratio (HR) of 0.6, corresponding to extension of median PFS from 6 months to 10 months
- The randomization ratio of treatment and control groups was 2:1
- Time-to-event variable assumed to follow exponential distribution
- The average enrolment rate assumed to be 13.6 subjects per month, and approximately 27 months needed to complete study enrolment
- Interim analysis conducted for PFS and type I error controlled by using O'Brien-Fleming method
- Drop-out rate for PFS in the two treatment groups assumed to be 5% every 12 months.

Based on the above assumptions, approximately 368 patients were planned to be randomised, and approximately 262 PFS events were needed to detect the maximum HR of 0.774.

If PFS result is positive, overall survival (OS) is tested in a two-sided log-rank test at a significance level of 5%. Number of events needed for OS analysis were estimated based on the following assumptions:

- o A power of 83% to detect the OS HR of 0.67, corresponding to extension of median OS from 22 months to 32.8 months
- o Time-to-event data assumed to follow exponential distribution
- o Interim analysis to be conducted for OS with approximate Pocock boundary
- o Drop-out rate for OS in the two treatment groups assumed to be 2% every 12 months.

Based on this sample size and the above assumptions, the final OS analysis was planned to be performed when approximately 260 deaths occurred. The maximum detectable HR for this event quantity was about 0.75.

## Randomisation

Eligible subjects were randomized in 2:1 to receive sugemalimab or placebo by stratification block randomization by IVRS/IWRS (Interactive Voice/Web Response System).

Stratification factors for randomization were: ECOG status (0 versus 1), chemoradiotherapy (concurrent versus sequential) and total radiotherapy dose (&lt;60 Gy and ≥ 60 Gy).

Patients were to be randomized within 42 days after the last radiotherapy. No more than 40% of randomized subjects were to have received sequential chemoradiotherapy

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

Study CS1001-301 was a double-blinded study.

## Statistical methods

## Analysis populations

The ITT set included all randomized patients with treatment groups assigned in accordance with the randomization. The analysis of PFS, OS and TTDM was based on the ITT set. ORR analysis was based on ITT population with measurable disease at baseline. Duration of response analysis was based on ITT population who achieved objective response.

The safety analysis set included all subjects who have received at least one dose of study treatment.

## Primary analysis

The primary efficacy endpoint was the PFS evaluated by BICR according to RECIST v1.1. Comparison between CS1001 and placebo was performed using a two-sided stratified log-rank test at a significance level of 5%. Stratified Cox regression model was used for estimating efficacy, and PFS hazard ratio (HR) and its 95% confidence interval (CI) was provided. Stratification factors were the same as those used for randomisation, and the order of the three stratification factors were specified as ECOG status, mode of prior chemoradiotherapy, and total dose of baseline radiotherapy. In stratified analysis, if the number of patients in a stratum did not meet the requirement of analytical test, for example, less than 10 patients, then the relevant stratified groups would be combined for analysis. A sensitivity test for the unstratified analysis would also be performed. Kaplan-Meier method was used to estimate median PFS (by Brookmeyer Crowley method), PFS rate at different time points and their 95% CIs (by Greenwood method). A KaplanMeier curve was provided to visually describe PFS changes over time.

## Secondary analysis

Secondary endpoints: OS, PFS (by investigators according to RECIST v1.1), Duration of response (DoR, by BICR and investigators), and Time to death/distant metastasis (TTDM, by BICR and investigators) were also analysed using the same statistical analysis method as that for the primary efficacy endpoint. Censoring rules according to the statistical analysis plan are summarized in the table:

| Endpoint   | Censoring rules                                                                                                                                                                                                                                                                                                                                 |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PFS        | Subjects without event (no disease progression or death) were censored at the date of 'last tumour assessment'. Subjects without tumour assessment after baseline were censored at the date of randomization. Subjects with two or more missed tumour evaluations and subjects who initiated a new therapy before progression were not censored |
| OS         | Subjects without death report before data cutoff were censored at the date of last survival confirmation. Subjects without any data after baseline were censored at the date of randomization.                                                                                                                                                  |
| DoR        | For subjects who were alive without progression following the qualified response, duration of response was censored on the date of 'last tumour assessment'. If no tumour assessment was performed after the first                                                                                                                              |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|      | occurrence of CR or PR, DoR was censored at the date when CR or PR first occurs. Subjects with two or more missed tumour evaluations and subjects who initiated a new therapy before progression were not censored   |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TTDM | Subjects without event (no distant metastasis or death) were censored at the date of 'last tumour assessment'. Subjects without tumour assessment after baseline were censored at the date of randomization.         |

Objective response rate (ORR, by BICR and investigators) was analysed using stratified MantelHaenszel test. A subject who failed to receive any tumour assessment after baseline was considered as a non-responder.

## Sensitivity analyses

The following sensitivity analyses of the primary efficacy endpoint and secondary efficacy endpoint were carried out with the same statistical method as used in the primary analysis.

Based on the number of subjects using anti-cancer treatment not permitted by this protocol, the impact of anti-cancer treatment on the PFS (by BICR according to RECIST v1.1) and OS were assessed. Sensitivity analysis was performed when more than 5% of subjects in either treatment group use unallowed anti-neoplastic treatment. Subjects who used non-protocol permitted anticancer treatment before any PFS event (by BICR according to RECIST v1.1) were censored at the date of 'last tumour assessment' prior to the non-protocol permitted anti-cancer treatment. Subjects without event (no disease progression or death) were censored at the date of 'last tumour assessment' prior to the non-protocol permitted anti-cancer treatment. Subjects who had no post-baseline tumour were censored on the randomization day. Subjects who used non-protocol permitted anti-cancer treatment before any OS event were censored at the date of the nonprotocol permitted anti-cancer treatment using day. Subjects without death report before data cutoff were censored on the date of non-protocol permitted anti-cancer treatment using day. Subjects without any data after baseline were censored at the date of randomization.

Sensitivity analysis was performed for the impact of missing tumour assessments on PFS (as per BICR's evaluation according to RECIST v1.1). Subjects who had two or more missing tumour assessments prior to PFS event were censored at the day of 'last tumour assessment' prior to the relevant event. Subjects without event (no disease progression or death) were censored at the date of 'last tumour assessment'. Subjects without any data after baseline were censored at the date of randomization.

The impact of COVID-19 on PFS (by BICR according to RECIST v1.1) was analysed as follows: The patients with a delay of CS1001/placebo administration &gt; 9 weeks due to COVID-19 (the delay duration is calculated according to IxRS scheduled visit date) were censored on the day of 'last tumour assessment' prior to the start of COVID-19. The start time of COVID-19 was set as 22Jan2020. For other patients, those who did not have an event were censored at the 'last tumour assessment'. Subjects without tumour assessment data after baseline were censored at the date of randomization.

## Subgroup analyses

Subgroup analyses were performed for PFS (by BICR according to RECIST v1.1), OS, and ORR (by BICR) providing a forest plot containing each subgroup factor as follows: demographics, stratification factors, histopathological type, best response of chemoradiotherapy, and prior anticancer treatment other than chemoradiotherapy, to evaluate the consistency of study results between each subgroup.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Multiplicity

The sequential testing method was used to control overall type I error. If PFS (evaluated by BICR according to RECIST v1.1) interim or final analysis show that the null hypothesis was rejected, i.e. CS1001 is superior to placebo, the sequential testing of secondary efficacy endpoints was conducted in the following order:

- 1) OS
- 2) TTDM by BICR
- 3) ORR by BICR.

First, OS hypothesis testing (at a significance level of 0.05) was conducted; if OS interim analysis results indicate the null hypothesis is rejected, hypothesis testing (at a significance level of 0.05) of TTDM final analysis was to be conducted, and the data cutoff is consistent with that of the OS interim analysis; if final TTDM analysis results indicate the null hypothesis is rejected, hypothesis testing (at a significance level of 0.05) of ORR final analysis was to be conducted, and the data cutoff is consistent with that of the OS interim analysis; if OS interim analysis results indicate the null hypothesis is not rejected, while the final analysis results indicate the null hypothesis is rejected, the hypothesis testing (at a significance level of 0.05) of TTDM and ORR final analysis was to be conducted using the data cutoff that of the OS interim analysis; if TTDM final analysis results indicate the null hypothesis is rejected, hypothesis testing (at a significance level of 0.05) of ORR final analysis was to be conducted.

## Interim analysis

Interim PFS analysis was planned to be conducted when approximately 194 PFS events (74% of data information) were observed or last patient is enrolled, whichever occurs later. The interim analysis was estimated to be conducted at around 27 months after the first patient enrolment. Final PFS analysis was planned to be performed when approximately 262 PFS events are observed, which was estimated to be at around 33 months after the first patient enrolment. O'Brien-Fleming method was used to control two-sided overall type I error &lt; 0.05. The PFS interim analysis was conducted with a total of 197 PFS events as of the data cutoff date (08 March 2021). The PFS final analysis was conducted with a total of 244 PFS events as of the data cutoff date (01 March 2022).

If the interim or final PFS analysis result was positive, interim OS analysis was performed when approximately 175 deaths (67% of data information) occur, which was estimated to be around 40 months after the first subject enrolment. The final OS analysis was to be performed when approximately 260 OS events were observed. This analysis was estimated to be done at 68 months after the first subject enrolment. Lan-DeMets method with an approximation Pocock boundary were to be used to control overall type I error &lt;0.05. The OS interim analysis was conducted with a total of 180 OS events as of the data cutoff date (03 April 2023).

Independent data monitoring committee (iDMC) evaluated the safety data collected in the trial regularly every 6 months after the first patient enrolment. Members of iDMC were from outside the sponsor, who must follow the guidance about duties and responsibilities. Any safety monitoring result that may affect the conduct of this trial must be notified to the investigator so that Ethics Committee (EC) will be informed. iDMC monitored the data for interim PFS analysis and made recommendations to sponsor according to the following ending boundaries. Constitution, roles and responsibilities and execution of iDMC were described in iDMC guidance.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 4: Boundaries for PFS and OS analyses (for the planned number of events)

<!-- image -->

The boundary values were updated according to the observed number of events.

## Changes of the planned analyses

The statistical analysis plan (SAP) was authored on 12 April 2021, based on the protocol version 5 (from 20 November 2020). No changes were made in the SAP.

In the protocol version 5, the primary objective and endpoint of the study were revised from \"Progression-free Survival (PFS) by the investigator according to RECIST v1.1\" to \"PFS by Blinded Independent Central Review (BICR) according to RECIST v1.1\". Also, the planned study sample size was changed from 402 to 368. In an earlier protocol version, a section on multiple comparisons was added.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Figure 8: Participant Disposition - Study CS1001-301 (OS Interim Analysis DCO3 - 03 April 2023)

<!-- image -->

DCO3 date: 03 April 2023

Abbreviation: ITT = intention-to-treat.

a All participants who were randomised into the study.

b All participants who were randomised and received at least one dose of the study drug.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 5: Patient disposition

|                                                              | CS1001   | CS1001      | Placebo   | Placebo                                | Total   | Total                                  |
|--------------------------------------------------------------|----------|-------------|-----------|----------------------------------------|---------|----------------------------------------|
| Screened                                                     |          |             |           |                                        | 564     |                                        |
| Screen failure                                               |          |             |           |                                        | 182     |                                        |
| Screen success but not randomized                            |          |             |           |                                        | 1       |                                        |
| Randomized                                                   |          |             |           |                                        |         | 255 (100.08) 126 (100.08)381 (100.08)  |
| Treated                                                      |          |             |           |                                        |         | 255 (100.08) 126 (100.08) 381 (100.08) |
| Discontinued from study treatment                            |          |             |           | 255 (100.08) 126 (100.0$) 381 (100.08) |         |                                        |
| Adverse event                                                | 46       | 5(18.0%)    | 6         | 4.8%)                                  | 52      | (13.68)                                |
| Radiographic disease progression                             |          | 127 (49.88) | 88        | 3(69.88)215(56.48)                     |         |                                        |
| Symptomatic deterioration without radiographic evidence      | 0        |             | 0         |                                        | 0       |                                        |
| Subject's decision                                           |          | 26 (10.2%)  | 10（       | 7.9%)                                  |         | 36 (9.48)                              |
| Investigator's decision                                      | 13       | (5.18)      | 2         | 1.6%)                                  | 15      | 5(3.98)                                |
| Study terminated by sponsor                                  | 0        |             | 0         |                                        | 0       |                                        |
| Need for prohibited medications                              | 0        |             | 0         |                                        | 0       |                                        |
| Severe non-compliance with the study and/or study procedures | 0        |             | 0         |                                        | 0       |                                        |
| Lost to follow-up                                            | 0        |             |           | 0.88)                                  |         | 1(0.38)                                |
| Death                                                        | 0        |             | 0         |                                        | 0       |                                        |
| Pregmancy                                                    | 0        |             | 0         |                                        | 0       |                                        |
| Maximum treatment cycle reached                              | 4        | (1.6%)      |           | 1 (0.8%)                               | 5       | (1.38)                                 |
| Other                                                        | 39       | (15.38)     | 18        | 3(14.38)                               |         | 57(15.08)                              |
| Discontinued from study                                      | 255      | (100.0%)    |           | 126 (100.0%)                           |         | 381 (100.0%)                           |
| Death                                                        | 116      | 5(45.58)    | 66        | （52.48)                                |         | 182 (47.88)                            |
| Lost to follow up                                            | 6        | (2.48)      |           | 3(2.48)                                | 9       | (2.48)                                 |
| Withdrawal by subject                                        | 3        | 1.28)       | 0         |                                        | 3       | 3(0.8%)                                |
| Other                                                        |          | 130 (51.08) |           |                                        |         | 57(45.2$）187 (49.18)                   |

All patients that discontinued from study under 'other' did so due to the termination of the study by the sponsor.

## Recruitment

A total of 564 patients were screened at 50 study sites, all in China, and a total of 381 patients were randomised in a 2:1 ratio to the sugemalimab group (255 patients) and the placebo group (126 patients) from 26 October 2018 to 30 December 2020.

## Conduct of the study

## Protocol amendments

Latest protocol version 5.1 - 15 July 2022

Updated procedures at the completion of the study following the termination after the OS interim analysis. This included the termination of BICR evaluation and PK and ADA samples.

Added guidance for immune-related myocarditis.

Protocol version 5.0 - 30 November 2020 updates

Increased number of sites from 40 to 50.

Primary endpoint updated from INV to BICR and revision of secondary endpoints in line with this.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Decreased sample size from 402 to 368 patients, reduced number of events for the IA and final PFS analysis, the method for controlling the type I error was changed from Hwang-Shil-DeCani to O'Brien-Fleming.

Updated the evaluation of PD to be consistent with RECIST v1.1.

## Protocol version 4.0 - 11 May 2020 updates

Added requirement concerning concurrent chemoradiotherapy.

Added sequential testing of secondary endpoints.

Added the requirement to obtain routine laboratory tests and thyroid function tests within 3 days prior to study drug administration from Cycle 2 and onwards.

Revised safety follow-up to include 'or initiation of new anti-cancer therapy.

Added confirmation criteria for disease progression.

Added the value of Gamma parameter of Hwang-Shil-DeCani methods and the precision of p-value bound.

Added that irradiated lesions were to be considered as measurable disease if the criteria for measurable disease and target lesion selection requirements were met considering consistent assessment of anti-tumour efficacy according to RECIST (v1.1)

## Protocol version 3.1 - 29 October 2019 updates

Added exclusion criteria 8: 'Subjects with squamous cell lung cancer who had prior treatment of antiangiogenic drugs'

## Protocol version 3.0 - 12 September 2019 updates

The pre-screening phase were added to the study procedures.

The TMB-related study objectives and endpoints were adjusted to lower the requirements on tumour tissue sections for TMB test.

Removed efficacy comparison in the subgroup with tumour mutational burden ≥ 10.

Patients with cytologically confirmed locally advanced, unresectable stage III NSCLC were included in the enrolled population.

Requirement for patients with unknown EGFR, ALK or ROS status to be tested centrally were removed.

Inclusion criteria of radiation received in the heart was reduced in accordance with NCCN NSCLC guideline for organ-specific radiation dose.

Modified inclusion criteria 13 regarding supportive treatment before assessment of adequate organ function from 14 days to 7 days.

Modified exclusion criteria 9 reducing the wash-out time of systemic corticosteroid treatment from 14 days to 7 days.

No patients were included under previous protocol versions; hence these are not commented further.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Table 6: Summary of Important Protocol Deviations-Intent-to-Treat Analysis Set

| Deviation Category Types of Deviations                            | Sugemalimab (N=255)   | Placebo (N=126)   | Total (N=381)   |
|-------------------------------------------------------------------|-----------------------|-------------------|-----------------|
| Number of patients with at least one important protocol deviation | 50 (19.6%)            | 16 (12.7%)        | 66 (17.3%)      |
| Overall total number of important protocol deviations             | 54                    | 22                | 76              |
| Study Conduct/Procedures                                          | 31 (12.2%)            | 9 (7.1%)          | 40 (10.5%)      |
| Screening                                                         | 9 (3.5%)              | 2 (1.6%)          | 11 (2.9%)       |
| Inclusion/Exclusion Criteria                                      | 8 (3.1%)              | 2 (1.6%)          | 10 (2.6%)       |
| Study Restrictions/Withdrawal Criteria                            | 5 (2.0%)              | 3 (2.4%)          | 8 (2.1%)        |
| Sample Processing/Storage                                         | 3 (1.2%)              | 1 (0.8%)          | 4 (1.0%)        |
| StudyAssessment                                                   | 2 (0.8%)              | 2 (1.6%)          | 4 (1.0%)        |
| Dose Formulation/Dose Administration                              | 2 (0.8%)              | 0                 | 2 (0.5%)        |
| Sample Collection                                                 | 2 (0.8%)              | 0                 | 2 (0.5%)        |
| Safety                                                            | 11 (4.3%)             | 5 (4.0%)          | 16 (4.2%)       |
| Reporting/Follow-up                                               | 11 (4.3%)             | 5 (4.0%)          | 16 (4.2%)       |
| Recording                                                         | 1 (0.4%)              | 0                 | 1 (0.3%)        |
| Informed Consent                                                  | 7 (2.7%)              | 3 (2.4%)          | 10 (2.6%)       |
| Presence/Absence                                                  | 6 (2.4%)              | 2 (1.6%)          | 8 (2.1%)        |
| Signature/Date                                                    | 1 (0.4%)              | 0                 | 1 (0.3%)        |
| Version                                                           | 0                     | 1 (0.8%)          | 1 (0.3%)        |
| InvestigationalProduct                                            | 1 (0.4%)              | 2 (1.6%)          | 3 (0.8%)        |
| Handling/Storage/Retention                                        | 1 (0.4%)              | 2 (1.6%)          | 3 (0.8%)        |

Source: Tablet dv ITT 2

A patient was only counted once if experiencing more than one deviation of the same type.

Important protocol deviations due to the COVID-19 pandemic occurred in 2 (0.8%) patients in the sugemalimab group and 1 (0.8%) patient in the placebo group, which were categorized as study conduct/procedures and informed consent.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 7: Demographic and Baseline Characteristics-Intent-to-Treat Analysis Set

|                          | Sugemalimab (N=255)   | Placebo (N=126)   | Total (N=381)   |
|--------------------------|-----------------------|-------------------|-----------------|
| Sex                      |                       |                   |                 |
| Male                     | 236 (92.5%)           | 115 (91.3%)       | 351 (92.1%)     |
| Female                   | 19 (7.5%)             | 11 (8.7%)         | 30 (7.9%)       |
| Age (years)              |                       |                   |                 |
| n1                       | 255                   | 126               | 381             |
| Mean (SD)                | 60.5 (6.62)           | 59.9 (6.72)       | 60.3 (6.65)     |
| Median                   | 61.0                  | 60.0              | 61.0            |
| Min, Max                 | 46, 78                | 42, 73            | 42.78           |
| Age category             |                       |                   |                 |
| <65 years                | 182 (71.4%)           | 94 (74.6%)        | 276 (72.4%)     |
| >=65 years               | 73 (28.6%)            | 32 (25.4%)        | 105 (27.6%)     |
| Race                     |                       |                   |                 |
| Asian                    | 255 (100.0%)          | 126 (100.0%)      | 381 (100.0%)    |
| Height (cm)              |                       |                   |                 |
| n1                       | 252                   | 125               | 377             |
| Mean (SD)                | 166.9 (6.64)          | 166.8 (6.43)      | 166.9 (6.57)    |
| Median                   | 168.0                 | 168.0             | 168.0           |
| Min, Max                 | 143,185               | 150,188           | 143,188         |
| Weight at baseline (kg)  |                       |                   |                 |
| n1                       | 255                   | 126               | 381             |
| Mean (SD)                | 63.8 (10.07)          | 63.7 (9.91)       | 63.8 (10.00)    |
| Median                   | 62.0                  | 63.0              | 62.0            |
| Min, Max                 | 43.98                 | 43,93             | 43.98           |
| BMI at baseline (kg/m^2) |                       |                   |                 |
| n1                       | 252                   | 125               | 377             |
| Mean (SD)                | 22.9 (3.07)           | 22.9 (2.93)       | 22.9 (3.02)     |
| Median                   | 22.7                  | 22.7              | 22.7            |
| Min, Max                 | 15, 32                | 17, 32            | 15, 32          |
| Smoking history          |                       |                   |                 |
| Never                    | 42 (16.5%)            | 16 (12.7%)        | 58 (15.2%)      |
| Former                   | 195 (76.5%)           | 101 (80.2%)       | 296 (77.7%)     |
| Current                  | 18 (7.1%)             | 9 (7.1%)          | 27 (7.1%)       |
| ECOG PS                  |                       |                   |                 |
| 0                        | 78 (30.6%)            | 38 (30.2%)        | 116 (30.4%)     |
| 1                        | 177 (69.4%)           | 88 (69.8%)        | 265 (69.6%)     |
| Prior platinum treatment |                       |                   |                 |
| Cisplatin                | 130 (51.0%)           | 61 (48.4%)        | 191 (50.1%)     |
| Carboplatin              | 82 (32.2%)            | 47 (37.3%)        | 129 (33.9%)     |
| Nedaplatin               | 56 (22.0%)            | 20 (15.9%)        | 76 (19.9%)      |

Source:Table t\\_dm\\_ITT\\_2

Abbreviation: BMI = body mass index; ECOG = eastem cooperative oncology group: PS = performance status: SD = standard deviation.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 8: Baseline Disease Characteristics -Intent-to-Treat Analysis Set

|                                       | Sugemalimab (N=255)   | Placebo (N=126)   | Total (N=381)   |
|---------------------------------------|-----------------------|-------------------|-----------------|
| Time since initial diagnosis (months) |                       |                   |                 |
| n1                                    | 255                   | 126               | 381             |
| Mean (SD)                             | 5.2 (3.85)            | 7.6 (21.79)       | 6.0 (12.94)     |
| Median                                | 4.4                   | 4.6               | 4.5             |
| Min, Max                              | 2,41                  | 2, 219            | 2,219           |
| Stage of non-small cell lung cancer   |                       |                   |                 |
| before chemoradiotherapy              |                       |                   |                 |
| Stage IIIA                            | 74 (29.0%)            | 32 (25.4%)        | 106 (27.8%)     |
| Stage IIIB                            | 146 (57.3%)           | 65 (51.6%)        | 211 (55.4%)     |
| Stage IIIC                            | 33 (12.9%)            | 28 (22.2%)        | 61 (16.0%)      |
| Other                                 | 2 (0.8%)              | 1 (0.8%)          | 3 (0.8%)        |
| Histology type                        |                       |                   |                 |
| Squamous cell carcinoma               | 177 (69.4%)           | 89 (70.6%)        | 266 (69.8%)     |
| Non-squamous cell carcinoma           | 76 (29.8%)            | 37 (29.4%)        | 113 (29.7%)     |
| Missing                               | 2 (0.8%)              | 0                 | 2 (0.5%)        |
| Chemoradiotherapy type                |                       |                   |                 |
| Sequential chemoradiotherapy          | 86 (33.7%)            | 41 (32.5%)        | 127 (33.3%)     |
| Concurrent chemoradiothéerapy         | 169 (66.3%)           | 85 (67.5%)        | 254 (66.7%)     |
| Best response to chemoratdiotherapy   |                       |                   |                 |
| CR                                    | 4 (1.6%)              | 2 (1.6%)          | 6 (1.6%)        |
| PR                                    | 172 (67.5%)           | 77 (61.1%)        | 249 (65.4%)     |
| SD*                                   | 79 (31.0%)            | 47 (37.3%)        | 126 (33.1%)     |

Source: Table t dm dx ITT 2

Abbreviation: CR = complete response; PD = disease progression; PR = partial response:

SD* = stable disease: SD = standard deviation.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 9: Prior Treatment History of Non-small Cell Lung Cancer -Intent-to-Treat Analysis Set

|                                                                                   | Sugemalimab (N=255)                                                               | Placebo (N=126)                                                                   |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Duration of chemotherapy in prior chemoradiotherapy (months)                      | Duration of chemotherapy in prior chemoradiotherapy (months)                      | Duration of chemotherapy in prior chemoradiotherapy (months)                      |
| nn                                                                                | 255                                                                               | 126                                                                               |
| Mean (SD)                                                                         | 2.0 (1.20)                                                                        | 2.0 (1.20)                                                                        |
| Median                                                                            | 1.5                                                                               | 1.5                                                                               |
| Min, Max                                                                          | 0,13                                                                              | 1,8                                                                               |
| Whether induction chemotherapy was received in prior concurrent chemoradiotherapy | Whether induction chemotherapy was received in prior concurrent chemoradiotherapy | Whether induction chemotherapy was received in prior concurrent chemoradiotherapy |
| Yes                                                                               | 103 (40.4%)                                                                       | 60 (47.6%)                                                                        |
| No                                                                                | 66 (25.9%)                                                                        | 25 (19.8%)                                                                        |
| Duration of induction chemotherapy in prior concurrent chemoradiotherapy (months) | Duration of induction chemotherapy in prior concurrent chemoradiotherapy (months) | Duration of induction chemotherapy in prior concurrent chemoradiotherapy (months) |
| n                                                                                 | 103                                                                               | 60                                                                                |
| Mean (SD)                                                                         | 1.5 (1.30)                                                                        | 1.8 (1.24)                                                                        |
| Median                                                                            | 1.3                                                                               | 1.5                                                                               |
| Min, Max                                                                          | 0,12                                                                              | 0.6                                                                               |
| Anatomic sites receiving rarliotherapy in prior chemoradiotherapy                 | Anatomic sites receiving rarliotherapy in prior chemoradiotherapy                 | Anatomic sites receiving rarliotherapy in prior chemoradiotherapy                 |
| Lung                                                                              | 246 (96.5%)                                                                       | 124 (98.4%)                                                                       |
| Regional lymph node                                                               | 113 (44.3%)                                                                       | 50 (39.7%)                                                                        |
| Distant lymph nodes                                                               | 1 (0.4%)                                                                          | 0                                                                                 |
| Trachea                                                                           | 1 (0.4%)                                                                          | 0                                                                                 |
| Other                                                                             | 2 (0.8%)                                                                          | 2 (1.6%)                                                                          |
| Cumulative total dose of radiotherapy received in prior chemoradiotherapy (Gy)    | Cumulative total dose of radiotherapy received in prior chemoradiotherapy (Gy)    | Cumulative total dose of radiotherapy received in prior chemoradiotherapy (Gy)    |
| Dose<60                                                                           | 43 (16.9%)                                                                        | 21 (16.7%)                                                                        |
| Dose≥60                                                                           | 212 (83.1%)                                                                       | 105 (83.3%)                                                                       |
| Prior anti-tumour drug therapy other than chemoradiotherapy                       | Prior anti-tumour drug therapy other than chemoradiotherapy                       | Prior anti-tumour drug therapy other than chemoradiotherapy                       |
| Yes                                                                               | 22 (8.6%)                                                                         | 6 (4.8%)                                                                          |
| No                                                                                | 233 (91.4%)                                                                       | 120 (95.2%)                                                                       |
| Other prior radiotherapy other than chemoradiotherapy                             | Other prior radiotherapy other than chemoradiotherapy                             | Other prior radiotherapy other than chemoradiotherapy                             |
| Yes                                                                               | 0                                                                                 | 0                                                                                 |
| No                                                                                | 255 (100.0%)                                                                      | 126 (100.0%)                                                                      |
| Prior cancer-related surgery                                                      | Prior cancer-related surgery                                                      | Prior cancer-related surgery                                                      |
| Yes                                                                               | 13 (5.1%)                                                                         | 6 (4.8%)                                                                          |
| No                                                                                | 242 (94.9%)                                                                       | 120 (95.2%)                                                                       |

Source: Table t\\_pr\\_pchemrad\\_ITT\\_2

Abbreviation: SD = standard deviation.

Table 10: Frequency of PD-L1 results -Intent-to-Treat Analysis Set

|             | Sugemalimab (N=255)   | Placebo (N=126)   | Total (N=381)   |
|-------------|-----------------------|-------------------|-----------------|
| PD-L1 (TC%) |                       |                   |                 |
| < 1%        | 51 ( 20.0%)           | 29 ( 23.0%)       | 80 ( 21.0%)     |
| >= 1%       | 72 ( 28.2%)           | 23 ( 18.3%)       | 95 ( 24.9%)     |
| Not tested  | 132 ( 51.8%)          | 74 ( 58.7%)       | 206 ( 54.1%)    |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Information on other actionable mutations is not available because these were not tested.

## Numbers analysed

Table 11: Summary of Analysis Sets

|                                         |   Sugemalimab |   Placebo |   Total |
|-----------------------------------------|---------------|-----------|---------|
| Intent-to-Treat Analysis Set (ITT)      |           255 |       126 |     381 |
| Safety Analysis Set (SAS)               |           255 |       126 |     381 |
| Pharmacokinetic Analysis Set (PKAS)     |           252 |         0 |     252 |
| Anti-drug Antibody Analysis Set (ADAAS) |           255 |         0 |     255 |

Intent-to-treat analysis set consisted of all patients who were randomised.

Safety analysis set consisted of all patients who received at least one dose of study drug, and patients would be assigned as treated.

Pharmacokinetic analysis set consisted of all patients who received at least one dose of study drug and had at least one post-baseline pharmacokinetic assessment.

Anti-drug antibody analysis set consisted of all patients who received at least one dose of study drug and had at least one post-baseline anti-drug antibody assessment.

## Outcomes and estimation

As of the data cutoff date (03 April 2023) for the OS interim analysis, the median follow-up time (range) was 40.4 (0.23+ -53.26) months in the sugemalimab group and 35.4 (2.40+-51.19) months in the placebo group.

## Primary endpoint, Progression Free Survival

The alpha-protected final PFS was reported for the final PFS analysis (DCO 01 March 2022) and also for the OS interim analysis (DCO 03 April 2023).

As of the data cutoff date for PFS final analysis, 154 (60.4%) PFS events (129 disease progression and 25 deaths) had occurred in the sugemalimab group and 90 (71.4%) PFS events (85 disease progression and 5 deaths) had occurred in the placebo group. The median PFS assessed by BICR in the sugemalimab group was 10.5 (95% CI: 8.3, 17.1) versus 6.2 months (95% CI: 4.2, 8.1) in the  placebo  group. The stratified  HR was 0.65 (95% CI: 0.50, 0.84) and a two-sided stratified logrank test p=0.0012). The final PFS analysis was also multiplicity controlled, and the result was statistically significant.

Table 12: Summary of Progression-free Survival by BICR - Intent-to-Treat Analysis Set (DCO 01 March 2022, PFS final analysis)

|                                    | Sugemalimab (N=255)   | Placebo (N=126)   |
|------------------------------------|-----------------------|-------------------|
| Participants with event            | 154 (60.4%)           | 90 (71.4%)        |
| Progressive disease                | 129                   | 85                |
| Death                              | 25                    | 5                 |
| Participants censored              | 101 (39.6%)           | 36 (28.6%)        |
| Progression-free survival (months) |                       |                   |
| Median                             | 10.51                 | 6.21              |
| 95% CI                             | (8.25, 17.12)         | (4.21, 8.08)      |
| 25% and 75% percentiles            | 4.01, -               | 2.33, 20.04       |

<div style=\"page-break-after: always\"></div>

|                                | Sugemalimab (N=255)               | Placebo (N=126)                   |
|--------------------------------|-----------------------------------|-----------------------------------|
| Range                          | 0.03 + to 38.24 +                 | 0.03 + to 35.25                   |
| Stratified analysis *          |                                   |                                   |
| 2-sided p-value (log-rank)     | 0.0012                            | 0.0012                            |
| Hazard ratio                   | 0.65                              | 0.65                              |
| 95% CI                         | (0.50, 0.84)                      | (0.50, 0.84)                      |
| Unstratified analysis          |                                   |                                   |
| 2-sided p-value (log-rank)     | 0.0014                            | 0.0014                            |
| Hazard ratio                   | 0.65                              | 0.65                              |
| 95% CI                         | (0.50, 0.85)                      | (0.50, 0.85)                      |
| Progression-free survival rate |                                   |                                   |
| 6 months                       | 67.0%                             | 52.4%                             |
| 95% CI                         | (60.84%, 72.46%) (43.29%, 60.80%) | (60.84%, 72.46%) (43.29%, 60.80%) |
| Difference                     | 14.6%                             | 14.6%                             |
| 95% CI                         | (4.04%, 25.14%)                   | (4.04%, 25.14%)                   |
| 12 months                      | 49.5%                             | 32.3%                             |
| 95% CI                         | (43.09%, 55.59%) (24.11%, 40.84%) | (43.09%, 55.59%) (24.11%, 40.84%) |
| Difference                     | 17.2%                             | 17.2%                             |
| 95% CI                         | (6.64%, 27.67%)                   | (6.64%, 27.67%)                   |
| 18 months                      | 41.4%                             | 26.4%                             |
| 95% CI                         | (34.94%, 47.81%) (18.41%, 35.03%) | (34.94%, 47.81%) (18.41%, 35.03%) |
| Difference                     | 15.1%                             | 15.1%                             |
| 24 months                      | 38.6%                             | 23.1%                             |
| 95% CI                         | (32.04%, 45.16%) (14.34%, 33.07%) | (32.04%, 45.16%) (14.34%, 33.07%) |
| Difference                     | 15.5%                             | 15.5%                             |
| 95% CI                         | (3.96%, 27.12%)                   | (3.96%, 27.12%)                   |
| 30 months                      | 30.7%                             | 15.4%                             |
| 95% CI                         | (23.55%, 38.02%) (4.84%, 31.45%)  | (23.55%, 38.02%) (4.84%, 31.45%)  |
| Difference                     | 15.3%                             | 15.3%                             |
| 95% CI                         | (-0.39%, 30.92%)                  | 0                                 |
| 95% CI                         | 34.87%)                           | (-, -)                            |
| 36 months                      | 26.1%                             |                                   |
|                                | (18.02%,                          |                                   |
| Difference                     | 26.1%                             | 26.1%                             |
| 95% CI                         | (-, -)                            | (-, -)                            |

DCO2 date: 01 March 2022

Abbreviations: BICR = blinded independent central review; CI = confidence interval.

Summaries of progression-free survival (median, percentiles) were Kaplan-Meier estimates.

Confidence interval for the median was computed using the method of Brookmeyer and Crowley.

Confidence interval for event-free rate was computed using the Greenwood method.

Confidence interval for difference in rates was computed based on normal approximation with pooled standard error.

Hazard ratios were estimated by Cox regression.

+  was for the minimum or maximum value from censored participants.

*  The stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy from IxRS (Interactive Voice/Web Response System).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 13: Reasons for censoring of PFS - Intent-to-Treat Analysis Set (DCO 01March 2022, PFS final analysis)

|                                      | Sugemalimab (N=255)   | Placebo (N=126)   |
|--------------------------------------|-----------------------|-------------------|
| Patients Censored                    | 101 (39.6%)           | 36 (28.6%)        |
| Alive without documented progression | 99 (38.8%)            | 35 (27.8%)        |
| No post-baseline assessment          | 0                     | 1 (0.8%)          |
| Withdrawal by subject                | 2 (0.8%)              | 0                 |

Figure 9: Kaplan-Meier Curve of Progression-free Survival (PFS) by BICR - Intent-toTreat Analysis Set (DCO 01March 2022, PFS final analysis)

<!-- image -->

DCO2 date: 01 March 2022

Abbreviation: BICR = blinded independent central review; CI = confidence interval.

Medians were Kaplan-Meier estimates. Confidence interval for the median was computed using the method of Brookmeyer and Crowley.

Hazard ratio was estimated by stratified Cox regression model with stratification factors from IxRS (Interactive Voice/Web Response System).

P-value was from stratified log rank test with stratification factors from IxRS.

The stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 14: Summary of Progression-free Survival by BICR (descriptive PFS analysis Intent-to-Treat Analysis Set (DCO 03 April 2023, OS interim analysis)

|                                    | Sugemalimab (N=255)   | Placebo (N=126)   |
|------------------------------------|-----------------------|-------------------|
| Patients with event                | 169 (66.3%)           | 90 (71.4%)        |
| Progressive disease                | 137                   | 85                |
| Death                              | 32                    | 5                 |
| Patients censored                  | 86 (33.7%)            | 36 (28.6%)        |
| Progression-free survival (months) |                       |                   |
| Median                             | 10.55                 | 6.24              |
| 95% CI                             | (8.35, 16.82)         | (4.24, 8.31)      |
| 25% and 75% percentiles            | 4.01, -               | 2.66, 27.66       |
| Range                              | 0.03 + to 50.17 +     | 0.03 + to 43.76 + |
| Stratified analysis *              |                       |                   |
| 2-sided p-value (log-rank) a       | 0.0175                |                   |
| Hazard ratio                       | 0.73                  |                   |
| 95% CI                             | (0.56, 0.95)          |                   |

Abbreviation: BICR = blinded independent central review; CI = confidence interval. Summaries of progression-free survival (median, percentiles) were Kaplan-Meier estimates.

Hazard ratios were estimated by Cox regression.

+  was for the minimum or maximum value from censored patients.

*  The stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy from IxRS (Interactive Voice/Web Response System). a)  Descriptive p-value.

Table 15: Reasons for censoring of PFS - Intent-to-Treat Analysis Set (DCO 03 April 2023, OS interim analysis)

|                                      | Sugemalimab (N=255)   | Placebo (N=126)   |
|--------------------------------------|-----------------------|-------------------|
| Patients Censored                    | 86 (33.7%)            | 36 (28.6%)        |
| Alive without documented progression | 83 (32.5%)            | 35 (27.8%)        |
| No post-baseline assessment          | 0                     | 1 (0.8%)          |
| Withdrawal by subject                | 2 (0.8%)              | 0                 |
| Lost to follow-up                    | 1 (0.4%)              | 0                 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 10: Kaplan-Meier Curve of Progression-free Survival (PFS) by BICR - Intent-toTreat Analysis Set (DCO 03 April 2023, OS interim analysis)

<!-- image -->

Abbreviation: BICR = blinded independent central review; CI = confidence interval.

Medians were Kaplan-Meier estimates. Confidence interval for the median was computed using the method of Brookmeyer and Crowley. Hazard ratio was estimated by stratified Cox regression model with stratification factors from IxRS (Interactive Voice/Web Response System).  P-value was from stratified log rank, test with stratification factors from IxRS, descriptive.

The stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy.

## Secondary endpoints

## Overall survival

OS did not reach statistical significance at the OS interim analysis.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 16: Summary of  Overall Survival - Intent-to-Treat  Analysis Set  (DCO 03 April 2023, OS interim analysis)

|                                                 | Sugemalimab (N=255)               | Placebo (N=126)        |
|-------------------------------------------------|-----------------------------------|------------------------|
| Patients with event                             | 114 (44.7%)                       | 66 (52.4%)             |
| Death                                           | 114                               | 66                     |
| Patients censored                               |                                   | 60 (47.6%)             |
| Overall survival (months)                       | 141 (55.3%)                       |                        |
| Median 95% CI 25% and 75% percentiles           | 47.38 (34.33. -)                  | 32.39 (24.12. -)       |
| Range                                           | 19.19, -                          | 14.95, 50.79           |
|                                                 | 0.23 to 53.26+                    | 2.40 to 51.19+         |
| Hazard ratio 95% CI                             |                                   |                        |
| Stratified analysis* 2-sided p-value (log-rank) | 0.78                              |                        |
|                                                 | 0.1036                            |                        |
| Unstratified analysis                           | (0.57, 1.05)                      |                        |
|                                                 | 0.0872                            |                        |
| 2-sided p-value (log-rank) Hazard ratio         | 0.77 (0.57, 1.04)                 |                        |
| 95% CI                                          |                                   |                        |
| Overall survival rate 6 months                  |                                   | 96.0% (90.70%, 98.32%) |
| 95% CI Difference                               | 96.0% (92.78%, 97.86%) 0.0%       | 83.2% (75.39%, 88.70%) |
| 95% CI 12months I%56 Difference                 | (-4.15%, 4.21%) 86.1%             |                        |
| 95% CI                                          | (81.15%, 89.80%) 2.9%             |                        |
|                                                 | (-4.94%, 10.73%)                  | 68.6%                  |
| 18 months 95% CI                                | 76.4%                             | (59.64%, 75.98%)       |
| Difference 95% CI                               | 7.8% (-1.89%, 17.54%)             |                        |
|                                                 | (70.66%, 81.21%)                  | 60.4%                  |
| 24 months                                       | 67.9%                             | (51.25%, 68.43%)       |
| 95% CI Difference 95% CI                        | 7.4%                              |                        |
|                                                 | (61.67%, 73.28%) (-2.97%, 17.82%) |                        |
| 30 months 95% CI                                | 59.8%                             | 53.5%                  |
| Difference                                      | (53.36%, 65.64%)                  | (44.27%, 61.93%)       |
| 95% CI                                          | 6.3% (-4.53%, 17.07%)             |                        |
| 36 months                                       | 56.0%                             | 43.2%                  |
| 95% CI                                          | (49.41%, 62.12%)                  |                        |
| Difference 95% CI                               | 12.8% (1.24%, 24.43%)             | (33.40%, 52.59%)       |
| 42 months                                       |                                   |                        |
| 95% CI                                          | 52.5% (45.54%, 58.90%)            | 43.2%                  |
| Difference                                      | 9.3%                              | (33.40%, 52.59%)       |
| 95% CI                                          | (-2.52%, 21.04%)                  |                        |
|                                                 | 47.8%                             | 43.2%                  |
| 48 months 95% CI                                |                                   |                        |
|                                                 | (39.48%, 55.61%)                  | (33.40%, 52.59%)       |
| Difference                                      | 4.6%                              |                        |
| 95% CI                                          |                                   |                        |
|                                                 | (-8.05%, 17.23%)                  |                        |

Table 17: Reasons for censoring of OS - Intent-to-Treat Analysis Set (DCO 03 April 2023, OS interim analysis)

|                           | Sugemalimab (N=255)   | Placebo (N=126)   |
|---------------------------|-----------------------|-------------------|
| Alive                     | 130 (51.0%)           | 57 (45.2%)        |
| Death date not available* | 2 (0.8%)              | 0                 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Withdrawal by subject   | 3 (1.2%)   | 0        |
|-------------------------|------------|----------|
| Lost to follow-up       | 6 (2.4%)   | 3 (2.4%) |

Figure 11: Kaplan-Meier Curve of Overall Survival  - Intent-to-Treat Analysis Set (DCO 03 April 2023, OS interim analysis)

<!-- image -->

Abbreviation: CI = confidence interval.

Medians were Kaplan-Meier estimates. Confidence interval for the median was computed using the method of Brookmeyer and Crowley. Hazard ratio was estimated by stratified Cox regression model with stratification factors from IxRS (Interactive Voice/Web Response System).  P-value was from stratified log rank test with stratification factors from IxRS.

## Post-progression anti-cancer treatment

137 (53.7%) of patients treated with sugemalimab and 85 (67.5%) of patients treated with placebo received follow-up anti-cancer treatment. Platinum compounds and taxanes were used to treat 69 (27.1%) and 69 (27.1%) patients previously treated with sugemalimab and 47 (37.3%) and 44 (34.9%) patients previously treated with placebo. More patients previously treated with placebo received PD-1/PD-L1 inhibitor as follow-up anti-cancer treatment, 52 (41.3%) compared to 30 (11.8%) patients from the sugemalimab group. Several different PD-1/PD-L1 inhibitors were used, most common was sintilimab.

## Progression free survival by INV

At the OS interim analysis (03 April 2023), 182 (71.4%) PFS events (170  disease  progression  and 12  deaths)  h a d   occurred  in  the  sugemalimab  group  and  103  (81.7%) PFS events (100 disease progression and 3 deaths) had occurred in the placebo group. The median PFS assessed by Investigator was 10.4 months (95% CI: 8.3, 12.8) in the  sugemalimab group and 7.1 months (95% CI: 5.3, 8.3) in the placebo group, with a stratified HR 0.70 (95% CI: 0.55, 0.90) and a nominal two-sided stratified log-rank test P = 0.0053.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 18: Concordance Analysis between the BICR Determined and the Investigator Determined PD Status - Intent-to-Treat Analysis Set (DCO 03 April 2023, OS interim analysis)

|                                                                         | CS1001 (N=255)   | CS1001 (N=255)   | Placebo (N=126)   | Placebo (N=126)   |
|-------------------------------------------------------------------------|------------------|------------------|-------------------|-------------------|
| Patients included in the analysis*                                      | 243              |                  | 123               |                   |
| PD occurrence                                                           |                  |                  |                   |                   |
| Concordance                                                             |                  | 180(74.18)       |                   | 98(79.78)         |
| PD per BICR and PD per investigator                                     | 121              | (49.88)          | 80                | (65.08)           |
| No PD per BICR and no PD per investigator                               | 59               | (24.38)          | 18                | (14.68)           |
| Discordance                                                             | 63               | (25.98)          |                   | 25(20.38)         |
| PD per BICR and no PD per investigator                                  | 15               | ( 6.2$)          | 5                 | (4.1$)            |
| No PD per BICR and PD per investigator                                  |                  | 48(19.88)        |                   | 20(16.38)         |
| PD occurrence and timing of PD                                          |                  |                  |                   |                   |
| Concordance                                                             |                  | 146 ( 60.18)     |                   | 80(65.08)         |
| PD per BICR and PD per investigator, dates within 10 weeks              | 87               | (35.88)          |                   | 62(50.48)         |
| No PD per BICR and no PD per investigator                               | 59               | (24.38)          |                   | 18(14.68)         |
| Discordance                                                             | 97               | (39.98)          |                   | 43(35.08)         |
| PD per BICR and no PD per investigator                                  | 15               | 6.2$)            | 5                 | ( 4.1$)           |
| No PD per BIcR and PD per investigator                                  | 48               | (19.88)          | 20                | (16.38)           |
| a 1  '1a 1      Weeks                                                   |                  | 34(14.08)        |                   | 18(14.68)         |
| Differences in timing between BICR and investigator PD dates > 10 weeks |                  |                  |                   |                   |
| BICR PD earlier than investigator PD                                    |                  | 30(12.38)        |                   | 15 (12.28)        |
| 10to 20 weeks                                                           | 13               | ( 5.3$)          | 9                 | ( 7.3$)           |
| 20 to 30 weeks                                                          | 7                | ( 2.98)          |                   | (2.4$)            |
| > 30 weeks                                                              | 10（              | 4.1$)            |                   | 3(2.48)           |

Abbreviation: BICR = blinded independent central review; PD = progressive disease.

* was defined as patients evaluable for concordance, which was intent-to-treat analysis set with at least one post-baseline tumor assessments available.

Percentages were based on the number of patients included in the analysis.

## Overall response rate

The ORR analysis set was all randomised patients with measurable disease at baseline.

The sugemalimab group and the placebo group had 204 and 101 patients, respectively, who were included in the ORR analysis set. A total of 51 patients in the sugemalimab group and 25 patients in the placebo group were not included in the ORR analysis set, as they did not have measurable lesions at baseline according to the BICR assessment.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 19: Overall Response Assessed by BICR  - Intent-to-Treat Analysis Set with Measurable Disease at Baseline (03 April 2023, OS interim analysis)

|                                                              | Sugemalimab (N=204)         | Placebo (N=101)             |
|--------------------------------------------------------------|-----------------------------|-----------------------------|
| Objective response rate (CR+PR) 95% CI                       | 50 (24.5%) (18.77%, 31.00%) | 25 (24.8%) (16.70%, 34.33%) |
| Rate difference (sugemalimab-Placebo) 95% CI 2-sided P-value | -0.2% (-10.52%, 10.04%)     | -0.2% (-10.52%, 10.04%)     |
| Best overall response                                        |                             |                             |
| Complete response (CR) 95% CI                                | 1 (0.5%) (0.01%, 2.70%)     | 1 (1.0%) (0.03%, 5.39%)     |
| Partial response (PR) 95% CI                                 | 49 (24.0%) (18.33%, 30.48%) | 24 (23.8%) (15.86%, 33.26%) |
| Stable disease (SD)                                          | 104 (51.0%)                 | 48 (47.5%)                  |
| 95% CI                                                       | (43.90%, 58.03%)            | (37.49%, 57.70%)            |
| Disease progression (PD) 95% CI                              | 43 (21.1%) (15.69%, 27.32%) | 26 (25.7%) (17.56%, 35.40%) |
|                                                              |                             | 0                           |
| Not evaluable                                                | 0                           |                             |
| Not applicable                                               | 7 (3.4%)                    | 2 (2.0%)                    |

Source: Table t\\_ef\\_bor\\_bicr\\_ITT\\_m2\\_2

Abbreviation: BICR = blinded independent central review; CI = confidence interval.

Best overall response was defined as the best response during the period between the first dose and the first documented PD, death, or date of subsequent therapy, whichever occurs first.

*Patients were classified as not applicable if no post-baseline response assessments were available.

Confidence interval for rate was calculated using Clopper-Pearson method.

Confidence interval for rate difference was calculated using the normal approximation of binomial distribution.

P-value was calculated using stratified Mantel-Haenszel method with stratification factors from IxRS (Interactive Voice/Web Response System).

The stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy.

The median DoR assessed by BICR was 24.1 months (95% CI: 11.6, not reached) and 8.4 months (95% CI: 4.2, not reached) in the sugemalimab group and placebo group, respectively.

## Time to death/distant metastasis

As of the data cutoff date for the OS interim analysis (03 April 2023), the sugemalimab group experienced 173 (67.8%) TTDM events, comprising 111 distant metastases and 62 deaths. In contrast, the placebo group had 92 (73.0%) TTDM events, consisting of 59 distant metastases and 33 deaths. The median TTDM, as assessed by BICR, was found to be 15.2 months (95% CI: 10.3, 19.1) in the sugemalimab group and 10.5 months (95% CI: 7.1, 17.0) in the placebo group. A stratified analysis yielded a hazard ratio of 0.83 (95% CI: 0.64, 1.07) for the sugemalimab group compared to the placebo group.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analysis PFS

## Figure 12: Forest Plot of Hazard Ratio of Progression-free Survival Assessed by BICRIntent-to-Treat Analysis Set (DCO 01 March 2022, PFS final analysis)

<!-- image -->

| Subgroups                   | CS1001 (N=255) event/n Median   | event/n Median                | Placebo (N=126)               |        | Hazard Ratio (95% CI)          |                       | CS1001 Better         | Placebo Better   |                |
|-----------------------------|---------------------------------|-------------------------------|-------------------------------|--------|--------------------------------|-----------------------|-----------------------|------------------|----------------|
| All patients                | 154/255 10.51                   |                               | 90/126                        | 6.21   |                                | 0.65 (0.50,0.84)      |                       |                  |                |
| Sex                         |                                 |                               |                               |        |                                |                       |                       |                  |                |
| M=l=                        | 142/236 12.91                   |                               | 81/115                        | 6.21   | 0.64                           | (0 .49,               | 0.84)                 |                  |                |
| Female                      | 12/ 19 6.47                     |                               | 9/ 11                         | 7.13   | 0.91                           | (0.38,                | 2.17)                 |                  |                |
| Age                         |                                 |                               |                               |        |                                |                       |                       |                  |                |
| <65 years                   | 108/182 12.88                   |                               | 64/ 94                        | 7.13   | 0.72                           | (0.53，                | 0.99)                 |                  |                |
| >=65 years                  | 46/7310.51                      |                               | 26/ 32                        | 4.07   | 0.47                           | (0.29,                | 0.78)                 |                  |                |
| Smoking history             |                                 |                               |                               |        |                                |                       |                       |                  |                |
|                             | 22/4214.13                      |                               | 13/ 16                        | 5.75   | 0.45                           | (0.22,0.90)           |                       |                  |                |
| Former or current           | 132/213 10.45                   |                               | 77/110                        | 6.24   | 0.70                           | (0.53,                | 0.93)                 |                  |                |
| ECOG PS                     |                                 |                               |                               |        |                                |                       |                       |                  |                |
| 0                           | 40/78 24.51                     |                               | 28/ 38                        | 8.08   | 0.43                           | (0.26,                | 0 . 70)               |                  |                |
| 1                           | 114/177 8.35                    |                               | 62/ 88                        | 6.11   | 0.76                           | (0.56,                | 1. 04)                |                  |                |
| Cancer stage before         |                                 |                               |                               |        |                                |                       |                       |                  |                |
| chemoradiotherapy           |                                 |                               |                               |        |                                |                       |                       |                  |                |
| Stage IIIA                  | 41/ 7413.14                     |                               | 20/ 32                        | 6.21   | 0.79                           | (0.46,                | 1.35)                 |                  |                |
| g111 =549                   | 92/146 10.48                    |                               | 50/ 65                        | 6.21   | 0.57                           | (0.40,                | 0 . 81)               |                  |                |
| DIII =54g                   | 21/ 33 8.38                     |                               | 20/ 28                        | 5.39   | 0.73                           | (0.39,                | 1. 36)                |                  |                |
| Unknown                     | 0/ 2 一                          |                               | 0/                            |        | （-，                            | -)                    |                       |                  |                |
|                             |                                 |                               |                               | 1      |                                |                       |                       |                  |                |
|                             |                                 |                               |                               |        |                                |                       | 0.1                   | 1                | cr             |
| Subgroups                   | CS1001 (N=255) event/n Median   | CS1001 (N=255) event/n Median | CS1001 (N=255) event/n Median |        | Placebo (N=126) event/n Median | Hazard Ratio (95% CI) | Hazard Ratio (95% CI) | Better           | Placebo Better |
| Histology ad                |                                 |                               |                               |        |                                |                       |                       |                  |                |
| Squamous cell carcinoma     |                                 | 115/177                       | 8.38                          | 67/ 89 | 4.27                           | 0.63                  | (0.47，0.86)           |                  |                |
| Non-squamous cell carcinoma |                                 | 37/ 76 24.51                  |                               | 23/ 37 | 9.92                           | 0.65                  | (0.38,1.10)           |                  |                |
| Missing                     |                                 | 2/ 2                          | 3.02                          | 0/     | 0                              | (-,                   | -)                    |                  |                |
| Chemoradiotherapy type      |                                 |                               |                               |        |                                |                       |                       |                  |                |
| Sequential                  |                                 | 63/86                         | 8.08                          | 38/ 41 | 4.07                           |                       | 0.56(0.37,0.85)       |                  |                |
| Concurrent                  |                                 | 91/169 15.67                  |                               | 52/ 85 | 8.31                           | 0.70                  | (0.50,0.99)           |                  |                |
| Radiotherapy dose           |                                 |                               |                               |        |                                |                       |                       |                  |                |
| <60Gv                       |                                 | 25/ 43 15.80                  |                               | 17/21  | 4.27                           | 0.49                  | (0.26,0.92)           |                  |                |
| >=60GV                      |                                 | 129/212 10.48                 |                               | 73/105 | 6.24                           | 0.69                  | (0.52,0.93)           |                  |                |
| Best response to prior CRT  |                                 |                               |                               |        |                                |                       |                       |                  |                |
| Complete response           |                                 | 3/4                           | 5.82                          | 1/     | 2                              | -（-，                  | -)                    |                  |                |
| Partial response            |                                 | 104/172                       | 10.51                         | 51/    | 77 8.02                        | 0.73                  | (0.52,1.03)           |                  |                |
| Stable disease              |                                 |                               | 47/ 79 13.54                  | 38/ 47 | 4.24                           | 0.50                  | (0.32,0.77)           |                  |                |
| Non-CR/non-PD               | 0/                              |                               | 0 一                           | 0/     | 0                              |                       | )                     |                  |                |
|                             |                                 |                               |                               |        |                                |                       | 0.1                   | 0.5 1            | 3 5            |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Subgroups                                                  | CS1001 (N=255)   | event/n Median   | Placebo (N=126)   |       | event/n Median   | Hazard Ratio (95% CI)   |       |
|------------------------------------------------------------|------------------|------------------|-------------------|-------|------------------|-------------------------|-------|
| PD-L1(TC+)                                                 |                  |                  |                   |       |                  |                         |       |
| <1#                                                        | 30/ 51           | 8.38             | 20/ 29            | 8.38  | 0.93             | (0.52,                  | 1.63) |
| >= 1                                                       | 42/ 72           | 10.55            | 13/ 23            | 10.38 | 0.96             | (0.51,                  | 1.79) |
| Missinq                                                    | 82/132           | 13.14            | 57/ L             | 4.17  | 0.52             | (0.37，                  | 0.73) |
| PD-L1(IC)                                                  |                  |                  | 9/                |       |                  |                         |       |
| <10#                                                       | 30/ 53           | 13.54            | 15                | 10.51 | 0.85             | 0*0)                    | 1.80) |
| >= 10                                                      | 40/ 65           | 8.25             | 20/ 32            | 9.92  | 1.03             | (0.60,                  | 1.76) |
| Missing                                                    | 84/137           | 13.54            | 61/ 79            | 4.21  | 0.52             | (0 .37。                 | 0.73} |
| Tumor mutation burden                                      |                  |                  | 23/               |       |                  |                         |       |
| <10_mut/Mb                                                 | 45/ 71           | 8.51             | 32                | 5.03  | 0. 69            | (0.42,                  | 1.16) |
| >=10 mut/Mb                                                | 64/ 99           | 8.97             | 34/ 45            | 4.27  | 0.65             | (0 .42,                 | 0.98) |
| Missing                                                    | 45/ 85           | 15.67            | 33/ 49            | 6.37  | 0. 60            | (0.38,                  | 0.95) |
| Prior platinum treatment                                   |                  |                  | 43/               |       |                  |                         |       |
| Cisplatin                                                  | 77/130           | 12.88            | 61                | 8.08  | 0.71             | (0.49,                  | 1.03) |
| Carboplatin                                                | 51/ 82           | 10.55            | 33/ Lb            | 6.11  | 0. 67            | (0 .43,                 | 1.05) |
| Nedaplatin                                                 | 36/ 56           | 8.97             | 16/ 20            | 4.11  | 0. 45            | (0.25,                  | (88*0 |
| Time from completion of chemoradiotherapy to randomisation |                  |                  |                   |       |                  |                         |       |
| <=14 days                                                  | 26/4714.19       |                  | 13/24             | 9.92  | 0.88             | *s*0)                   | 1.72) |
| >14 days                                                   | 128/208          | 10.51            | 77/102            | 4.80  | 0 . 62           | *9*0)                   | 28*0  |
| Time from completion of chemoradiotherapy to               |                  |                  |                   |       |                  |                         |       |
| randomization <=25day=                                     | 67/121           | 14.19            | 52/77             | 8.0B  | 0 .69            | (0.48,                  | 0.99) |
| >25 days                                                   | 87/134 10.48     |                  | 38/49             | 4.21  | 0.58             | (0.39，                  | 0.86) |

<!-- image -->

Source: Figure f\\_ef\\_pfs\\_bicr\\_sub\\_ITT\\_1

eastern cooperative oncology group;PD =disease progression;PD-L1 =programmed death ligand-1; PS =performance status.

Hazard ratio and 95% CI were calculated using unstratified univariate Cox regression,except for the analysis for all patients which used stratified Cox regression with the stratification factors from theIxRS (Interactive Voice/Web Response System),the stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy.

Medians wereKaplan-Meier estimates.

For subgroup analysis, ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy from EDC (Electronic Data Capture). If total event number&lt;10within one subgroup,hazardratio(95%CI)is not displayed.

receiving more than one type of platinum.

## Subgroup analysis OS

Figure 13: Forest Plot of Hazard Ratio of Overall Survival- Intent-to-Treat Analysis Set(03 April 2023, OS interim analysis)

| Subgroups                             | CS1001 (N=255) event/n Median   | Placebo (N=126) event/n Median   | Hazard Ratio (95% CI)   |
|---------------------------------------|---------------------------------|----------------------------------|-------------------------|
| All patients                          | 114/255 47.38                   | 66/126 32.39                     | 0.78 (0.57,1.05)        |
| Sex                                   |                                 |                                  |                         |
| Male                                  | 109/236 43.37                   | 61/115 32.30                     | 0.79 (0.57,1.08)        |
| Female                                | 5/ 19                           | 5/ 11 33.12                      | 0.51 (0.14, 1.77)       |
| Age                                   |                                 |                                  |                         |
| <65 years                             | 75/182                          | 48/ 94β3.12                      | 0.72 (0.50,1.04)        |
| >=65 years                            | 39/ 73 28.06                    | 18/ 32 31.84                     | 0.86 (0.49,1.50)        |
| Smoking history                       |                                 |                                  |                         |
| Never                                 | 10/42 一                         | 8/ 16 31.84                      | 0.37 (0.14, 0.94)       |
| Former or current                     | 104/213 39.82                   | 58/110 32.39                     | 0.86 (0.63,1.19)        |
| ECOG PS                               |                                 |                                  |                         |
| 0                                     | 31/78                           | 19/ 38 32.30                     | 0.64 (0.36,1.13)        |
| 1                                     | 83/177 43.37                    | 47/ 88 32.39                     | 0.83 (0.58, 1.19)       |
| Cancer stage before chemoradiotherapy |                                 |                                  |                         |
| Stage IIIA                            | 32/ 7443.63                     | 16/ 32 30.03                     | 0.78 (0.43， 1.42)       |
| Stage IIIB                            | 69/146 43.37                    | 36/ 65 32.92                     | 0.76 (0.51, 1.13)       |
| Stage IIIC                            | 13/ 33 -                        | 14/ 28 25.92                     | 0.75 (0.35,1.60)        |
|                                       | 0/ 2 一                          | 0/ 1                             |                         |
| Unknown                               |                                 |                                  | (-，-)                   |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroups                                                 | CS1001 (N=255) event/n Median   | CS1001 (N=255) event/n Median   |                               | Placebo (N=126)         | Hazard Ratio (95% CI)                              | Hazard Ratio (95% CI)                              | (0.51,1.02) (0.48,1.75) (0.57,1.22) (0.67,1.32) (0.46,1.23) 2.14) 3.21) 0 .86) 2.071 2.90) 0 . B3) 1.63) 1.01) 1. 46) 1.19) 1.37) 1.08) 3.08) 0.94)   | (0.51,1.02) (0.48,1.75) (0.57,1.22) (0.67,1.32) (0.46,1.23) 2.14) 3.21) 0 .86) 2.071 2.90) 0 . B3) 1.63) 1.01) 1. 46) 1.19) 1.37) 1.08) 3.08) 0.94)   | (0.51,1.02) (0.48,1.75) (0.57,1.22) (0.67,1.32) (0.46,1.23) 2.14) 3.21) 0 .86) 2.071 2.90) 0 . B3) 1.63) 1.01) 1. 46) 1.19) 1.37) 1.08) 3.08) 0.94)   |                                                    |                                                    |
|-----------------------------------------------------------|---------------------------------|---------------------------------|-------------------------------|-------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                           |                                 |                                 |                               | event/n Median          |                                                    |                                                    |                                                                                                                                                       | Placebo Better                                                                                                                                        |                                                                                                                                                       |                                                    |                                                    |
| Histology type                                            |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Squamous cell carcinoma                                   | 86/177                          | 38.70                           | 52/                           | 89 27.66                | 0.73                                               |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Non-squamous cell carcinoma                               | 27/ 76                          |                                 | 14/                           | 37 一                    | 0.92                                               |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Missing                                                   | 1/ 2                            |                                 | 0/                            | 0                       | （-，                                                | -)                                                 |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Chemoradiotherapy type                                    |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Seouential                                                | 42/86                           | 41.17                           | 25/                           | 4124.12                 | 0.68                                               |                                                    | (0.41, 1.11)                                                                                                                                          |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Concurrent                                                | 72/169 47.38                    |                                 | 41/                           | 85 32.92                | 0.83                                               |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Radiotherapy dose                                         |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| <60GV                                                     | 15/ 43                          | 一                               | 17/2                          | 21 20.40                | 0.32                                               |                                                    | (0.16, 0.64)                                                                                                                                          |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| >=60GV                                                    | 99/212                          | 43.37                           |                               | 49/105 35.25            | 0.94                                               |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Best response to prior CRT                                |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Complete response                                         | 1/ 4                            | 一                               | 0/                            | 2                       | (-                                                 | -)                                                 |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Partial response                                          | 74/172                          | 47.38                           | 38/                           | 77 32.92                | 0.77                                               |                                                    | (0.52， 1.14)                                                                                                                                          |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Stable disease                                            | 39/ 79                          | 34.33                           | 28/                           | 47 29.40                |                                                    | 0.76                                               |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Non-CR/non-PD                                             | 0/ 0                            |                                 | 0/                            | 0                       | （-，                                                | -)                                                 |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
|                                                           |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       | 1 2 3457913                                                                                                                                           |                                                                                                                                                       |                                                    |                                                    |
| Subgroups                                                 | eventn Median                   |                                 | Placebo (N=126) eventn Median |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
|                                                           | CS1001 (N=255)                  | CS1001 (N=255)                  |                               |                         | Hazard Ratio (95% CI) CS100l Better Placebo Better | Hazard Ratio (95% CI) CS100l Better Placebo Better | Hazard Ratio (95% CI) CS100l Better Placebo Better                                                                                                    | Hazard Ratio (95% CI) CS100l Better Placebo Better                                                                                                    | Hazard Ratio (95% CI) CS100l Better Placebo Better                                                                                                    | Hazard Ratio (95% CI) CS100l Better Placebo Better | Hazard Ratio (95% CI) CS100l Better Placebo Better |
| PD-L1(TC#) <1#                                            | 31/51                           | 27.79                           | 16/ 29 29.40 23               |                         | 1.17 1. 40                                         | (0.64, (0.62)                                      |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| >= 1# Missing                                             | 29/72                           |                                 | 7/                            |                         |                                                    | (0.38,                                             |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
|                                                           | 54/132                          |                                 | 43/ 74                        | 27.66                   | 0.57                                               |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| PD-L1 (IC#)                                               |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| <10 >= 10#                                                | 22/ 53 36/                      | 65 28.62                        | 7f 15 13/ 32                  | 33.12                   | 0.88 1.53                                          | (0.38 (0.81,                                       |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Missing                                                   | 56/137                          |                                 | 46/ 79 27.04                  |                         | 0.56                                               | (0.38,                                             |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| xoun mutation burden                                      |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| <10_mut/M >=10 mut/Mb                                     | 34/ 71 46/ 99                   | 43.37 39.82                     | 16/ 32 27/ 45                 | 33.12 24.97             | 0.90 0.63                                          | (0.50, (0.39)                                      |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Missing                                                   | 34/ B5                          |                                 | 23/ 49                        | 50.79                   | 0.85                                               | (0.50, (0.50,                                      |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Prior platinum treatment Cispiatin Carboplatin Nedaplatin | 57/130 37/ B2 26/               | 43.63 56 39.82                  | 31/ 61 24/ 47 13/ 20          | 33.12 31.84 23.56       | 0.77 0.82 0.55                                     | (0.49, (0.28,                                      |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| Time fxom completion of chenoradiotherapy to              |                                 |                                 |                               |                         |                                                    |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| randomisation                                             | 21/47 93/208                    | 43.37 47.38                     | 8/24 58/102                   | 29.31                   | 1.35 0. 68                                         |                                                    |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| >14 days Time fxom completion of                          |                                 |                                 |                               |                         |                                                    | (0.60, (0.49;                                      |                                                                                                                                                       |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| <=14days                                                  |                                 | 54/121 43.37                    |                               |                         |                                                    |                                                    | 1.17)                                                                                                                                                 |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
| chenoradiotherapy to randomisation <=25days >25 days      | 60/134 47.38                    |                                 |                               | 40/ 7732.92 26/ 4932.30 | 0.78 0.76                                          | (0.51,                                             | (0.48,1.20)                                                                                                                                           |                                                                                                                                                       |                                                                                                                                                       |                                                    |                                                    |
|                                                           |                                 |                                 |                               |                         |                                                    |                                                    | 0.1                                                                                                                                                   | 1 2 3 457913                                                                                                                                          |                                                                                                                                                       |                                                    |                                                    |

## Source:Figure f\\_ef\\_os\\_sub\\_ITT\\_2

Abbreviation:CI=confidence interval;CR=complete response;CRT=chemoradiotherapy;ECOG=eastern cooperative oncology group;PD=disease

MedianswereKaplan-Meierestimates.

Hazard ratio and 95% CI were calculated using unstratified univariate Cox regression, except for the analysis for all patients which used stratified Cox regression with the stratification factors from the IxRS (Interactive Voice/Web Response System), the stratification factors are ECOG performance status, chemoradiotherapy type, and total doseof prior radiotherapy.

For subgroup analysis,ECOG performance status, chemoradiotherapy type,and total dose of prior radiotherapy from EDC (Electronic Data Capture).

If total event number &lt;10 within one subgroup, hazard ratio (95% CI) is not displayed.

Stage of non-small cell lung cancer before chemoradiotherapy is categorized as Unknown'if nofurther category is available.There may be patients receiving more than one type of platinum.

## Analysis of OS adjusted by rank preserving structural failure time models

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 20: Overall Survival Adjusted by Rank Preserving Structural Failure Time Models ITT Analysis Set - Study CS1001-301 (OS Interim Analysis DCO3 - 03 April 2023)

|                            | Sugemalimab (N=255)   | Placebo adjusted by RPSFTM (N=126)   |
|----------------------------|-----------------------|--------------------------------------|
| Participants with event    | 114 (44.7%)           | 65 (51.6%)                           |
| Death                      | 114                   | 65                                   |
| Participants censored      | 141 (55.3%)           | 61 (48.4%)                           |
| Overall survival (months)  |                       |                                      |
| Median                     | 47.38                 | 29.31                                |
| 95% CI                     | (34.33, -)            | (21.16, -)                           |
| 25% and 75% percentiles    | 19.19, -              | 14.59, 50.79                         |
| Range                      | 0.23 to 53.26 +       | 2.40 to 50.79                        |
| Stratified analysis *      |                       |                                      |
| 2-sided p-value (log-rank) |                       | 0.0166                               |
| Hazard ratio               |                       | 0.69                                 |
| 95% CI                     |                       | (0.50, 0.94)                         |
| Unstratified analysis      |                       |                                      |
| 2-sided p-value (log-rank) |                       | 0.0134                               |
| Hazard ratio               |                       | 0.68                                 |
| 95% CI                     |                       | (0.50, 0.92)                         |

DCO3 date: 03 April 2023

Abbreviation: CI = confidence interval.

Summaries of overall survival (median, percentiles) were Kaplan-Meier estimates.

Confidence interval for the median was computed using the method of Brookmeyer and Crowley. Hazard ratios were estimated by Cox regression.

+  was for the minimum or maximum value from censored participants.

*  The stratification factors are ECOG performance status, chemoradiotherapy type, and total dose of prior radiotherapy from IxRS (Interactive Voice/Web Response System).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 14: Kaplan-Meier Curve of Overall Survival Adjusted by Rank Preserving Structural Failure Time Models - ITT Analysis Set - Study CS1001-301 (OS Interim Analysis DCO3 - 03 April 2023)

<!-- image -->

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 21: Summary of Efficacy for trial CS1001-301

| Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of CS1001-301 as Consolidation Therapy in Patients with Locally Advanced/unresectable (Stage III) Non-small Cell Lung Cancer Who Have Not Progressed After Concurrent/Sequential Chemoradiotherapy   | Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of CS1001-301 as Consolidation Therapy in Patients with Locally Advanced/unresectable (Stage III) Non-small Cell Lung Cancer Who Have Not Progressed After Concurrent/Sequential Chemoradiotherapy                                                                                                                                                                                                                                                                                                               | Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of CS1001-301 as Consolidation Therapy in Patients with Locally Advanced/unresectable (Stage III) Non-small Cell Lung Cancer Who Have Not Progressed After Concurrent/Sequential Chemoradiotherapy                                                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                           | CS1001-301 (GEMSTONE-301)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CS1001-301 (GEMSTONE-301)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                     | This is a randomised, double-blind, placebo-controlled, multicenter Phase III study to compare the efficacy and safety between sugemalimab versus placebo as consolidation therapy in patients with locally advanced/unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy. Eligible patients were randomised to receive sugemalimab or placebo by stratified block randomisation with a 2:1 ratio until disease progression, intolerable toxicity, withdrawal of informed consent, death, or other reasons specified in the protocol. | This is a randomised, double-blind, placebo-controlled, multicenter Phase III study to compare the efficacy and safety between sugemalimab versus placebo as consolidation therapy in patients with locally advanced/unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy. Eligible patients were randomised to receive sugemalimab or placebo by stratified block randomisation with a 2:1 ratio until disease progression, intolerable toxicity, withdrawal of informed consent, death, or other reasons specified in the protocol. |
| Design                                                                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24 months not applicable not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hypothesis                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                          | Sugemalimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 1200 mg sugemalimab Q3W Up to 24 months N- 255                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                                          | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PlaceboQ3W Up to 24 months N- 126                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                         | Progression-free survival (PFS)                                                                                                                                                                                                                                                                                                                                                          | Progression-free survival (PFS)                                                                                                                                                                                                                                                                                                                                                          | PFS assessed by blinded independent central review committee (BICR) according to RECIST v1.1. PFS was defined as the time from the date of randomisation to first documented disease progression or all- cause death, whichever occurred first.                                                                                                                                          | PFS assessed by blinded independent central review committee (BICR) according to RECIST v1.1. PFS was defined as the time from the date of randomisation to first documented disease progression or all- cause death, whichever occurred first.                                                                                                                                          |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                       | Overall survival (OS)                                                                                                                                                                                                                                                                                                                                                                    | Overall survival (OS)                                                                                                                                                                                                                                                                                                                                                                    | OS defined as the time interval between the date of randomisation to the date of all- cause death. Patients alive were censored at the last known alive date.                                                                                                                                                                                                                            | OS defined as the time interval between the date of randomisation to the date of all- cause death. Patients alive were censored at the last known alive date.                                                                                                                                                                                                                            |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                       | Progression-free survival - Investigator assessed (PFS-Inv)                                                                                                                                                                                                                                                                                                                              | Progression-free survival - Investigator assessed (PFS-Inv)                                                                                                                                                                                                                                                                                                                              | PFS assessed by investigator according to RECIST v1.1.                                                                                                                                                                                                                                                                                                                                   | PFS assessed by investigator according to RECIST v1.1.                                                                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                       | Objective response rate (ORR, ORR-Inv)                                                                                                                                                                                                                                                                                                                                                   | Objective response rate (ORR, ORR-Inv)                                                                                                                                                                                                                                                                                                                                                   | Assessed by BICR and investigator according to RECIST v1.1; the number and proportion of patients who achieved objective tumours response (CR or PR).                                                                                                                                                                                                                                    | Assessed by BICR and investigator according to RECIST v1.1; the number and proportion of patients who achieved objective tumours response (CR or PR).                                                                                                                                                                                                                                    |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                       | Duration of Response (DoR, DoR-Inv)                                                                                                                                                                                                                                                                                                                                                      | Duration of Response (DoR, DoR-Inv)                                                                                                                                                                                                                                                                                                                                                      | Assessed by BICR and investigator according to RECIST v1.1; duration of response for responders (CR or PR) is defined as the time interval between the date of the earliest qualified response and the date of disease progression or all-cause death, whichever occurs first.                                                                                                           | Assessed by BICR and investigator according to RECIST v1.1; duration of response for responders (CR or PR) is defined as the time interval between the date of the earliest qualified response and the date of disease progression or all-cause death, whichever occurs first.                                                                                                           |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                       | Time to death/distant metastasis (TTDM, TTDM-Inv)                                                                                                                                                                                                                                                                                                                                        | Time to death/distant metastasis (TTDM, TTDM-Inv)                                                                                                                                                                                                                                                                                                                                        | Assessed by BICR and investigator according to RECIST v1.1; Defined as the time from the date of randomisation to distant metastasis or all-cause death, whichever occurs first.                                                                                                                                                                                                         | Assessed by BICR and investigator according to RECIST v1.1; Defined as the time from the date of randomisation to distant metastasis or all-cause death, whichever occurs first.                                                                                                                                                                                                         |
| Database lock                                   | 01 March 2022 for PFS final analysis 03 April 2023 for OS interim analysis                                                                                                                                                                                                                                                                                                               | 01 March 2022 for PFS final analysis 03 April 2023 for OS interim analysis                                                                                                                                                                                                                                                                                                               | 01 March 2022 for PFS final analysis 03 April 2023 for OS interim analysis                                                                                                                                                                                                                                                                                                               | 01 March 2022 for PFS final analysis 03 April 2023 for OS interim analysis                                                                                                                                                                                                                                                                                                               | 01 March 2022 for PFS final analysis 03 April 2023 for OS interim analysis                                                                                                                                                                                                                                                                                                               |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                         |
| Analysis population and time point description  | Intent to treat; defined as all randomised patients The PFS interim analysis was conducted based on a 08 March 2021 data cut-off date. The final PFS analysis was conducted based on a 01 March 2022 data cut-off date. The pre-specified OS interim analysis was conducted based on a 03 April 2023 data cut- off date and used to support analyses of OS and other secondary endpoints | Intent to treat; defined as all randomised patients The PFS interim analysis was conducted based on a 08 March 2021 data cut-off date. The final PFS analysis was conducted based on a 01 March 2022 data cut-off date. The pre-specified OS interim analysis was conducted based on a 03 April 2023 data cut- off date and used to support analyses of OS and other secondary endpoints | Intent to treat; defined as all randomised patients The PFS interim analysis was conducted based on a 08 March 2021 data cut-off date. The final PFS analysis was conducted based on a 01 March 2022 data cut-off date. The pre-specified OS interim analysis was conducted based on a 03 April 2023 data cut- off date and used to support analyses of OS and other secondary endpoints | Intent to treat; defined as all randomised patients The PFS interim analysis was conducted based on a 08 March 2021 data cut-off date. The final PFS analysis was conducted based on a 01 March 2022 data cut-off date. The pre-specified OS interim analysis was conducted based on a 03 April 2023 data cut- off date and used to support analyses of OS and other secondary endpoints | Intent to treat; defined as all randomised patients The PFS interim analysis was conducted based on a 08 March 2021 data cut-off date. The final PFS analysis was conducted based on a 01 March 2022 data cut-off date. The pre-specified OS interim analysis was conducted based on a 03 April 2023 data cut- off date and used to support analyses of OS and other secondary endpoints |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                          | Treatment group                                                                                                                                                                                                                                                                                                                                                                          | Sugemalimab                                                                                                                                                                                                                                                                                                                                                                              | Sugemalimab                                                                                                                                                                                                                                                                                                                                                                              | Placebo                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                       | Number of subjects                                                                                                                                                                                                                                                                                                                                                                       | 255                                                                                                                                                                                                                                                                                                                                                                                      | 255                                                                                                                                                                                                                                                                                                                                                                                      | 126                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | PFS*, patients with event (%)                                                                                                                                                                                                                                                                                                                                                            | PFS*, patients with event (%)                                                                                                                                                                                                                                                                                                                                                            | 154 (60.4)                                                                                                                                                                                                                                                                                                                                                                               | 154 (60.4)                                                                                                                                                                                                                                                                                                                                                                               | 90 (71.4)                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | PFS* , Median (months) 95% CI                                                                                                                                                                                                                                                                                                                                                            | PFS* , Median (months) 95% CI                                                                                                                                                                                                                                                                                                                                                            | 10.51 (8.25, 17.12)                                                                                                                                                                                                                                                                                                                                                                      | 10.51 (8.25, 17.12)                                                                                                                                                                                                                                                                                                                                                                      | 6.21 (4.21, 8.08)                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | OS** , patient with event                                                                                                                                                                                                                                                                                                                                                                | OS** , patient with event                                                                                                                                                                                                                                                                                                                                                                | 114 (44.7)                                                                                                                                                                                                                                                                                                                                                                               | 114 (44.7)                                                                                                                                                                                                                                                                                                                                                                               | 66 (52.4)                                                                                                                                                                                                                                                                                                                                                                                |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                | OS** , Median (months) 95% CI   | 47.38 (34.33, NR)           | 47.38 (34.33, NR)        | 32.39 (24.12, NR)        |
|--------------------------------|---------------------------------|-----------------------------|--------------------------|--------------------------|
|                                | ORR** (%) 95% CI                | 50 (24.5) (18.77, 31.00)    | 50 (24.5) (18.77, 31.00) | 25 (24.8) (16.70, 34.33) |
|                                | DoR** , Median (months) 95% CI  | 24.05 (11.60, NR)           | 24.05 (11.60, NR)        | 8.44 (4.21, NR)          |
|                                | TTDM** , Median (months) 95% CI | 15.18 (10.28, 19.12)        | 15.18 (10.28, 19.12)     | 10.51 (7.13, 16.95)      |
| Effect estimate per comparison | Comparison groups               | Comparison groups           | Sugemalimab vs. placebo  | Sugemalimab vs. placebo  |
| Effect estimate per comparison | Primary endpoint PFS*           | Hazard ratio §              | 0.65                     | 0.65                     |
| Effect estimate per comparison | Primary endpoint PFS*           | 95% CI                      | (0.50, 0.84)             | (0.50, 0.84)             |
| Effect estimate per comparison | Primary endpoint PFS*           | P-value 2-side (log rank) § | 0.0012                   | 0.0012                   |
| Effect estimate per comparison | Secondary endpoint OS**         | Comparison groups           | Sugemalimab vs. placebo  | Sugemalimab vs. placebo  |
| Effect estimate per comparison | Secondary endpoint OS**         | Hazard ratio §              | 0.78                     | 0.78                     |
| Effect estimate per comparison | Secondary endpoint OS**         | 95% CI                      | (0.57; 1.05)             | (0.57; 1.05)             |
| Effect estimate per comparison | Secondary endpoint OS**         | P-value 2-side (log rank) § | 0.1036                   | 0.1036                   |

NR: Not reached.

## In vitro biomarker test for patient selection for efficacy

Any patients who signed the master ICF needed to provide tumour tissue sections and blood sample (2 mL whole blood) for TMB test (10 sections) and PD-L1 expression assay (3 sections), if permitted by the Ethics Committee. Requirements for biomarker sample collection were detailed in the study protocol. PD-L1 expression levels were measured by VENTANA PD-L1 (SP263) immunohistochemistry in a central laboratory. The evaluation method is the proportion of tumour cells with PD-L1 membrane staining of any intensity above background staining.

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The pivotal study supporting this application is Study CS1001-301 (GEMSTONE-301). This study was terminated following the OS interim analysis (DCO 03 April 2023).

This was a Phase 3, multicentre, randomised, double-blind, placebo-controlled, study of sugemalimab in participants with locally advanced/unresectable (Stage III) NSCLC that had not progressed after prior concurrent/sequential chemoradiotherapy. Both squamous and nonsquamous NSCLC patients were included. Patients with known mutation/translocation status of EGFR, ALK and ROS1 were excluded. PD-L1 status was not systematically assessed.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Platinum-containing chemotherapy were to include platinum (either cisplatin, carboplatin or nedaplatin) and at least one of: etoposide, vinorelbine, vinblastine, pemetrexed, a taxane, or gemcitabine. Nedaplatin (used in prior chemotherapy by 20% of the study population) is not approved in the EU, but is deemed sufficiently similar to carboplatin based on available literature. The chemotherapy was to follow instructions of the Chinese Society of Clinical Oncology (CSCO) Guideline for Diagnosis and Treatment of Primary Lung Cancer 2017 V1. The total dose of radiotherapy was to be 60 Gy ± 10% (54 Gy - 66 Gy). Prior treatment of antibody/drug that targets at T-cell coregulatory proteins (immune checkpoints, including PD-1, PD-L1, CTLA4, TIM3 and LAG3, etc.) was not allowed. The chemoradiation therapy given is broadly in line with ESMO guidance.

Patients were randomised 2:1 to sugemalimab or placebo. Randomisation stratification factors included ECOG performance status (PS) (0 vs 1), mode of prior chemoradiotherapy (sequential chemoradiotherapy vs concurrent chemoradiotherapy), and the total dose of baseline radiotherapy (&lt; 60 Gy vs ≥ 60 Gy).

Participants received sugemalimab (1200 mg, intravenous infusion [IV], every 3 weeks [Q3W]) or placebo, and the treatment was continued until disease progression, intolerable toxicity, withdrawal of consent, death, or other reasons specified in the protocol. Treatment duration of sugemalimab was up to 24 months.

The primary endpoint was PFS assessed by BICR per RECIST v1.1 defined as the time from randomisation to disease progression or all-cause death, whichever occurred first.

The secondary efficacy endpoints were OS, PFS (by INV per RECIST v1.1), ORR, DoR and Time to death/distant metastasis (TTDM). The secondary efficacy endpoints were tested sequentially in the order of OS, TTDM, and ORR, as prespecified in the Statistical Analysis Plan (SAP).

Overall, the study design, including comparators and endpoints, are considered appropriate.

## Statistical/methodological considerations

The primary endpoint PFS (evaluated by BICR) was evaluated by conventional time-to-event analysis methods. A stratified log-rank test was used for statistical testing between CS1001 and placebo, while stratified Cox regression model was used for estimation of efficacy. The model included same stratification factors as those used for randomisation. For PFS, subjects without event (no disease progression or death) were censored at the date of 'last tumour assessment'. Subjects without tumour assessment after baseline were censored at the date of randomization. Subjects with two or more missed tumour evaluations and patients who initiated a new therapy before progression were not censored.

Secondary variables: OS, Duration of response, and TTDM were analysed using the same statistical analysis methods as that for the primary efficacy endpoint.

The overall Type I error rate was controlled dually, i.e. by using error spending methods due to interim analyses in a group-sequential study design, and by using hierarchical testing procedure for the 4 efficacy endpoints that were tested in a prespecified order. The PFS (evaluated by BICR) and OS had an interim and a final analysis planned each, with boundary values derived using O'BrienFleming method and Lan-DeMets method with Pocock boundary, respectively. The primary and the main secondary endpoints were tested in a prespecified order (PFS by BICR, OS, TTDM by BICR, ORR by BICR). With these methods, the Type I error is considered controlled at 5% two-sided.

Since the OS was not statistically significant at the interim analysis, testing of TTDM and ORR is considered to fall outside multiplicity control.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Major changes in the planned statistical analyses were documented in the protocol version 5, where the primary objective and endpoint of the study were revised from \"Progression-free Survival (PFS) by the investigator according to RECIST v1.1\" to \"PFS by Blinded Independent Central Review (BICR) according to RECIST v1.1\". Also, the planned study sample size was changed from 402 to 368, and the required number of events and the alpha spending function were updated. Since the study was double-blind and the changes documented prior to the interim PFS analysis, these changes are deemed acceptable.

## Recruitment and conduct

The study was conducted exclusively in China. A total of 564 patients were screened and 381 patients were randomised in a 2:1 ratio to sugemalimab group (255 patients) and placebo group (126 patients) from 26 October 2018 to 30 December 2020. All patients received the allocated treatment. Cross-over was not permitted.

The proportion of patients with at least one important protocol deviation is high, 19.6% (n=50) for the sugemalimab arm and 12.7% (n=16) for the placebo arm. Most of these are due to study conduct/procedures and safety, e.g. deviations from screening procedure, not fulfilling inclusion/exclusion criteria, deviations from sample collection/processing/storage and deviations from safety reporting/follow-up. It is noted that 2.6% (n=10) of patients had important protocol deviations for informed consent. Important protocol deviations related to the COVID-19 pandemic were reported for a total of 3 patients.

## Efficacy data and additional analyses

BICR-assessed PFS was analysed in the ITT population, which included all randomly assigned participants, at 2 prespecified time points: (1) an interim PFS analysis and (2) a final PFS analysis. The PFS analysis was also updated at the interim OS analysis data cut.

Overall distribution of baseline characteristics is generally well balanced between the two treatment arms. Patients were exclusively of Asian origin. The median age of included patients was 61 years. 72.4% of patients were younger than 65 years. It is notable that there is a very strong male dominance with 92.1% males, hampering the assessment of efficacy in females. However, gender is not a known effect modifier in this clinical situation, or when treating with PD-L1 targeting agents.

PD-L1 testing was not mandatory but results are available for a subpopulation of patients (n=175). Section 5.1 of the SmPC clearly states that Test for PD-L1 status was not mandatory and was not systematically assessed. Apart from testing for EGFR mutational status in participants with nonsquamous NSCLC, no further information of other actionable mutations is available as it was not tested. The exclusion of patients with known actionable mutations is acceptable.

69.8% of the patients had squamous cell carcinoma. 66.7% of all patients were treated following concurrent chemoradiotherapy. The proportion of patients that were treated after sequential chemoradiotherapy were capped at 40%.

The study was performed exclusively in China. Several agents targeting PD-1 or PD-L1 have been approved for use in NSCLC in the EU based on global studies including predominantly Caucasian patients (e.g., pembrolizumab, atezolizumab, durvalumab). Moreover, several agents, including Cejemly, have been approved for similar use based on studies performed exclusively in China, which have shown similar benefits. The present application for Cejemly is in a similar niche where the positive B/R of durvalumab was shown in a study with centers in North and Latin America,

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Europe, and Asia Pacific, including approximately 70% Caucasian patients. Thus, the external validity for EU patients of the present pivotal study is accepted.

## Results

At the final PFS analysis (DCO: 01 March 2022) were a total of 154 PFS events observed in the sugemalimab group, compared to 90 in the placebo group. Median PFS was 10.5 months (95% CI: 8.3, 17.1) in the sugemalimab group versus 6.2 months (95% CI: 4.2, 8.1) in the placebo group (stratified HR 0.65; [95% CI: 0.50, 0.84]; two-sided P = 0.0012). The median follow-up was 27.1 months and 23.5 months for the sugemalimab group and placebo group, respectively.

At the time of the OS interim analysis (DCO: 03 April 2023) were the median PFS 10.6 months (95% CI: 8.4, 16.8) in the sugemalimab group versus 6.2 months (95% CI: 4.2, 8.3) in the placebo group (stratified HR 0.73 [95% CI: 0.56, 0.95]; two-sided P = 0.0175 (nominal p-value)). The median follow-up was 40.4 months and 35.4 months for the sugemalimab group and placebo group, respectively.

OS did not reach statistical significance at the OS interim analysis (DCO: 03 April 2023). The study was subsequently terminated, hence there will not be any more updates from this study.

The OS interim analysis was performed after 180 OS events had occurred (47% maturity). A total of 114 OS events were observed in the sugemalimab, compared to 66 in the placebo group. The median OS was 47.4 months (95% CI: 34.3, NR [not reached]) in the sugemalimab group and 32.4 months (95% CI: 24.1, NR) in the placebo group (stratified HR 0.78 [95% CI: 0.57, 1.05], two-sided P = 0.1036) and the actual statistical superiority boundary of 0.0392 was not reached.

More patients previously treated with placebo received PD-1/PD-L1 inhibitor as follow-up anticancer treatment, 52 (41.3%) compared to 30 (11.8%) patients from the sugemalimab group. A rank preserving structural failure time models (RPSFTM) was performed ad-hoc to investigate the potential impact of this imbalance. After adjustment, the median OS for the placebo group was 29.3 months compared to 32.4 months unadjusted. This adjustment also presented a stratified HR of 0.69 [95% CI: 0.50, 0.94], two-sided nominal of P = 0.0166. Given the uncertainties about bias control when modelling OS to account for the impact of post-progression therapies, no claims can be made on this basis.

Overall, subgroup analyses of PFS and OS do not raise concerns regarding lack of efficacy in any subgroup presented. However, PD-L1 expression status is missing in more than 50% of patients. Moreover, there is substantial heterogeneity of effects between those with PD-L1 expression data and those for whom this is missing - with no apparent effect of sugemalimab in those patients for whom PD-L1 status data are available. Therefore, these data are not representative of the full study population, and do not allow for any conclusion of the impact of PD-L1 expression on efficacy.

In a previous decision for the use of Imfinzi for similar use, the CHMP considered that interpretable data on PD-L1 expressors did not support use in these patients. Similar to sugelimumab, durvalumab is an inhibitor of PD-L1, which is dosed at a roughly similar intensity. Hence, the indication for sugemalimab is restricted to patients with PDL1 ≥1% in line with the only relevant precedent (Imfinzi) where the indication was restricted to patients expressing PD-L1 ≥ 1%.

As a result of this restriction of indication to patients expressing PD-L1 ≥ 1%, section 4.2 of the SmpC was updated in order to include information on PD-L1 testing. To determine eligibility for treatment, tumour cell PD-L1 expression should be assessed with a CE-marked IVD with the corresponding intended purpose. If a CE-marked IVD is not available, an alternative validated test should be used.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

PFS assessed by INV exhibits a similar hazard ratio (stratified HR 0.70, 95% CI: 0.55, 0.90) at the OS interim analysis compared to PFS assessed by BICR. However, the concordance between BICR and INV is less than 80% for both the sugemalimab and placebo arms. Despite this, PFS by INV achieves nominal significance, and since the robustness of the PFS estimate is not compromised, this issue is not further investigated.

The ORR analysis set was all randomised patients with measurable disease at baseline. 204 patients in the  sugemalimab group and 101 patients in the placebo group were included in the ORR analysis set based on BICR assessment. ORR (CR + PR, DCO: 03 April 2023, OS IA) assessed by BICR was 24.5% (95% CI: 18.8%, 31.0%) in the sugemalimab group and 24.8% (95% CI: 16.7%, 34.3%) in the placebo group. The median DoR assessed by BICR was 24.1 months (95% CI: 11.6, NR) in the sugemalimab group and 8.4 months (95% CI: 4.2, NR) in the placebo group at the OS IA.

The time to TTDM analysis at the OS IA (DCO 03 April 2023) included 173 (67.8%) TTDM events (111 distant metastases and 62 deaths) that occurred in the sugemalimab group, and 92 (73.0%) TTDM events (59 distant metastases and 33 deaths) that occurred in the placebo group. The median TTDM (95% CI) assessed by BICR was 15.2 months (10.3, 19.1) and 10.5 months (7.1, 17.0) in the sugemalimab and placebo groups, respectively,  with a stratified analysis HR 0.83 (95% CI: 0.64, 1.07). No difference was shown for TTDM that would support the primary endpoint.

PFS2 was not reported.

## 2.4.3. Conclusions on the clinical efficacy

Sugemalimab treatment for patients with unresectable NSCLC without EGFR mutations or ALK, ROS1 genomic tumour aberrations who have not progressed following platinum-based chemoradiotherapy has shown statistically significant PFS improvement over placebo in Study CS1001-301. OS did not reach statistical significance at the interim analysis. The study was subsequently terminated, hence there will not be any more OS updates from this study. Notably, given the extent of use of PD-L1 targeting agents on progression in the placebo control arm, the sensitivity of the study to show an OS gain was limited.

It is recognised that the ability to demonstrate an OS gain in this treatment niche may be limited due to post-progression use of the same drug class. Given available knowledge, a prolongation of PFS of the present magnitude after chemoradiotherapy for unresectable stage III NSCLC is considered to isolate clinical benefit, in the absence of any signal of a detrimental effect on OS.

Notably efficacy cannot be determined for PD-L1 low expressors as PD-L1 testing was lacking for the majority of patients in the study. Hence, the indication for sugemalimab is restricted to patients with PD-L1 ≥ 1%. As outlined, this is in line with the relevant precedent.

## 2.5. Clinical safety

## Introduction

The key safety data in support of this application were derived from study CS1001-301 (hereafter referred to as study 301). A total of 255 patients were exposed to sugemalimab monotherapy and 126 to placebo in study 301.

The full safety data set derives from a sugemalimab monotherapy pool consisting of 568 patients with advanced solid or haematologic malignancies exposed to the recommended sugemalimab dose of 1,200 mg/kg Q3W in two phase 1, two phase 2, and two phase 3 studies including study 301.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 22: List of clinical studies with sugemalimab included in the summary of clinical safety

| StudyID NCT Number Phase (Study Statusa)/ Countries/ DCO/LPLV (Report Type)                                                                                                  | Study Design                                                                                                                                                                                                                                                                                                                                                                               | Drug Product(s)/ Route ofAdministration/ Dosing Cycle                                                                                                                                                                                                                                                                                        | Number of Participants Treated (Safety Analysis Set)                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PivotalPhase3Study                                                                                                                                                           | PivotalPhase3Study                                                                                                                                                                                                                                                                                                                                                                         | PivotalPhase3Study                                                                                                                                                                                                                                                                                                                           | PivotalPhase3Study                                                                                                                          |
| CS1001-301/ NCT03728556 Phase 3 (Completed)/ China/ 03 Apr 2023 LPLV (Full CSR)                                                                                              | Randomised,double-blind, placebo-controlled study of sugemalimab in participants with locally advanced/unresectableStage III NSCLC who have not progressed after prior concurrent/sequential chemoradiotherapy                                                                                                                                                                             | Sugemalimab 1200 mgfixed dose or placebo/ IV infusion/ Q3W                                                                                                                                                                                                                                                                                   | Total:381 Sugemalimab:255 Placebo:126                                                                                                       |
| SupportiveStudies                                                                                                                                                            | SupportiveStudies                                                                                                                                                                                                                                                                                                                                                                          | SupportiveStudies                                                                                                                                                                                                                                                                                                                            | SupportiveStudies                                                                                                                           |
| CS1001-302 NCT03789604 Phase 3 (Ongoing)/ China/ 22 Nov 2021 DCO (Full CSR)                                                                                                  | Randomised,multicentre,double-blind, placebo-controlled study of sugemalimab in combination with chemotherapy as first-line treatment in participants with Stage IV NSCLC                                                                                                                                                                                                                  | Double-blind phase: Sugemalimab1200mgfixed doseincombinationwith platinum-based chemotherapy or placebo in combination with platinum-based chemotherapy/ IV infusion/ Q3W; 4 cycles for platinum-based chemotherapy Maintenance:Uptoatotalof~35cyclesof sugemalimab or placebo Crossover phase: Sugemalimab1200mgfixeddose/ IV infusion/ Q3W | Total: 479 Double-blind phase: Sugemalimab:320 Placebo:159 Crossover phase: Sugemalimab:45 (received placebo during the double-blind phase) |
| CS1001-101a/CS1001-101b NCT03312842 Phase 1a (Completed)/ China/ 30 Nov 2018 DCO (Full CSR) Phase 1b (Ongoing) China/ 16 Aug 2021DCO (Full CSR; excludesCohort12andCohort13) | Phase 1a: Open-label, first-in-human, multiple-dose, dose-escalation, dose-expansion study of sugemalimab in participants with advanced solid tumours or lymphomas Phase 1b:Indication expansion phase for preliminaryevaluationofantitumourefficacy ofsugemalimabinmonotherapyandin combination with standard therapies in participants with multiple types of solid tumours or lymphomas | Phase 1a: Sugemalimab 3, 10, 20, and 40 mg/kg and 1200 mgfixed dose IV infusion/ Q3W Phase1b:Sugemalimab1200 mgfixeddose(as monotherapy[Cohorts1to4]orincombinationwith chemotherapy[Cohorts5to9],targeted therapy [Cohorts 10 to 12], or radiotherapy [Cohort 13])/ IV infusion/ Q3W                                                        | Total: 246 Phase 1a: 29 3 to 40 mg/kg:13 1200 mg:16 Phase 1b: 217 Cohorts 1 to 4:79 Cohorts 5 to9:115 Cohort 11: 23                         |
| CS1001-102/ NCT03744403 Phase 1 (Completed) US/                                                                                                                              | Open-label,multiple-dose,dose-escalation bridging study of sugemalimab in participants with advanced solid tumours                                                                                                                                                                                                                                                                         | Sugemalimab10mg/kgand1200mgfixeddose/ IV infusion/ Q3W                                                                                                                                                                                                                                                                                       | Total: 24 10 mg/kg:12 1200 mg: 12                                                                                                           |
| 19 Oct2020LPLV(Ful1CSR) CS1001-201/ NCT03595657 Phase 2 (Ongoing)/ China, USb/ 10 Nov 2021 DCO (Ful1 CSR)                                                                    | Single-arm,multicentre study of sugemalimab in participants withrelapsed or refractory ENKTL                                                                                                                                                                                                                                                                                               | Sugemalimab1200mgfixed dose/ IV infusion/ Q3W                                                                                                                                                                                                                                                                                                | Total: 80                                                                                                                                   |
| CS1001-202/ NCT03505996 Phase 2 (Ongoing)/ China/ 19 Feb 2020 DCO (Full CSR)                                                                                                 | Single-arm,multicentre study of sugemalimab in participants withrelapsed or refractoryclassicalHodgkinlymphoma                                                                                                                                                                                                                                                                             | Sugemalimab1200mgfixed dose/ IV infusion/ Q3W                                                                                                                                                                                                                                                                                                | Total: 81                                                                                                                                   |

## Patient exposure

Sugemalimab IV was administered Q3W until disease progression or unacceptable toxicity.

At the data cut-off (DCO) of 03 April 2023 all patients in study 301 had discontinued sugemalimab or placebo treatment and discontinued from the study.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 23: Summary of exposure to sugemalimab or placebo, study CS1001-301 (safety analysis set)

|                           | Sugemalimab (N=255)   | Placebo (N =126)   |
|---------------------------|-----------------------|--------------------|
| TreatmentDuration(months) |                       |                    |
| Mean (SD)                 | 14.7 (13.33)          | 12.1 (10.47)       |
| Median                    | 9.0                   | 7.6                |
| Min, max                  | 0.2, 50.7             | 0.7, 42.2          |
| Number of Cycles          |                       |                    |
| Mean (SD)                 | 19.8 (18.08)          | 16.3 (14.10)       |
| Median                    | 12.0                  | 10.0               |
| Min, max                  | 1, 72                 | 1, 60              |
| Total CumulativeDose(mg)  |                       |                    |
| Mean (SD)                 | 23760.0 (21699.35)    | 19561.9 (16923.84) |
| Median                    | 14400.0               | 12000.0            |
| Min, max                  | 1200,86400            | 1200, 72000        |

Treatmentdurationisdefinedasminimum of(treatment end date ofstudydrug-treatmentstart dateof study

Total cumulative doseisdefined as thesum of actual dosageadministered duringeach cycle.

Source:Study CS1001-301 CSR,Tablet\\_ex\\_SA\\_2

CSR = clinical study report, max = maximum; min = minimum; SD = standard deviation.

## Adverse events

Table 24: Overview of treatment-emergent adverse events, study CS1001-301 (safety analysis set)

|                                                        | Sugemalimab (N=255) n (96)   | Placebo (N =126) (%6) u   |
|--------------------------------------------------------|------------------------------|---------------------------|
| Number of participants with at least one               |                              |                           |
| TEAE                                                   | 248 (97.3)                   | 121 (96.0)                |
| Treatment-related TEAE                                 | 201 (78.8)                   | 81 (64.3)                 |
| Serious TEAE                                           | 94 (36.9)                    | 37 (29.4)                 |
| Treatment-related serious TEAE                         | 49 (19.2)                    | 12 (9.5)                  |
| Grade 3-5 TEAE                                         | 87 (34.1)                    | 38 (30.2)                 |
| Treatment-related Grade 3-5 TEAE                       | 37 (14.5)                    | 8 (6.3)                   |
| Immune-related TEAE assessed by investigator*          | 150 (58.8)                   | 49 (38.9)                 |
| Immune-related TEAE Grade 3-5 assessed by imvestigator | 21 (8.2)                     | 0                         |
| Infusion-related reaction                              | 1 (0.4)                      | 2 (1.6)                   |
| TEAE leading to drug permanently discontinued          | 47 (18.4)                    | 6 (4.8)                   |
| TEAE leading to infusion interruption                  | 1 (0.4)                      | 1 (0.8)                   |
| TEAE leading to treatment cycle delay                  | 101 (39.6)                   | 36 (28.6)                 |
| TEAE leading to death                                  | 12 (4.7)                     | 3 (2.4)                   |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Adverse events by system organ class and preferred term

Table 25: Most frequently reported treatment-emergent adverse events (&gt; 10%) by system organ class and preferred term, study CS1001-301 (safety analysis set)

| System Organ Class Preferred Term               | Sugemalimab (N =255) n (%6)   | Placebo (N = 126) n (%)   |
|-------------------------------------------------|-------------------------------|---------------------------|
| Number of Participants With at Least One Event  | 248 (97.3)                    | 121 (96.0)                |
| Investigations                                  | 173 (67.8)                    | 78 (61.9)                 |
| Alanine amimotransferase imcreased              | 63 (24.7)                     | 20 (15.9)                 |
| Aspartate aminotransferase increased            | 52 (20.4)                     | 13 (10.3)                 |
| Weight imcreased                                | 41 (16.1)                     | 14 (11.1)                 |
| White blood cell count decreased                | 28 (11.0)                     | 15 (11.9)                 |
| Platelet coumt decreased                        | 19 (7.5)                      | 13 (10.3)                 |
| Respiratory, thoracic and mediastinal disorders | 147 (57.6)                    | 72 (57.1)                 |
| Cough                                           | 54 (21.2)                     | 34 (27.0)                 |
| Pneumonitis                                     | 37 (14.5)                     | 24 (19.0)                 |
| Metabolism and nutrition disorders              | 115 (45.1)                    | 67 (53.2)                 |
| Hyperglycaemia                                  | 34 (13.3)                     | 13 (10.3)                 |
| Hypercholesterolaemia                           | 31 (12.2)                     | 12 (9.5)                  |
| Hypertiglyceridaemia                            | 27 (10.6)                     | 16 (12.7)                 |
| Hypoalbuminaemia                                | 27 (10.6)                     | 19 (15.1)                 |
| Hyperuricaemia                                  | 23 (9.0)                      | 18 (14.3)                 |
| Infections and infestations                     | 107 (42.0)                    | 54 (42.9)                 |
| Pneumonia                                       | 42 (16.5)                     | 17 (13.5)                 |
| Upper respiratory tract infection               | 27 (10.6)                     | 19 (15.1)                 |
| Blood and lymphatic system disorders            | 78 (30.6)                     | 43 (34.1)                 |
| Anaemia                                         | 62 (24.3)                     | 31 (24.6)                 |
| Injury; poisoning and procedural complications  | 77 (30.2)                     | 32 (25.4)                 |
| Radiation pneumonitis                           | 63 (24.7)                     | 25 (19.8)                 |
| Endocrine disorders                             | 75 (29.4)                     | 19 (15.1)                 |
| Hypothyroidism                                  | 53 (20.8)                     | 15 (11.9)                 |
| Hyperthyroidism                                 | 40 (15.7)                     | 6 (4.8)                   |
| Skin and subcutaneous tissue disorders          | 60 (23.5)                     | 14 (11.1)                 |
| Rash                                            | 27 (10.6)                     | 9 (7.1)                   |

Source: Study CS1001-301 CSR, Table t\\_ae\\_SA\\_2

Infusion-related reactions (IRRs) occurred in one (0.4%) patient in the sugemalimab arm vs. two (1.6%) patients in the placebo arm.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Treatment-related adverse events by system organ class and preferred term

Table 26: Most frequently reported sugemalimab/placebo-related treatment-emergent adverse events (&gt; 5%) by system organ class and preferred term, study CS1001-301 (safety analysis set)

| System OrganClass Preferred Term               | Sugemalimab (N = 255) (%)   | Placebo (N =126) n (%)   |
|------------------------------------------------|-----------------------------|--------------------------|
| Number of Participants With at Least One Event | 201 (78.8)                  | 81 (64.3)                |
| Investigations                                 | 119 (46.7)                  | 48 (38.1)                |
| Alanine aminotransferase increased             | 42 (16.5)                   | 14 (11.1)                |
| Aspartate aminotransferaseincreased            | 35 (13.7)                   | 7 (5.6)                  |
| Blood thyroid stimulating hormone increased    | 22 (8.6)                    | 4 (3.2)                  |
| Blood thyroid stimulating hormone decreased    | 20 (7.8)                    | 7 (5.6)                  |
| Blood bilirubin increased                      | 15 (5.9)                    | 5 (4.0)                  |
| Gamma-glutamyltransferase increased            | 13 (5.1)                    | 3 (2.4)                  |
| White blood cell count decreased               | 12 (4.7)                    | 8 (6.3)                  |
| Endocrine disorders                            | 72 (28.2)                   | 16 (12.7)                |
| Hypothyroidism                                 | 50 (19.6)                   | 12 (9.5)                 |
| Hyperthyroidism                                | 40 (15.7)                   | 5 (4.0)                  |
| Respiratory,thoracic and mediastinal disorders | 71 (27.8)                   | 27 (21.4)                |
| Immune-mediated lung disease                   | 25 (9.8)                    | 4 (3.2)                  |
| Pneumonitis                                    | 25 (9.8)                    | 18 (14.3)                |
| Interstitial lung disease                      | 16 (6.3)                    | 4 (3.2)                  |
| Metabolismandnutritiondisorders                | 50 (19.6)                   | 19 (15.1)                |
| Hyperglycaemia                                 | 19 (7.5)                    | 6 (4.8)                  |
| Hypertriglyceridaemia                          | 14 (5.5)                    | 6 (4.8)                  |
| Hypercholesterolaemia                          | 13 (5.1)                    | 2 (1.6)                  |
| Skin and subcutaneous tissue disorders         | 49 (19.2)                   | 8 (6.3)                  |
| Rash                                           | 22 (8.6)                    | 6 (4.8)                  |
| Pruritus                                       | 17 (6.7)                    | 3 (2.4)                  |
| Blood and lymphatic system disorder's          | 24 (9.4)                    | 10 (7.9)                 |
| Anaemia                                        | 17 (6.7)                    | 7 (5.6)                  |

The participant is counted only once per unique SOC and once per unique PT within SOC.

\"Related\" is defined as the relationship to sugemalimab or placebo is related or missing.

MedDRA version 26.0.

CSR = clinical study report; MedDRA =Medical Dictionary for Regulatory Activities;PT =preferred term;

SOC = system organ class.

Source: Study CS1001-301 CSR, Table t\\_ae\\_rel\\_SA\\_2

## Adverse reactions

The following methodology was used for classification of ADRs:

All TEAEs observed in &gt; 2 patients or ≤ 2 patients for immune-related class effect events and/or events falling into an EMA Designated Medical event (DME) category in the sugemalimab + chemotherapy combination safety pool (n=435) and the sugemalimab monotherapy safety pool

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

(n=568), were selected for individual medical review. The Bradford-Hill criteria were used for assessment and ADR identification and if a reasonable possibility of a causal relationship with sugemalimab was present, the TEAE was included as an ADR. ADRs representing the same or similar medical concepts were grouped.

Of note, the change in frequencies of ADRs pertaining to Cejemly in combination with chemotherapy for the ADRs haemolytic, anaemia, ANCA-positive vasculitis, colitis, and myositis were originally added to the ADR table during the initial approval of Cejemly for the combination therapy indication ((EMEA/H/C/006088/0000) although these specific ADRs were only observed for Cejemly monotherapy. Since there is now a separate ADR column for monotherapy ADRs, these specific ADRs have been moved to the new column and the footnote removed, changing the frequencies overall of some of the ADR observed in the combination therapy pool.

Table 27 : combination therapy adverse reactions table

| Grouped Term                                            | All Grade CS1001 + Chemo (N=435)   | Grade 3-5 CS1001 + Chemo   |
|---------------------------------------------------------|------------------------------------|----------------------------|
| Number of Patients with at least one event listed below | 416( 95.6%)                        | 144( 33.1%)                |
| Anaemia                                                 | 337( 77.5%)                        | 76( 17.5%)                 |
| Hepatic enzyme increased                                | 185( 42.5%)                        | 10( 2.3%)                  |
| Rash                                                    | 114( 26.2%)                        | 6( 1.4%)                   |
| Hyperlipidaemia                                         | 94( 21.6%)                         | 10( 2.3%)                  |
| Hyperglycaemia                                          | 80( 18.4%)                         | 7( 1.6%)                   |
| Hyponatraemia                                           | 73( 16.8%)                         | 19( 4.4%)                  |
| Hypokalaemia                                            | 68( 15.6%)                         | 13( 3.0%)                  |
| Hypothyroidism                                          | 68( 15.6%)                         | 1( 0.2%)                   |
| Hyperthyroidism                                         | 66( 15.2%)                         | 0                          |
| Proteinuria                                             | 61( 14.0%)                         | 0                          |
| Abdominal pain                                          | 60( 13.8%)                         | 3( 0.7%)                   |
| Fatigue                                                 | 58( 13.3%)                         | 6( 1.4%)                   |
| Arthralgia                                              | 53( 12.2%)                         | 1( 0.2%)                   |
| Hypoaesthesia                                           | 50( 11.5%)                         | 1( 0.2%)                   |
| Hypocalcaemia                                           | 44( 10.1%)                         | 1( 0.2%)                   |
| Blood creatinine increased                              | 38( 8.7%)                          | 2( 0.5%)                   |
| Hyperuricaemia                                          | 38( 8.7%)                          | 0                          |
| Hypochloraemia                                          | 37( 8.5%)                          | 3( 0.7%)                   |
| Stomatitis                                              | 31( 7.1%)                          | 4( 0.9%)                   |
| Blood creatine phosphokinase increased                  | 30( 6.9%)                          | 1( 0.2%)                   |
| Hypomagnesaemia                                         | 27( 6.2%)                          | 1( 0.2%)                   |
| Hepatic function abnormal                               | 25( 5.7%)                          | 8( 1.8%)                   |
| Hypertension                                            | 25( 5.7%)                          | 6( 1.4%)                   |
| Amylase increased                                       | 24( 5.5%)                          | 9( 2.1%)                   |
| Blood bilirubin increased                               | 22( 5.1%)                          | 2( 0.5%)                   |
| Myalgia                                                 | 22( 5.1%)                          | 0                          |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Tachycardia                  | 21( 4.8%)   | 1( 0.2%)   |
|------------------------------|-------------|------------|
| Pneumonitis                  | 18( 4.1%)   | 5( 1.1%)   |
| Conjunctivitis               | 14( 3.2%)   | 0          |
| Nephritis                    | 12( 2.8%)   | 4( 0.9%)   |
| Neuropathy peripheral        | 12( 2.8%)   | 0          |
| Diabetes mellitus            | 7( 1.6%)    | 3( 0.7%)   |
| Bone pain                    | 6( 1.4%)    | 0          |
| Dry eye                      | 6( 1.4%)    | 0          |
| Hepatitis                    | 6( 1.4%)    | 4( 0.9%)   |
| Dry mouth                    | 5( 1.1%)    | 0          |
| Infusion related reaction    | 5( 1.1%)    | 0          |
| Lipase increased             | 5( 1.1%)    | 3( 0.7%)   |
| Skin hypopigmentation        | 5( 1.1%)    | 0          |
| immune-related hypophysitis  | 5( 1.1%)    | 0          |
| Anaphylactic reaction        | 4( 0.9%)    | 1( 0.2%)   |
| Dyslipidaemia                | 4( 0.9%)    | 0          |
| Adrenal insufficiency        | 2( 0.5%)    | 0          |
| Troponin T increased         | 2( 0.5%)    | 0          |
| Cortisol decreased           | 1( 0.2%)    | 0          |
| Immune-mediated arthritis    | 1( 0.2%)    | 0          |
| Immune-mediated encephalitis | 1( 0.2%)    | 0          |
| Immune-mediated myocarditis  | 1( 0.2%)    | 0          |
| Immune-mediated thyroiditis  | 1( 0.2%)    | 0          |
| Pancreatitis                 | 1( 0.2%)    | 0          |
| Proctitis                    | 1( 0.2%)    | 0          |

Table 28: Monotherapy adverse reactions table

| Grouped Term                                            | All Grade CS1001 (N=568)   | Grade 3-5 CS1001   |
|---------------------------------------------------------|----------------------------|--------------------|
| Number of Patients with at least one event listed below | 463( 81.5%)                | 95( 16.7%)         |
| Hepatic enzyme increased                                | 161( 28.3%)                | 17( 3.0%)          |
| Anaemia                                                 | 130( 22.9%)                | 18( 3.2%)          |
| Hypothyroidism                                          | 128( 22.5%)                | 5( 0.9%)           |
| Rash                                                    | 97( 17.1%)                 | 7( 1.2%)           |
| Pyrexia                                                 | 87( 15.3%)                 | 2( 0.4%)           |
| Hyperthyroidism                                         | 82( 14.4%)                 | 1( 0.2%)           |
| Blood bilirubin increased                               | 74( 13.0%)                 | 10( 1.8%)          |
| Hyperlipidaemia                                         | 73( 12.9%)                 | 7( 1.2%)           |
| Proteinuria                                             | 70( 12.3%)                 | 0                  |
| Hyperglycaemia                                          | 62( 10.9%)                 | 4( 0.7%)           |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Pneumonitis                                              | 52( 9.2%)   | 5( 0.9%)   |
|----------------------------------------------------------|-------------|------------|
| Hypokalaemia                                             | 41( 7.2%)   | 8( 1.4%)   |
| Hyponatraemia                                            | 40( 7.0%)   | 8( 1.4%)   |
| Diarrhoea                                                | 28( 4.9%)   | 0          |
| Arthralgia                                               | 27( 4.8%)   | 0          |
| Blood creatine phosphokinase increased                   | 27( 4.8%)   | 4( 0.7%)   |
| Hypertension                                             | 23( 4.0%)   | 9( 1.6%)   |
| Blood creatinine increased                               | 22( 3.9%)   | 0          |
| Tachycardia                                              | 17( 3.0%)   | 1( 0.2%)   |
| Fatigue                                                  | 16( 2.8%)   | 2( 0.4%)   |
| Hepatic function abnormal                                | 11( 1.9%)   | 4( 0.7%)   |
| Stomatitis                                               | 10( 1.8%)   | 1( 0.2%)   |
| Amylase increased                                        | 8( 1.4%)    | 0          |
| Myalgia                                                  | 7( 1.2%)    | 0          |
| Nephritis                                                | 7( 1.2%)    | 2( 0.4%)   |
| Myocarditis                                              | 5( 0.9%)    | 1( 0.2%)   |
| Myositis                                                 | 5( 0.9%)    | 1( 0.2%)   |
| Conjunctivitis                                           | 3( 0.5%)    | 0          |
| Diabetes mellitus                                        | 3( 0.5%)    | 1( 0.2%)   |
| Hepatitis                                                | 2( 0.4%)    | 0          |
| Hypersensitivity                                         | 2( 0.4%)    | 0          |
| Infusion related reaction                                | 2( 0.4%)    | 0          |
| Troponin T increased                                     | 2( 0.4%)    | 0          |
| immune-related hypophysitis                              | 2( 0.4%)    | 0          |
| Anti-neutrophil cytoplasmic antibody positive vasculitis | 1( 0.2%)    | 0          |
| Colitis                                                  | 1( 0.2%)    | 1( 0.2%)   |
| Haemolytic anaemia                                       | 1( 0.2%)    | 1( 0.2%)   |
| Immune-mediated arthritis                                | 1( 0.2%)    | 0          |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Adverse events by severity

Table 29: Grade 3-5 treatment-emergent adverse events (&gt; 1%) by system organ class and preferred term, study CS1001-301 (safety analysis set)

| System Organ Class Preferred Term           | Sugemalimab (N = 255) n (%)   | Placebo (N=126) n (%)   |
|---------------------------------------------|-------------------------------|-------------------------|
| NumberofParticipantsWithat LeastOneEvent    | 87 (34.1)                     | 38 (30.2)               |
| Infectionsandinfestations                   | 26 (10.2)                     | 13 (10.3)               |
| Pneumonia                                   | 23 (9.0)                      | 8 (6.3)                 |
| Upper respiratory tract infection           | 1 (0.4)                       | 2 (1.6)                 |
| Metabolismandnutritiondisorders             | 22 (8.6)                      | 14 (11.1)               |
| Hyperuricaemia                              | 6 (2.4)                       | 5 (4.0)                 |
| Hyponatraemia                               | 6 (2.4)                       | 0                       |
| Hypertriglyceridaemia                       | 5 (2.0)                       | 3 (2.4)                 |
| Hypercalcaemia                              | 0                             | 3 (2.4)                 |
| Hypokalaemia                                | 0                             | 3 (2.4)                 |
| Investigations                              | 21 (8.2)                      | 10 (7.9)                |
| Lymphocyte count decreased                  | 4 (1.6)                       | 0                       |
| Neutrophilcountdecreased                    | 4 (1.6)                       | 0                       |
| Blood cholesterolincreased                  | 3 (1.2)                       | 0                       |
| Weight increased                            | 3 (1.2)                       | 2 (1.6)                 |
| Gamma-glutamyltransferase increased         | 2 (0.8)                       | 3 (2.4)                 |
| Plateletcountdecreased                      | 2 (0.8)                       | 2 (1.6)                 |
| Respiratory,thoracicandmediastinaldisorders | 18 (7.1)                      | 4 (3.2)                 |
| Immune-mediatedlungdisease                  | 8 (3.1)                       | 0                       |
| Vasculardisorders                           | 7 (2.7)                       | 2 (1.6)                 |
| Hypertension                                | 5 (2.0)                       | 1 (0.8)                 |
| Skinandsubcutaneoustissuedisorders          | 6 (2.4)                       | 0                       |
| Rash                                        | 3 (1.2)                       | 0                       |
| Bloodand lymphaticsystem disorders          | 5 (2.0)                       | 5 (4.0)                 |
| Leukopenia                                  | 3 (1.2)                       | 0                       |
| Anaemia                                     | 2 (0.8)                       | 4 (3.2)                 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 30: Summary of treatment-emergent adverse events by grade 3, 4, and 5 (&gt; 1% of participants in either treatment group), study CS1001-301

|                                     | Sugemalimab (N=255)   | Sugemalimab (N=255)   | Sugemalimab (N=255)   | Placebo (N=126)   | Placebo (N=126)   | Placebo (N=126)   |
|-------------------------------------|-----------------------|-----------------------|-----------------------|-------------------|-------------------|-------------------|
| MedDRAPreferredTerm                 | Grade 3               | Grade 4               | Grade 5               | Grade 3           | Grade 4           | Grade 5           |
| Numberofpatientswithatleastoneevent | 64 (25.1%)            | 11 (4.3%)             | 12 (4.7%)             | 27 (21.4%)        | 8 (6.3%)          | 3 (2.4%)          |
| Pneumonia                           | 19 (7.5%)             | 0                     | 4 (1.6%)              | 7 (5.6%)          | 0                 | 1 (0.8%)          |
| Immune-mediated Iungdisease         | 5 (2.0%)              | 2 (0.8%)              | 1 (0.4%)              | 0                 | 0                 | 0                 |
| Hyperuricaemia                      | 0                     | 6 (2.4%)              | 0                     | 0                 | 5 (4.0%)          | 0                 |
| Hyponatraemia                       | 6 (2.4%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Hypertriglyceridaemia               | 5 (2.0%)              | 0                     | 0                     | 2 (1.6%)          | 1 (0.8%)          | 0                 |
| Hypertension                        | 5 (2.0%)              | 0                     | 0                     | 1 (0.8%)          | 0                 | 0                 |
| Lymphocytecountdecreased            | 3 (1.2%)              | 1 (0.4%)              | 0                     | 0                 | 0                 | 0                 |
| Neutrophil count decreased          | 4 (1.6%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Weightincreased                     | 3 (1.2%)              | 0                     | 0                     | 2 (1.6%)          | 0                 | 0                 |
| Bloodcholesterolincreased           | 3 (1.2%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Leukopenia                          | 2 (0.8%)              | 1 (0.4%)              | 0                     | 0                 | 0                 | 0                 |
| Rash                                | 3 (1.2%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Anaemia                             | 2 (0.8%)              | 0                     | 0                     | 4 (3.2%)          | 0                 | 0                 |
| Gamma-glutamyltransferaseincreased  | 2 (0.8%)              | 0                     | 0                     | 3 (2.4%)          | 0                 | 0                 |
| Plateletcountdecreased              | 1 (0.4%)              | 1 (0.4%)              | 0                     | 1 (0.8%)          | 1 (0.8%)          | 0                 |
| Hypophosphataemia                   | 2 (0.8%)              | 0                     | 0                     | 0                 | 1 (0.8%)          | 0                 |
| Pneumonitis                         | 2 (0.8%)              | 0                     | 0                     | 1 (0.8%)          | 0                 | 0                 |
| Radiation pneumonitis               | 1 (0.4%)              | 1 (0.4%)              | 0                     | 1 (0.8%)          | 0                 | 0                 |
| Coronaryarterydisease               | 2 (0.8%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Haemoptysis                         | 0                     | 0                     | 2 (0.8%)              | 0                 | 0                 | 0                 |
| Hyperglycaemia                      | 2 (0.8%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Hypothyroidism                      | 2 (0.8%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Inguinal hernia                     | 2 (0.8%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Neutropenia                         | 1 (0.4%)              | 1 (0.4%)              | 0                     | 0                 | 0                 | 0                 |
| Rectal cancer                       | 2 (0.8%)              | 0                     | 0                     | 0                 | 0                 | 0                 |
| Upper respiratory tract infection   | 1 (0.4%)              | 0                     | 0                     | 2 (1.6%)          | 0                 | 0                 |
| Hypercalcaemia                      | 0                     | 0                     | 0                     | 2 (1.6%)          | 1 (0.8%)          | 0                 |
| Hypokalaemia                        | 0                     | 0                     | 0                     | 2 (1.6%)          | 1 (0.8%)          | 0                 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Treatment-related adverse events by severity

Table 31: Most common (&gt; 5%) treatment-related treatment-emergent adverse events by highest NCI-CTCAE grade grouped by all grades and grade 3-5, study CA1001-301 (safety analysis set)

|                                                 | CS1001 (N=255)   | CS1001 (N=255)   | Placebo (N=126)   | Placebo (N=126)   |
|-------------------------------------------------|------------------|------------------|-------------------|-------------------|
| MedDRASystemOrganClass MedDRA Preferred Term    | All Grades       | Grade 3-5        | All Grades        | Grade 3-5         |
| Numberofpatientswithatleastoneevent             | 201 ( 78.88)     | 37(14.58)        | 81( 64.3%)        | 8(6.38)           |
| Investigations                                  | 119 (46.78)      | 9 （ 3.58)        | 48 (38.18)        | 1 0.88)           |
| Alanine aminotransferase increased              | 42 (16.58)       | 0                | 14 11.18)         | 0                 |
| Aspartate aminotransferase increased            | 35 (13.78)       | 1 0.48)          | 7 5.6%)           | 0                 |
| Blood thyroid stimulating hormone increased     | 22 （ 8.6%)       | 0                | 4 3.28)           | 0                 |
| Bloodthyroidstimulatinghormonedecreased         | 20 （ 7.88)       | 0                | 7 5.68)           | 0                 |
| Blood bilirubin increased                       | 15 （ 5.9%)       | 0                | 5 4.0%)           | 0                 |
| Gamma-glutamyltransferaseincreased              | 13 （ 5.18)       | 1 （ 0.48)        | 3 2.4%)           | 0                 |
| Whiteblood cell count decreased                 | 12 4.78)         | 0                | 8 6.38)           | 0                 |
| Endocrine disorders                             | 72 (28.28)       | 2 （ 0.88)        | 16 12.7%)         | 0                 |
| Hypothyroidism                                  | 50 (19.6%)       | 2 0.88)          | 12 9.58)          | 0                 |
| Hyperthyroidism                                 | 40 (15.78)       | 0                | 5 4.08)           | 0                 |
| Respiratory, thoracic and mediastinal disorders | 71 (27.88)       | 11 4.38)         | 27 (21.48)        | 1 （ 0.88)         |
| Immune-mediated lungdisease                     | 25 9.88)         | 8 3.1$)          | 4 3.28)           | 0                 |
| Pneumonitis                                     | 25 L 9.8$)       | 2 0.8%)          | 18 (14.38)        | 0.88)             |
| Interstitial lung disease                       | 16 6.3%)         | 0                | 4 （ 3.28)         | 0                 |
| Metabolism and nutrition disorders              | 50 (19.68)       | 6 （ 2.48)        | 19 (15.18)        | 2 1.68)           |
| Hyperglycaemia                                  | 19 （ 7.58)       | 0                | 6 4.88)           | 0                 |
| Hypertriglyceridaemia                           | 14 （ 5.58)       | 3 1.2$)          | 6 4.88)           | 0.8%)             |
| Hypercholesterolaemia                           | 13 （ 5.18)       | 0                | 2 1.6%)           | 0                 |
| Skin and subcutaneous tissue disorders          | 49 (19.28)       | 6 2.48)          | 8 6.38)           | 0                 |
| Rash                                            | 22 （ 8.6%)       | 3 1.2%)          | 6 4.88)           | 0                 |
| Pruritus                                        | 17 （ 6.7%)       | 1 0.48)          | 3 2.4%)           | 0                 |
| Blood and lymphatic system disorders            | 24 （ 9.48)       | 2 0.88)          | 10 7.9%)          | 1 ? 0.8%)         |
| Anaemia                                         | 17 6.7%)         | 1 0.48)          | 7 5.68)           | 1 0.8%)           |

Grade 4 sugemalimab- or placebo-related TEAEs were reported in three (1.2%) and two (1.6%) participants, respectively. Grade 4 sugemalimab-related TEAEs were immune-mediated lung disease (two [0.8%] participants), metabolic acidosis (one [0.4%] participant) and respiratory alkalosis (one [0.4%] participant). Grade 4 placebo-related TEAEs were hypercalcaemia, hypophosphatemia and platelet count decreased (one [0.8%] participant each).

Grade 5 (fatal) TEAEs considered related to sugemalimab or placebo by the Investigator were reported in three (1.2%) participants in the sugemalimab group and none in the placebo group.

## Adverse events leading to dose interruption

TEAEs leading to infusion interruption of sugemalimab or placebo were reported in one participant in each study arm (0.4% vs 0.8%). The reasons were vomiting and dizziness (sugemalimab) and dizziness (placebo), respectively.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Averse events leading to treatment cycle delay

Table 32: Treatment-emergent adverse events leading to treatment cycle delay, study CS1001-301 (safety analysis set)

| MedDRASystem OrganClass MedDRAPreferredTerm    | CS1001 (N=255)   | Placebo (N=126)   |
|------------------------------------------------|------------------|-------------------|
| Numberofpatientswithatleastoneevent            | 101(39.68)       | 36(28.68)         |
| RespiratorY,thoracic and mediastinal disorders | 35 13.78)        | 19 15.18)         |
| Pneumonitis                                    | 16 ( 6.38)       | 14 11.18)         |
| Immune-mediatedlungdisease                     | 9 3.58)          | 2 ( 1.68)         |
| Interstitiallungdisease                        | 9 3.58)          | 2 ( 1.68)         |
| Chronicobstructivepulmonarydisease             | 2 0.88)          | 0                 |
| Dyspnoea                                       | 1 0.48)          | 0                 |
| Trachealfistula                                | 1 0.48)          | 0                 |
| Pleuraleffusion                                | 0                | 1 0.88)           |
| Infections and infestations                    | 28 11.08)        | 13 10.38)         |
| Pneumonia                                      | 15 5.98)         | 4 （ 3.28)         |
| COVID-19                                       | 12 ( 4.78)       | 5 ( 4.08)         |
| Herpeszoster                                   | 2 0.88)          | 1 ( 0.88)         |
| Lower respiratory tractinfection               | 1 0.48)          | 1 ( 0.88)         |
| Laryngopharyngitis                             | 0                | 1 0.88)           |
| Upper respiratorytract infection               | 0                | 2 ( 1.68)         |
| Injury，poisoning andprocedural complications   | 25 9.88)         | 9 ( 7.18)         |
| Radiation pneumonitis                          | 22 8.68)         | 8 ( 6.38)         |
| Joint injury                                   | 1 0.48)          | 0                 |
| Pulmonary radiation injury                     | 1 （ 0.48)        | 0                 |
| Radiation fibrosis - lung                      | 1 0.48)          | 0                 |
| Claviclefracture                               | 0                | 1 0.88)           |
| Fracture                                       | 0                | 1 0.88)           |

Abbreviation:MedDRA=medicaldictionaryforregulatoryactivities. MedDRAVersion26.0.

Treatment-Emergentadverseevent(TEAE)wasdefinedasanyAEthatoccurredorworsenedon or after the initiation of study drug.

Forfrequencycountsbysystemorganclassorpreferredterm,multipleoccurrencesofthe Sameconditioninanindividualwerecountedonlyonce.

## Adverse events of special interest

Immune-related AEs (irAEs) are considered adverse events of special interest (AESIs) in the sugemalimab clinical studies.

|                                                      | cs1001 1200 mg (N=255)   | Placebo (N=126)   |
|------------------------------------------------------|--------------------------|-------------------|
| Number of Patients with at Least One Event           | 150(58.8%)               | 49(38.9%)         |
| Number of Patients with at Least One                 |                          |                   |
| Grade 3-5 Event                                      | 21(8.2%)                 | 0(0.0%)           |
| Serious Event                                        | 40 (15.7%)               | 7(5.6%)           |
| Investigator Assessed asirAE                         | 150(58.8%)               | 49(38.9%)         |
| Event Leading to Drug PermanentlyDiscontinued        | 26(10.2%)                | 1(0.8%)           |
| Event Leading to Drug Interruption                   | 41 (16.1%)               | 13(10.3)          |
| Event Leading toDeath                                | 1(0.4%)                  | 0(0.0%)           |
| Event Treated with Systemic Corticosteroid           | 54(21.2)                 | 11 (8.7)          |
| Event Treated with High Dose Systemic Corticosteroid | 47(18.4%)                | 7(5.6%)           |

Table 33: Summary of immune-related adverse events from Investigator assessment by category, study CS1001-301

<!-- image -->

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 34: Immune-related adverse events from investigator assessment by category, preferred term, study CS1001-301 (safety analysis set)

<!-- image -->

| Category                                                                                                                                                                 | CS10011200 mg (N=255)                                                                                                                                                    | Placebo (N=126)                                                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NumberofPatientswithatLeastOneEvent                                                                                                                                      | 150(58.8)                                                                                                                                                                | 49(38.9)                                                                                                                                                                 |
| Hepatitis                                                                                                                                                                | 22(8.66)                                                                                                                                                                 | 6(4.86)                                                                                                                                                                  |
| Alanine aminotransferase increased Aspartate aminotransferase increased                                                                                                  | 18 (7.1§) 14(5.56)                                                                                                                                                       | 6(4.85)                                                                                                                                                                  |
| Biiirubin conjugated increased                                                                                                                                           | 5(2.0§)                                                                                                                                                                  | 4(3.2) 1(0.8)                                                                                                                                                            |
| Blood bilirubin increased                                                                                                                                                | 6(2.4)                                                                                                                                                                   | 1(0.85)                                                                                                                                                                  |
| Immune-mediated hepatitis Transaminases increased                                                                                                                        | 1(0.4§) 1(0.4§)                                                                                                                                                          | 0(0.05) 0(0.05)                                                                                                                                                          |
| Pneumonitis                                                                                                                                                              | 55(21.65)                                                                                                                                                                | 20 (15.9)                                                                                                                                                                |
| Immune-mediated lung disease lung disease                                                                                                                                | 25(9.8) 14 (5.5)                                                                                                                                                         | 4(3.26) 4(3.2)                                                                                                                                                           |
| Interstitial Pneumonitis                                                                                                                                                 | 18 (7.1§)                                                                                                                                                                | 12(9.5)                                                                                                                                                                  |
| Colitis Colitis ulcerativ                                                                                                                                                | 5(2.05)                                                                                                                                                                  | 1 (0.85)                                                                                                                                                                 |
| Diarrhoea                                                                                                                                                                | 1(0.4$) 4(1.66)                                                                                                                                                          | (50.0)0 1(0.85)                                                                                                                                                          |
| Nephritis (including renal failure)                                                                                                                                      | 5(2.05)                                                                                                                                                                  | 2(1.6)                                                                                                                                                                   |
| Blood creatinine increased Blood urea increased                                                                                                                          | 2(0.85) 1(0.45)                                                                                                                                                          | 2(1.66) (50.0）0                                                                                                                                                          |
| Renal impairment                                                                                                                                                         | 1(0.4)                                                                                                                                                                   | 0(0.05)                                                                                                                                                                  |
| Renal injury                                                                                                                                                             | 1(0.4)                                                                                                                                                                   | 0(0.05)                                                                                                                                                                  |
| Hyperthyroidism                                                                                                                                                          | 54(21.2) 14(5.56)                                                                                                                                                        | 12(9.5) 4(3.2)                                                                                                                                                           |
| Blood thyroid stimulating hormone decreased                                                                                                                              |                                                                                                                                                                          |                                                                                                                                                                          |
| Hyperthyroidi sm                                                                                                                                                         | 37(14.5)                                                                                                                                                                 | 5(4.05)                                                                                                                                                                  |
| Thyroxine free increased                                                                                                                                                 | 4(1.6) 2(0.8)                                                                                                                                                            | 1(0.85)                                                                                                                                                                  |
| Thyroxine increased Tri-iodothyronine free                                                                                                                               | 8(3.1)                                                                                                                                                                   | 0(0.05) 2(1.65)                                                                                                                                                          |
| Tri-iodothyronine increased                                                                                                                                              | 1(0.4)                                                                                                                                                                   | 0(0.05)                                                                                                                                                                  |
| Hypothyroidism                                                                                                                                                           | 63(24.7)                                                                                                                                                                 | 16(12.7)                                                                                                                                                                 |
| Blood thyroid stimulating hormone increased                                                                                                                              | 18 (7.1§)                                                                                                                                                                | 4(3.2)                                                                                                                                                                   |
| Hypothyroidism Thyroxine decreased                                                                                                                                       | 47(18.45) 1(0.4)                                                                                                                                                         | 11(8.7) 0(0.05)                                                                                                                                                          |
| Thyroxine free decreased Tri-iodothyronine decreased                                                                                                                     | 7(2.74) 0(0.0) 2(0.8)                                                                                                                                                    | 2(1.66) 1(0.86)                                                                                                                                                          |
| Tri-iodothyronine free decreased Thyroiditis                                                                                                                             | 2(0.8)                                                                                                                                                                   | （00）0                                                                                                                                                                    |
| Thyroid disorder Diabetes Mellitus                                                                                                                                       | 2(0.8) 9(3.5)                                                                                                                                                            | 0(0.05) 0(0.05) 0(0.05)                                                                                                                                                  |
| Blood glucose increased                                                                                                                                                  |                                                                                                                                                                          | 0（0.0) 0（0.06)                                                                                                                                                           |
| Hyperglycaemia                                                                                                                                                           | 3(1.2) 6(2.45)                                                                                                                                                           |                                                                                                                                                                          |
| Severe skin adverse reactions                                                                                                                                            | 6(2.45)                                                                                                                                                                  | 0(0.05) 0（0.05) 0(0.05)                                                                                                                                                  |
| Pruritus Rash                                                                                                                                                            | 1(0.4) 3(1.2)                                                                                                                                                            | 0(0.0%)                                                                                                                                                                  |
| Rash maculo-papular Urticaria                                                                                                                                            | 1(0.4§) 1(0.4$)                                                                                                                                                          | 0（0.0)                                                                                                                                                                   |
| thrombocytopenia Platelet count decreased                                                                                                                                | 1(0.45) 1(0.4)                                                                                                                                                           | 0(0.05) 0（0.05)                                                                                                                                                          |
| Rhabdomyolysis/Myopathy Myoglobin blood increased                                                                                                                        | 1(0.4) 1(0.4§)                                                                                                                                                           | 0(0.05) 0(0.05)                                                                                                                                                          |
| Myocarditis Atrial fibrillation                                                                                                                                          | 8(3.15)                                                                                                                                                                  | 1(0.8)                                                                                                                                                                   |
| Blood creatine phosphokinase MB                                                                                                                                          | 1(0.4) 1(0.4$)                                                                                                                                                           | 0(0.0) 1(0.85)                                                                                                                                                           |
| increased Immune-mediatedmyocarditis                                                                                                                                     | 2(0.8) 2(0.8)                                                                                                                                                            | 0(0.05) 0(0.05)                                                                                                                                                          |
| Myocarditis Supraventricular tachycardia                                                                                                                                 | 1(0.45)                                                                                                                                                                  |                                                                                                                                                                          |
| Troponin I increased                                                                                                                                                     |                                                                                                                                                                          | 0(0.05)                                                                                                                                                                  |
| Ventricular extrasystoles                                                                                                                                                | 1(0.45) 1(0.4)                                                                                                                                                           | 0(0.0) 0(0.05)                                                                                                                                                           |
| Myositis                                                                                                                                                                 | 11 (4.3§) 7(2.7)                                                                                                                                                         | 3(2.4)                                                                                                                                                                   |
| Bloodcreatinephosphokinase increased Immune-mediated myositis                                                                                                            | 2(0.8)                                                                                                                                                                   | 3(2.46)                                                                                                                                                                  |
| Myalgia                                                                                                                                                                  | 2(0.8)                                                                                                                                                                   | (50.0）0 (0.0）0                                                                                                                                                           |
| Skin reaction (excluding Dermatitis                                                                                                                                      | 36（14.1) 2(0.85)                                                                                                                                                         | 5(4.0) (50.0）0 (50.0)0                                                                                                                                                   |
| Dermatitis acneiform Eczema                                                                                                                                              | 1(0.4$)                                                                                                                                                                  |                                                                                                                                                                          |
| Immune-mediated dermatitis Leukoderma                                                                                                                                    | 2(0.8) 3(1.2) 1(0.4)                                                                                                                                                     | 0(0.05)                                                                                                                                                                  |
| Rash                                                                                                                                                                     |                                                                                                                                                                          | 0(0.05) 0(0.05) 2(1.6)                                                                                                                                                   |
|                                                                                                                                                                          | 14 (5.5)                                                                                                                                                                 |                                                                                                                                                                          |
|                                                                                                                                                                          | 21(8.2) 1(0.4$)                                                                                                                                                          | 4(3.2)                                                                                                                                                                   |
| Rash maculo-papular                                                                                                                                                      | 1(0.4)                                                                                                                                                                   | 1(0.89) 0(0.05)                                                                                                                                                          |
| Arthritis Immune-mediated                                                                                                                                                | 1(0.49)                                                                                                                                                                  | (0.0）0                                                                                                                                                                   |
| arthritis Upper Gastrointestinal Disorders Mouth ulceration                                                                                                              | 2(0.8)                                                                                                                                                                   |                                                                                                                                                                          |
|                                                                                                                                                                          | 2(0.8)                                                                                                                                                                   |                                                                                                                                                                          |
|                                                                                                                                                                          |                                                                                                                                                                          | （0.0)0 (0.0)0                                                                                                                                                            |
| irAE. MedDRA Version 26.0.                                                                                                                                               |                                                                                                                                                                          |                                                                                                                                                                          |
| Abbreviations:NcI-CTcAE=NationalCancerInstitute CommonTerminologyCriteriaforAdverse Events;MedDRA=MedicalDictionaryfor RegulatoryActivities;AESI=Investigator Identified | Abbreviations:NcI-CTcAE=NationalCancerInstitute CommonTerminologyCriteriaforAdverse Events;MedDRA=MedicalDictionaryfor RegulatoryActivities;AESI=Investigator Identified | Abbreviations:NcI-CTcAE=NationalCancerInstitute CommonTerminologyCriteriaforAdverse Events;MedDRA=MedicalDictionaryfor RegulatoryActivities;AESI=Investigator Identified |
| Program:                                                                                                                                                                 | Program:                                                                                                                                                                 | Program:                                                                                                                                                                 |
| :andano Projects\\CS1001cS1001-301\\Re_20230403_0S_IA\\Program\\07_AESI\\t_ae_iirae sicat_pt_SA.rtf,                                                                          | :andano Projects\\CS1001cS1001-301\\Re_20230403_0S_IA\\Program\\07_AESI\\t_ae_iirae sicat_pt_SA.rtf,                                                                          | :andano Projects\\CS1001cS1001-301\\Re_20230403_0S_IA\\Program\\07_AESI\\t_ae_iirae sicat_pt_SA.rtf,                                                                          |
| Generated on: 12Nov2024                                                                                                                                                  | Generated on: 12Nov2024                                                                                                                                                  | Generated on: 12Nov2024                                                                                                                                                  |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## irAEs by severity

- Grade 1 irAEs: 59 (23.1%) in the sugemalimab arm vs. 32 (25.4%) in the placebo arm.
- Grade 2 irAEs: 70 (27.5%) sugemalimab vs. 17 (13.5%) placebo.
- Grade 3 irAEs: 18 (7.1%) sugemalimab vs. 0 placebo.
- Grade 4 irAEs: 2 (0.8%) sugemalimab vs. 0 placebo.
- Grade 5 irAEs: 1 (0.4%) sugemalimab vs. 0 placebo.

The grade 3 irAEs in the sugemalimab arm were pneumonitis and severe skin adverse reactions (six [2.4%] each), hepatitis (two [0.8%]), colitis, hypothyroidism, thrombocytopenia, and myocarditis (one [0.4%] each).

The two grade 4 and the one case of grade 5 irAEs pertained to pneumonitis.

## Serious irAEs

Serious irAEs were reported in 15.7% of patients: pneumonitis (32 [32.5%]), myocarditis (4 [1.6%]), myositis and colitis (2 [0.8%] each), and severe skin reaction 1 [0.4%]).

## Dose modifications due to irAEs

Interruption of sugemalimab treatment due to irAEs was reported in 41 pneumonitis (22 [8.6%]), severe skin reaction (4 [1.6%]), myositis (3 [1.2%]), hypothyroidism, hepatitis, myocarditis and colitis (2 [0.8%] each), hyperthyroidism, skin reaction (not severe), nephritis, and thrombocytopenia (1 [0.4%] each).

Permanent discontinuation of sugemalimab due to irAEs was reported in 26 patients: pneumonitis (21 [8.2%]) and skin reaction, severe skin reaction, myositis, myocarditis, and thrombocytopenia (1 [0.4%] each).

## Time to onset

Median time to onset (TTO) of first irAE event regardless of category was 125,0 days but varied between 61,0 days (range 20, 976) for ir-hyperthyroidism and 598,5 days (range 546, 651) days) for ir-thyroiditis.

The majority (67.3%) of all irAE events were resolved at DCO. The resolution rate for the individual irAEs where not all events were resolved was 20/22 (90.9%) for hepatitis, 20/55 (36.4%) for pneumonitis, 45/54 (83.3%) for hyperthyroidism, 32/63 (50.8%) for hypothyroidism, 0/2 (0%) for thyroiditis, 8/9 (88.9%) for diabetes mellitus, 4/8 (50.0%) for myocarditis, and 30/36 (83.3%) for myositis.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious adverse events

Table 35: Serious treatment-emergent adverse events (&gt; 1% of participants in either treatment group) by system organ class and preferred term, study CS1001-301 (safety analysis set)

| System Organ Class Preferred Term              | Sugemalimab (N = 255) n (%)   | Placebo (N =126) n (%)   |
|------------------------------------------------|-------------------------------|--------------------------|
| Number of Participants With at Least One Event | 94 (36.9)                     | 37 (29.4)                |
| Respiratory,thoracicandmediastinaldisorders    | 39 (15.3)                     | 12 (9.5)                 |
| Immune-mediatedlung disease                    | 17 (6.7)                      | 1 (0.8)                  |
| Pneumonitis                                    | 11 (4.3)                      | 8 (6.3)                  |
| Interstitial lung disease                      | 9 (3.5)                       | 3 (2.4)                  |
| Infections and infestations                    | 30 (11.8)                     | 12 (9.5)                 |
| Pneumonia                                      | 24 (9.4)                      | 8 (6.3)                  |
| Injury, poisoning and procedural complications | 19 (7.5)                      | 9 (7.1)                  |
| Radiation pneumonitis                          | 16 (6.3)                      | 6 (4.8)                  |
| Hepatobiliary disorders                        | 1 (0.4)                       | 3 (2.4)                  |
| Cholecystitis                                  | 0                             | 2 (1.6)                  |
| Nervoussystem disorders                        | 1 (0.4)                       | 2 (1.6)                  |
| Cerebral infarction                            | 0                             | 2 (1.6)                  |

MedDRA version 26.0.

The participant is counted only once per unique SOC and once per unique PT within SOC.

CSR = clinical study report; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SOC = system organ class.

Source: Study CS1001-301 CSR, Table t\\_ae\\_ser\\_SA\\_2

## Treatment-related serious adverse events

Table 36: Sugemalimab- or placebo-related serious treatment-emergent adverse events (&gt; 2 participants in either treatment group) by system organ class and preferred term, study CS1001-301 (safety analysis set)

| System Organ Class Preferred Term             | Sugemalimab (N = 255) n (%)   | Placebo (N =126) n (%)   |
|-----------------------------------------------|-------------------------------|--------------------------|
| Number ofParticipantsWith at Least OneEvent   | 49 (19.2)                     | 12 (9.5)                 |
| Respiratory,thoracicand mediastinal disorders | 33 (12.9)                     | 10 (7.9)                 |
| Immune-mediated lung disease                  | 17 (6.7)                      | 1 (0.8)                  |
| Pneumonitis                                   | 9 (3.5)                       | 7 (5.6)                  |
| Interstitial lung disease                     | 8 (3.1)                       | 2 (1.6)                  |
| Infections andinfestations                    | 10 (3.9)                      | 1 (0.8)                  |
| Pneumonia                                     | 8 (3.1)                       | 1 (0.8)                  |
| Cardiac disorders                             | 3 (1.2)                       | 0                        |
| Immune-mediatedmyocarditis                    | 2 (0.8)                       | 0                        |

MedDRA version 26.0.

CSR = clinical study report; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SOC = system organ class.

\"Related” is defined as the relationship to sugemalimab or placebo is related or missing.

Source: Study CS1001-301 CSR, Table t\\_ae\\_rel\\_ser\\_SA\\_2

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Deaths

In study 301, any death resulting from a non-drug related event that occurred &gt; 90 days after the last dose of study drug was not recorded as an AE but was recorded as a death due to other causes.

Table 37: Summary of deaths, study CS1001-301 (safety analysis set)

|                       | Sugemalimab (N=255)   | Placebo (N=126)   | Total (N=381)   |
|-----------------------|-----------------------|-------------------|-----------------|
| NumberofPatientDeaths | 116 (45.5%)           | 66 (52.4%)        | 182 (47.8%)     |
| Primarycauseofdeath   |                       |                   |                 |
| AdverseEvent          | 12 (4.7%)             | 3 (2.4%)          | 15 (3.9%)       |
| ProgressionofDisease  | 87 (34.1%)            | 58 (46.0%)        | 145 (38.1%)     |
| Other                 | 17 (6.7%)             | 5 (4.0%)          | 22 (5.8%)       |

Source:Tablet\\_dd\\_SA\\_2

Table 38: Treatment-emergent adverse events leading to death by system organ class and preferred term, study CS1001-301 (safety analysis set)

| MedDRA System Organ Class                                        | Sugemalimab (N=255)   | Placebo (N=126)   |
|------------------------------------------------------------------|-----------------------|-------------------|
| MedDRA Preferred Term Number of patients with at least one event | 12 (4.7%)             | 3 (2.4%)          |
| Infections andinfestations                                       | 5 (2.0%)              | 1 (0.8%)          |
| Pneumonia                                                        | 4 (1.6%)              | 1 (0.8%)          |
| Infection                                                        | 1 (0.4%)              | 0                 |
| Respiratory, thoracic and mediastinal disorders                  | 4 (1.6%)              | 1 (0.8%)          |
| Haemoptysis                                                      | 2 (0.8%)              | 0                 |
| Immune-mediatedlung disease                                      | 1 (0.4%)              | 0                 |
| Interstitial lung disease                                        | 1 (0.4%)              | 1 (0.8%)          |
| Cardiac disorders                                                | 1(0.4%)               | 1 (0.8%)          |
| Atrial flutter                                                   | 1 (0.4%)              | 0                 |
| Cardiac failure                                                  | 1 (0.4%)              | 0                 |
| Cardio-respiratory arrest                                        | 0                     | 1 (0.8%)          |
|                                                                  |                       | 0                 |
| Generaldisordersandadministrationsiteconditions Death            | 1 (0.4%) 1 (0.4%)     | 0                 |
| Neoplasms benign, malignant and unspecified (incl cysts and      | 1 (0.4%)              | 0                 |
| polyps) Acute myeloid leukaemia                                  | 1 (0.4%)              | 0                 |
| Nervous system disorders                                         | 1 (0.4%)              | 0                 |
| Haemorrhage intracranial                                         | 1 (0.4%)              | 0                 |
| Vascular disorders                                               | 0                     | 1 (0.8%)          |
| Shock                                                            | 0                     | 1 (0.8%)          |

Source:Tablet\\_ae\\_fatal\\_SA\\_2

Abbreviation: MedDRA = medical dictionary for regulatory activities.

MedDRAversion26.0.

Treatment-Emergent adverse event(TEAE)was defined as any AE that occurred or worsened on or after the initiation of study drug.

same condition in an individual were counted only once.

For frequency countsby system organ class or preferred term,multiple occurrences ofthe

Two cases of death due to pneumonia and the one case of death due to immune-mediated lung disease were assessed as related to sugemalimab by the investigator. In all three cases, patients had onset of symptoms shortly (&lt;1 month) after treatment with sugemalimab started.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Clinical chemistry

## Table 39: Laboratory abnormalities worsening from baseline - clinical chemistry safety analysis set

| Parameter                        | Direction   | All Grade    |     | Grade 3-4   | All Grade   | Grade 3-4   |          |
|----------------------------------|-------------|--------------|-----|-------------|-------------|-------------|----------|
| Alanine Aminotransferase (U/L)   | High        | 82(32.28)    |     | 2(0.8%)     | 31(24.68)   | 0           |          |
| Albumin (g/L)                    | Low         | 100 ( 39.28) | 0   |             | 42(33.38)   | 0           |          |
| Alkaline Phosphatase (U/L)       | High        | 45 ( 17.68)  | 0   |             | 28(22.28)   | 0           |          |
| Aspartate Aminotransferase (U/L) | High        | 84(32.9%)    |     | 2(0.8%)     | 22 (17.58)  |             | 1(0.8%)  |
| Bilirubin (umol/L)               | High        | 48(18.88)    | 0   |             | 16 ( 12.78) | 0           |          |
| Cholesterol (mmol/L)             | High        | 97(38.0%)    |     | 5( 2.0%)    | 53 (42.18)  | 0           |          |
| Correct Calcium (mmol/L)         | Low         | 39(15.38)    | 0   |             | 7 （ 5.6%)   | 0           |          |
| Correct Calcium (mmol/L)         | High        | 39(15.38)    |     | 0.8%)       | 18 ( 14.38) |             | 3(2.48)  |
| Creatinine (umol/L)              | High        | 224 (87.88)  | 0   |             | 107(84.9%)  | 0           |          |
| Fasting Glucose (mmol/L)         | Low         | 15（ 5.9%)    | 1（  | 0.48)       | 4（ 3.28)    | 0           |          |
| Fasting Glucose (mmol/L)         | High        | 126 ( 49.48) |     | 8(3.1%)     | 65 (51.68)  |             | 5(4.0%)  |
| Magmesium (mmol/L)               | Low         | 45(17.6%)    | 0   |             | 28(22.28)   | 1 （         | 0.88)    |
| Magmesium (mmol/L)               | High        | 38(14.98)    |     | 7(2.78)     | 20(15.9%)   |             | 5( 4.0%) |
| Phosphate (mmol/L)               | Low         | 89(34.9%)    | 11（ | 4.38)       | 45 ( 35.78) |             | 3(2.48)  |
| Potassium (mmol/L)               | Low         | 59( 23.1)    | 12  | 4.7%)       | 23 (18.38)  |             | 4(3.28)  |
| Potassium (mmol/L)               | High        | 17 （ 6.7%)   | 3 （ | 1.2%)       | 3 2.48)     | 0           |          |
| Sodium (mmol/L)                  | Low         | 80(31.4%)    | 11  | 4.3%)       | 36(28.68)   |             | 2 (1.68) |
| Sodium (mmol/L)                  | High        | 9( 3.58)     | 0   |             | 5 5(4.0%)   | 0           |          |

4.03.

ProgramLocation:

P:\\01\\_OngoingProjects\\c\\_092\\_ONc\\_CS1001\\_301\\Final\\original\\Programs\\tfl\\t\\_lb\\_chem\\_abnor mSA.sas

OutputLocation:

P:\\01\\_OngoingProjects\\c\\_092\\_ONc\\_CS1001\\_301\\Final\\original\\Programs\\tfl\\output\\t\\_lb\\_che m\\_abnorm\\_SA.rtf

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 40: Liver function laboratory findings

| LaboratoryFindings                            | CS1001 (N=255)   | Placebo (N=126)   |
|-----------------------------------------------|------------------|-------------------|
| ALTand/orAST>3*ULNandTBIL>=2*ULN，andALP<2*ULN | 0                | 0                 |
| ALTand/orAST>3*ULN，andTBIL>=2*ULN             | 0                | 0                 |
| ALTand/orAST>3*ULN，andTBIL>=1.5*ULN           | 0                | 0                 |
| ALTand/orAST                                  |                  |                   |
| >3*ULN                                        | 6 ( 3.5*)        | 2 1.68)           |
| >=5*ULN                                       | 3 ( 1.2)         | 1 C 0.8)          |
| >=10*ULN                                      | 0                | 0                 |
| >=20*ULN                                      | 0                | 0                 |
| ALT                                           |                  |                   |
| >3*ULN                                        | 8 ( 3.1%)        | 0                 |
| >=5*ULN                                       | 2 ( 0.8%)        | 0                 |
| >=10*ULN                                      | 0                | 0                 |
| >=20*ULN                                      | 0                | 0                 |
| AST                                           |                  |                   |
| >3*ULN                                        | 7 ( 2.7%)        | 2 ( 1.68)         |
| >=5*ULN                                       | 2 ( 0.8*)        | 1 0.8)            |
| >=10*ULN                                      | 0                | 0                 |
| >=20*ULN                                      | 0                | 0                 |
| TBIL                                          |                  |                   |
| >=1.5*ULN                                     | 9 ( 3.5*)        | 1 0.8%)           |
| >=2*ULN                                       | 5 （ 2.0%)        | 0                 |
| ALP                                           |                  |                   |
| >=1.5*ULN                                     | 6 (3.5)          | 8(6.3)            |

Abbreviation: ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; TBIL: Total Bilirubin; ALP = Alkaline Phosphatase; ULN = upper limit of normal. Numberofpatientswithpost-baselinetestresults(orcombinationoftestresultsfromthe Samevisit)thatmetthepredeterminedcriteriawerecounted.

Program Location:

P:\\01\\_OngoingProjects\\C\\_092\\_ONC\\_CS1001\\_301\\Final\\Original\\Programs\\tfl\\t\\_lb\\_1iver\\_SA. sas

Output Location:

P:\\01\\_OngoingProjects\\C\\_092\\_ONC\\_CS1001\\_301\\Final\\Original\\Programs\\tfl\\output\\t\\_1b\\_1i ver\\_SA.rtf

No cases met the criteria for Hy's law.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Haematology

## Table 41: Laboratory abnormalities worsening from baseline - haematology safety analysis set

|                      |           | CS1001 (N=255)   | CS1001 (N=255)   | CS1001 (N=255)   | CS1001 (N=255)   | Placebo (N=126)   | Placebo (N=126)   | Placebo (N=126)   | Placebo (N=126)   |
|----------------------|-----------|------------------|------------------|------------------|------------------|-------------------|-------------------|-------------------|-------------------|
| Parameter            | Direction |                  | All Grade        | Grade 3-4        |                  |                   | All Grade         | Grade 3-4         |                   |
| Hemoglobin (g/L)     | Low       | 42               | (16.58)          | 7（               | 2.78)            | 22                | 2(17.5%)          | 5( 4.0%)          |                   |
| Hemoglobin (g/L)     | High      | 11               | （ 4.38)          | 0                |                  |                   | 4(3.28)           | 0                 |                   |
| Leukocytes (10~9/L)  | Low       | 49               | (19.28)          | 5                | 2.08)            |                   | 32 (25.48)        | (3.2%)            |                   |
| Lymphocytes (10^9/L) | Low       |                  | 108 (42.48)      | 33               | (12.98)          |                   | 51(40.5%)         | 14 (11.1%)        |                   |
| Lymphocytes (10^9/L) | High      | 7                | 2.7%)            |                  | 0.8$)            | 0                 |                   | 0                 |                   |
| Neutrophils (10^9/L) | Low       |                  | 33(12.9%)        | 7 （              | 2.7%)            |                   | 19( 15.1$)        | 3(2.48)           |                   |
| Platelets(10^9/L)    | Low       | 39               | (15.38)          | 3                | ( 1.2%)          | 22                | (17.5$)           | 2 （ 1.6%)         |                   |

Laboratory results were graded using Common Terminology Criteria for AdverseEventsVersion 4.03.

ProgramLocation:

P:\\01\\_OngoingProjects\\c\\_092\\_ONc\\_Cs1001\\_301\\Final\\original\\Programs\\tfl\\t\\_lb\\_chem\\_abnor m SA.sas

Output Location:

P:\\01\\_OngoingProjects\\c\\_092\\_ONc\\_Cs1001\\_301\\Final\\original\\Programs\\tfl\\output\\t\\_lb\\_hem a\\_abnorm\\_SA.rtf

## Thyroid function tests

In study 301, thyroid function tests (thyrotropin, free triiodothyronine, free thyroxine) were performed regularly as part of the monitoring for immune-related thyroid disorders. Baseline values represent the patients' last observations prior to initiation of study drug.

The majority of patients hade normal thyrotropin, free triiodothyronine, and free thyroxine values at baseline (90.2%, 96.1%, and 97.3% of patients, respectively).

For each thyroid parameter, comparable proportions of patients experienced either high or low values post-baseline compared to baseline (thyrotropin 31.0% high vs. 32.5% low, free triiodothyronine 27.5% high vs. 20.4% low, free thyroxine 20.8% high vs. 27.1% low, respectively).

## Vital signs and physical findings

## Vital signs and weight

There were no clinically meaningful changes in vital signs (blood pressure, pulse rate, respiratory rate, body temperature) and weight from baseline and across treatments.

## Electrocardiogram

Abnormal ECG values determined by the Investigator to be clinically significant were reported as AEs. None of the TEAEs associated with abnormal ECG findings were grade &gt; 3 in severity, serious, or led to discontinuation of sugemalimab or placebo treatment.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 42: 12-lead ECG results (safety analysis set)

|                 |                                     | Baseline12-LeadECGResult   | Baseline12-LeadECGResult             | Baseline12-LeadECGResult         | Baseline12-LeadECGResult   | Baseline12-LeadECGResult   | Baseline12-LeadECGResult   |
|-----------------|-------------------------------------|----------------------------|--------------------------------------|----------------------------------|----------------------------|----------------------------|----------------------------|
| Treatment       | WorstPost-Baseline 12-LeadECGResult | Normal                     | Abnormal, not clinically significant | Abnormal, clinically significant | Not evaluable              | Missing                    | Total                      |
| CS1001 (N=255)  | Normal                              | 2（ 0.88)                   | 2(0.8)                               | 0                                | 0                          | 0                          | 4（ 1.6)                    |
|                 | Abnormal,not clinically sigmificant | 4（ 1.6)                    | 6(2.4)                               | 3(1.2%)                          | 0                          | 0                          | 13 ( 5.1)                  |
|                 | Abnormal, clinically sigmificant    | 8(3.1)                     | 8 (3.1)                              | 1（ 0.4)                          | 1 (0.4%)                   | 0                          | 18 ( 7.1)                  |
|                 | Not evaluable                       | 0                          | 0                                    | 0                                | 0                          | 0                          | 0                          |
|                 | Missing                             | 132 (51.8)                 | 75(29.4)                             | 8 ( 3.1)                         | 5 2.08)                    | 0                          | 220 (86.3)                 |
|                 | Total                               | 146 (57.3)                 | 91(35.7)                             | 12 （ 4.7%)                       | 2.48)                      | 0                          | 255 (100.0)                |
| Placebo (N=126) | Normal                              | 2.4)                       | 0.8)                                 | 1（ 0.8)                          | 0                          | 0                          | 5（ 4.0%)                   |
|                 | Abnormal，not clinically sigmificant | 2 一 1.6)                   | 2(1.6)                               | 0                                | 0                          | 0                          | 3.28)                      |
|                 | Abnormal, clinically sigmificant    | 1 0.88)                    | 2(1.6)                               | 0                                | 0                          |                            | 3(2.4)                     |
|                 | Not evaluable                       | 0                          | 0                                    | 0                                | 0                          | 0                          | 0                          |
|                 | Missing                             | 61 (48.4)                  | 37 (29.4)                            | 10（ 7.98)                        | 6 （ 4.8)                   | 0                          | 114 (90.5)                 |
|                 | Total                               | 67 (53.2)                  | 42 2（33.3)                           | 11（ 8.7%)                        | 6( 4.88)                   | 0                          | 126 (100.0)                |

Abbreviation:ECG= electrocardiograph;N= number of patients in specified group.

ProgramLocation:P:\\01OngoingProjects\\C092\\_ONCCS1001\\_301\\Final\\Original\\Programs\\tfl\\t\\_eg\\_SA.sas OutputLocation:P:\\01\\_OngoingProjects\\c\\_092\\_ONc\\_CS1001\\_301\\Final\\Original\\Programs\\tfl\\output\\t\\_eg\\_SA.rtf

## ECOG performance status

Table 43: Table of ECOG performance status (safety analysis set)

|                 |                                             | BaselineEcoGPerformanceStatus   | BaselineEcoGPerformanceStatus   | BaselineEcoGPerformanceStatus   | BaselineEcoGPerformanceStatus   | BaselineEcoGPerformanceStatus   |
|-----------------|---------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Treatment       | HighestPost-Baseline ECoGPerformance Status | 0                               | 1                               | >=2                             | Missing                         | Total                           |
| CS1001 (N=255)  | 0                                           | 46 (18.0)                       | 0                               | 0                               | 0                               | 46 (18.0%)                      |
|                 | 1                                           | 27(10.6)                        | 166 ( 65.1)                     | 0                               | 0                               | 193 ( 75.7)                     |
|                 | >=2                                         | 3 （ 1.2)                        | 6(2.4)                          | 0                               | 0                               | 9 （ 3.5)                        |
|                 | Missing                                     | 2 （ 0.8%)                       | 5 （ 2.0%)                       | 0                               | 0                               | 7 2.7%)                         |
|                 | Total                                       | 78 （30.6)                       | 177(69.4)                       | 0                               | 0                               | 255 5(100.0%)                   |
| Placebo (N=126) | 0                                           | 25 (19.88)                      | 0                               | 0                               | 0                               | 25 (19.8)                       |
|                 | 1                                           | 9 7.1)                          | 85 (67.5)                       | 0                               | 0                               | 94 (74.6)                       |
|                 | >=2                                         | 3 2.4)                          | 2 (1.6)                         | 0                               | 0                               | 5 ( 4.0%)                       |
|                 | Missing                                     | 1 0.8)                          | 1 0.8)                          | 0                               | 0                               | 2 1.6)                          |
|                 | Total                                       | 38(30.2)                        | 88(69.8)                        | 0                               | 0                               | 126 (100.0)                     |

Abbreviation:EcoG=easterncooperativeoncologygroup.

ProgramLocation:P:\\01\\_OngoingProjects\\C092\\_ONC\\_CS1001\\_301\\Final\\Original\\Programs\\tfl\\t\\_ecog\\_shiftSA.sas OutputLocation:P:\\01OngoingProjects\\C\\_092\\_ONC\\_CS1001\\_301\\Final\\Original\\Programs\\tfl\\output\\t\\_ecog\\_shift\\_SA.rtf

## Safety in special populations

Table 44: Overview of safety by sex and age groups, study CS1001-301

|                                          | Sugemalimab（N=255）   | Sugemalimab（N=255）   | Placebo(N=126)   | Placebo(N=126)   | Sugemalimab（N=255)   | Sugemalimab（N=255)   | Placebo(N=126)   | Placebo(N=126)   |
|------------------------------------------|----------------------|----------------------|------------------|------------------|----------------------|----------------------|------------------|------------------|
|                                          | Female (N=19)        | Male (N=236)         | Female (N=11)    | Male (N=115)     | Age<65 (N=182)       | Age >= 65 (N=73)     | Age<65 (N=94)    | Age >= 65 (N=32) |
| TEAEs (all grades)                       | 18 (94.7%)           | 230 (97.5%)          | 11 (100.0%)      | 110 (95.7%)      | 178 (97.8%)          | 70 (95.9%)           | 90 (95.7%)       | 31 (96.9%)       |
| TEAEsgrade>3                             | 5 (26.3%)            | 82 (34.7%)           | 0                | 38 (33.0%)       | 58 (31.9%)           | 29 (39.7%)           | 28 (29.8%)       | 10 (31.3%)       |
| SAES                                     | 6 (31.6%)            | 88 (37.3%)           | 2 (18.2%)        | 35 (30.4%)       | 70 (38.5%)           | 24 (32.9%)           | 24 (25.5%)       | 13 (40.6%)       |
| immune- relatedTEAEs                     | 12 (63.2%)           | 138 (58.5%)          | 7 (63.6%)        | 42 (36.5%)       | 113 (62.1%)          | 37 (50.7%)           | 39 (41.5%)       | 10 (31.3%)       |
| TEAEsleading to death                    | 0                    | 12 (5.1%)            | 0                | 3 (2.6%)         | 7 (3.8%)             | 5 (6.8%)             | 2 (2.1%)         | 1 (3.1%)         |
| TEAEsleadingto treatmentdisco ntinuation | 2 (10.5%)            | 45 (19.1%)           | 0                | 6 (5.2%)         | 32 (17.6%)           | 15 (20.5%)           | 4 (4.3%)         | 2 (6.3%)         |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 45: Overview of safety by weight groups and ECOG performance status, study CS1001-301

|                                          | Sugemalimab（N=255)   | Sugemalimab（N=255)   | Placebo(N=126)     | Placebo(N=126)    | Sugemalimab（N=255)   | Sugemalimab（N=255)   | Placebo(N=126)   | Placebo(N=126)   |
|------------------------------------------|----------------------|----------------------|--------------------|-------------------|----------------------|----------------------|------------------|------------------|
|                                          | Weight<= 62 (N=132)  | Weight >62 (N=123)   | Weight<= 62 (N=60) | Weight >62 (N=66) | ECOG=0 (N=78)        | ECOG=1 (N=177)       | ECOG=0 (N=38)    | ECOG= 1 (N=88)   |
| TEAEs (all grades)                       | 129 (97.7%)          | 119(96. 7%)          | 59 (98.3%)         | 62 (93.9%)        | 78 (100.0%)          | 170 (96.0%)          | 34 (89.5%)       | 87 (98.9%)       |
| TEAEsgrade>3                             | 43 (32.6%)           | 44 (35.8%)           | 16 (26.7%)         | 22 (33.3%)        | 26 (33.3%)           | 61 (34.5%)           | 10 (26.3%)       | 28 (31.8%)       |
| SAEs                                     | 46 (34.8%)           | 48 (39.0%)           | 17 (28.3%)         | 20 (30.3%)        | 29 (37.2%)           | 65 (36.7%)           | 11 (28.9%)       | 26 (29.5%)       |
| immune- relatedTEAEs                     | 73 (55.3%)           | 77 (62.6%)           | 22 (36.7%)         | 27 (40.9%)        | 43 (55.1%)           | 107 (60.5%)          | 11 (28.9%)       | 38 (43.2%)       |
| TEAEsleadingto death                     | 7 (5.3%)             | 5 (4.1%)             | 1 (1.7%)           | 2 (3.0%)          | 4 (5.1%)             | 8 (4.5%)             | 1 (2.6%)         | 2 (2.3%)         |
| TEAEsleadingto treatmentdisco ntinuation | 24 (18.2%)           | 23 (18.7%)           | 2 (3.3%)           | 4 (6.1%)          | 15 (19.2%)           | 32 (18.1%)           | 2 (5.3%)         | 4 (4.5%)         |

Table 46: Overview of safety by PD-L1 and ADA status, study CS1001-301

|                                         | Sugemalimab（N=255)   | Sugemalimab（N=255)   | Placebo(N=126)   | Placebo(N=126)   | Sugemalimab（N=255）   | Sugemalimab（N=255）   |
|-----------------------------------------|----------------------|----------------------|------------------|------------------|----------------------|----------------------|
|                                         | PDL1<1% (N=51)       | PDL1 >= 1% (N=72)    | PDL1<1% (N=29)   | PDL1 >= 1%(N=23) | ADA Negative (N=228) | ADAPositive (N=27)   |
| TEAEs(all grades)                       | 49 (96.1%)           | 71 (98.6%)           | 26 (89.7%)       | 22 (95.7%)       | 222 (97.4%)          | 26 (96.3%)           |
| TEAEsgrade>3                            | 18 (35.3%)           | 22 (30.6%)           | 6 (20.7%)        | 5 (21.7%)        | 80 (35.1%)           | 7 (25.9%)            |
| SAEs                                    | 12 (23.5%)           | 31 (43.1%)           | 6 (20.7%)        | 7 (30.4%)        | 86 (37.7%)           | 8 (29.6%)            |
| immune-relatedTEAEs                     | 31 (60.8%)           | 48 (66.7%)           | 11 (37.9%)       | 11 (47.8%)       | 132 (57.9%)          | 18 (66.7%)           |
| TEAEsleadingtodeath                     | 3 (5.9%)             | 1 (1.4%)             | 0                | 0                | 12 (5.3%)            | 0                    |
| TEAEsleadingtotreatment discontinuation | 7(13.7%)             | 12 (16.7%)           | 0                | 0                | 42 (18.4%)           | 5 (18.5%)            |

## Safety related to drug-drug interactions and other interactions

No formal drug-drug interaction studies have been conducted with sugemalimab.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 47: Treatment-emergent adverse events leading to permanent discontinuation of sugemalimab or placebo treatment by system organ class and preferred term, CS1001301 (safety analysis set)

| System Organ Class Preferred Term                                   | Sugemalimab (N=255) n (%6)   | Placebo (N =126) n (%)   |
|---------------------------------------------------------------------|------------------------------|--------------------------|
| Number of Participants With at Least One Event                      | 47(18.4)                     | 6 (4.8)                  |
| Respiratory, thoracic and mediastinal disorders                     | 25 (9.8)                     | 3 (2.4)                  |
| Immume-mediated lumg disease                                        | 13 (5.1)                     | 0                        |
| Pneumonitis                                                         | 7 (2.7)                      | 2 (1.6)                  |
| Interstitial lung disease                                           | 3 (1.2)                      | 1 (0.8)                  |
| Haemoptysis                                                         | 2 (0.8)                      | 0                        |
| Infections and infestations                                         | 6 (2.4)                      | 1 (0.8)                  |
| Pneumonia                                                           | 5 (2.0)                      | 1 (0.8)                  |
| Infection                                                           | 1 (0.4)                      | 0                        |
| Pulmonary tuberculosis                                              | 1 (0.4)                      | 0                        |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 5 (2.0)                      | 0                        |
| Acute myeloid leukaemia                                             | 1 (0.4)                      | 0                        |
| Hepatic cancer                                                      | 1 (0.4)                      | 0                        |
| Oesophageal cancer metastatic                                       | 1 (0.4)                      | 0                        |
| Oesophageal squamous cell carcinoma                                 | 1 (0.4)                      | 0                        |
| Rectal cancer                                                       | 1 (0.4)                      | 0                        |
| Metabolism and nutrition disorders                                  | 3 (1.2)                      | 0                        |
| Hypertriglyceridaemia                                               | 2 (0.8)                      | 0                        |
| Diabetic ketoacidosis                                               | 1 (0.4)                      | 0                        |
| Cardiac disorders                                                   | 2 (0.8)                      | 0                        |
| Atnial flutter                                                      | 1 (0.4)                      | 0                        |
| Cardiac failure                                                     | 1 (0.4)                      | 0                        |
| Immume-mediated myocarditis                                         | 1 (0.4)                      | 0                        |
| Injury, poisoning and procedural complications                      | 2 (0.8)                      | 2 (1.6)                  |
| Radiation pneumonitis                                               | 2 (0.8)                      | 1 (0.8)                  |
| Thoracic vertebral fracture                                         | 0                            | 1 (0.8)                  |
| Investigations                                                      | 2 (0.8)                      | 0                        |
| Blood creatine phosphokinase increased                              | 1 (0.4)                      | 0                        |
| Platelet count decreased                                            | 1 (0.4)                      | 0                        |
| System Organ Class Preferred Tem                                    | Sugemalimab (N=255) n (%)    | Placebo (N =126) n (%)   |
| Skin and subcutaneous tissue disorders                              | 2 (0.8%)                     | 0                        |
| Rash                                                                | 2 (0.8%)                     | 0                        |
| General disorders and administration site conditions                | 1 (0.4%)                     | 0                        |
| Death                                                               | 1 (0.4%)                     | 0                        |
| Nervous system disorders                                            | 1 (0.4%)                     | 0                        |
| Haemorrhage intracranial                                            | 1 (0.4%)                     | 0                        |

Source: Study CS1001-301 CSR, Table t\\_ae\\_disc\\_SA\\_2

Sugemalimab-related TEAEs leading to treatment discontinuation also led to death in 3 participants: immune-mediated lung disease in 1 participant and pneumonia in 2 participants (Table 15). No participant had placebo-related TEAEs leading to treatment discontinuation that fesulted in death. Additional details on TEAEs leading to death are provided in Section 2.1.2.1.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Supportive sugemalimab monotherapy pool

## Introduction

The sugemalimab monotherapy pool consisted of 568 patients with advanced or metastatic NSCLC, other solid tumours, and haematological malignancies who received at least one dose of sugemalimab 1,200 mg Q3W.

The sugemalimab arm of study 301 (n=255) accounted for 44.9% of the patients in the sugemalimab monotherapy pool.

It is noted that the TEAE incidences presented for the sugemalimab arm of study 301 in the pivotal study differs from the incidence numbers presented for the same study arm in the sugemalimab monotherapy pool tables. This is due to different DCOs. Study data 301 are presented as of DCO 03 April 2023 whereas the DCO of the studies included in the sugemalimab monotherapy pool, including study 301, was 08 March 2021.

Overall, the study 301 safety population and the sugemalimab monotherapy pool population were comparable as regards variables such as sex (majority male participants), race (Asian), median age at diagnosis (&lt; 65 years), median weight (&lt; 65 kg), and ECOG performance status (majority ECOG 1). Other factors, such as distribution of disease stage or histology were not comparable due to different study inclusion criteria. This also regarded prior treatments. Patients in the monotherapy pool were generally more heavily pretreated, with 41.4% having received 1 st  line and 28.9% 2 nd  line treatment, and 48.8% having underwent prior cancer-related surgery, whereas only 8.6% of the patients in the study 301 safety population had received prior cancer therapy other than chemoradiotherapy and 5.1% having underwent prior cancer-related surgery.

## Patient exposure

As of DCO 08 March 2021 for the studies included in the sugemalimab monotherapy pool, 164 (28.9%) of the patients were still on treatment and 404 (70.1%) had discontinued treatment. A total of 373 (65.7%) of the patients were still on study, whereas 195 (34.3%) had discontinued from study.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 48: Summary of exposure to sugemalimab, sugemalimab monotherapy pool (safety analysis set)

<!-- image -->

|                                        | CS1001- 101a/b (N = 95) n(46)          | CS1001- 102 (N = 12) n(46)             | CS1001- 201 (N = 80) n(%)              | CS1001- 202 (N = 81) n(%)              | CS1001- 301 (N =255) (90)              | CS1001- 302 Crossover (N = 45) m(96)   | Total (N = 568) n(40)                  |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Treatment Duration (months)            | Treatment Duration (months)            | Treatment Duration (months)            | Treatment Duration (months)            | Treatment Duration (months)            | Treatment Duration (months)            | Treatment Duration (months)            | Treatment Duration (months)            |
| Mean (SD)                              | 6.76 (8.708)                           | 4.72 (5.987)                           | 8.62 (9.593)                           | 7.67 (4.407)                           | 8.66 (6.884)                           | 5.67 (4.630)                           | 7.87 (7.272)                           |
| Median                                 | 3.65                                   | 2.07                                   | 5.19                                   | 6.24                                   | 6.34                                   | 4.34                                   | 5.59                                   |
| Min, max                               | 0.7,36.3                               | 0.7,20.0                               | 0.7,37.4                               | 0.1,19.8                               | 0.2,28.4                               | 0.4, 16.6                              | 0.1, 37.4                              |
| Number of Cycles                       | Number of Cycles                       | Number of Cycles                       | Number of Cycles                       | Number of Cycles                       | Number of Cycles                       | Number of Cycles                       | Number of Cycles                       |
| Mean (SD)                              | 9.2 (11.57)                            | 6.8 (8.62)                             | 12.3 (13.65)                           | 11.0 (6.37)                            | 11.7 (9.40)                            | 7.9 (6.58)                             | 10.9 (10.02)                           |
| Median                                 | 5.0                                    | 3.0                                    | 7.5                                    | 9.0                                    | 9.0                                    | 6.0                                    | 8.0                                    |
| Min, max                               | 1.50                                   | 1.29                                   | 1.54                                   | 1.29                                   | 1.41                                   | 1.24                                   | 1.54                                   |
| Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             | Total Cumulative Dose (mg)             |
| Mean (SD)                              | 11002.1 (13880.69)                     | 8200.0 (10346.01)                      | 14733.1 (16377.82)                     | 13192.3 (7658.66)                      | 14075.3 (11279.22)                     | 9493.3 (7901.39)                       | 13040.9 (12024.29)                     |
| Median                                 | 6000.0                                 | 3600.0                                 | 9000.0                                 | 10800.0                                | 10800.0                                | 7200.0                                 | 9600.0                                 |
| Min, max                               | 1200. 60000                            | 1200. 34800                            | 1200. 64800                            | 579. 34800                             | 1200, 49200                            | 1200, 28800                            | 579. 64800                             |
| Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) | Duration of Exposure, n (persou-years) |
| <1 month                               | 12 (0.698)                             | 2 (0.115)                              | 7 (0.402)                              | 2 (0.063)                              | 16 (0.854)                             | 2 (0.088)                              | 41 (2.220)                             |
| 1 to <3 months                         | 32 (5.008)                             | 7 (1.188)                              | 29 (5.185)                             | 11 (2.346)                             | 42 (7.422)                             | 17 (2.943)                             | 138 (24.093)                           |
| 3 to<6months                           | 20 (7.053)                             | 0                                      | 12 (5.218)                             | 24 (10.349)                            | 57 (21.344)                            | 9 (3.521)                              | 122 (47.485)                           |
| 6 to< 9months                          | 14 (8.019)                             | 1 (0.698)                              | 7(4.594)                               | 19 (11.537)                            | 53 (32.539)                            | 9 (5.273)                              | EO1 (62.661)                           |
| 9 to<12months                          | 1 (0.890)                              | 0                                      | 6 (5.394)                              | 11 (9.520)                             | 18 (15.483)                            | 2 (1.788)                              | 38 (33.073)                            |
| 12 to < 15 months                      | 3 (3.384)                              | 1 (1.051)                              | 3 (3.231)                              | 8 (9.287)                              | 19 (21.175)                            | 2 (2.171)                              | 36 (40.298)                            |
| 15 to <18months                        | 3 (4.186)                              | 0                                      | 6 (8.493)                              | 4 (5.405)                              | 16 (22.220)                            | 4 (5.487)                              | 33 (45.791)                            |
| 18 to <21 months                       | 1 (1.708)                              | 1 (1.667)                              | 1 (1.569)                              | 2(3.274)                               | 15 (24.608)                            | 0                                      | 20 (32.827)                            |
| ≥21 months                             | 9 (22.593)                             | 0                                      | 9 (23.357)                             | 0                                      | 19 (38.330)                            |                                        | 37 (84.279)                            |
| Total                                  | 95 (53.539)                            | 12 (4.720)                             | 80 (57.443)                            | 81 (51.781)                            | 255 (183.975)                          | 45 (21.270)                            | 568 (372.728)                          |

elup 'tt + Srup Apnis go aiep 1ueis uawean -Enup Apnis go alep pua tuaturanj go tumwgupu se pauyap st uopenp luawneail cutoff date -treatment start date of study drug + 1, study discontinue date - treatment start date of study drug + 1) /30.4375.

Total cumulative dose is defined as the sum of actual dosage administered during each cycle.

max =maximum; min =minimum; SD = standard deviation

The cumulative exposure in person-years = sum (total treatment duration [days]] / 365.25.

Sources: Module 5.3.5.3, Table 2.1.1 and Table 2.4.1

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 49: Overview of treatment-emergent adverse events, sugemalimab monotherapy pool (safety analysis set)

|                                                                | CS1001- 10la/b (N=95) n(%)   | CS1001- 102 (N =12) n (%)   | CS1001- 201 (N=80) n (%)   | CS1001- 202 (N=81) n (%)   | CS1001- 301 (N = 255) n (%)   | CS1001-302 Crossover (N= 45) n (%)   | Total (N= 568) n(%)   |
|----------------------------------------------------------------|------------------------------|-----------------------------|----------------------------|----------------------------|-------------------------------|--------------------------------------|-----------------------|
| NumberofParticipantsWith                                       |                              |                             |                            |                            |                               |                                      |                       |
| Any TEAE                                                       | 93 (97.9)                    | 12 (100.0)                  | 77 (96.3)                  | 73 (90.1)                  | 246 (96.5)                    | 40 (88.9)                            | 541 (95.2)            |
| AnyTEAEofGrade3to5                                             | 46 (48.4)                    | 9 (75.0)                    | 31 (38.8)                  | 22 (27.2)                  | 62 (24.3)                     | 11 (24.4)                            | 181 (31.9)            |
| Any serious TEAE                                               | 26 (27.4)                    | 6 (50.0)                    | 18 (22.5)                  | 15 (18.5)                  | 72 (28.2)                     | 7 (15.6)                             | 144 (25.4)            |
| Any TEAE leading to infusion interruption                      | 0                            | 0                           | 4 (5.0)                    | 0                          | 1 (0.4)                       | 0                                    | 5 (0.9)               |
| AnyTEAEleadingtotreatment cycledelayed                         | 27 (28.4)                    | 0                           | 13 (16.3)                  | 14 (17.3)                  | 82 (32.2)                     | 5 (11.1)                             | 141 (24.8)            |
| Any TEAE leading to treatment discontinuation                  | 11 (11.6)                    | 3 (25.0)                    | 10 (12.5)                  | 6 (7.4)                    | 29 (11.4)                     | 2 (4.4)                              | 61 (10.7)             |
| Any TEAE leading to death                                      | 2 (2.1)                      | 1 (8.3)                     | 5 (6.3)                    | 0                          | 10 (3.9)                      | 1 (2.2)                              | 19 (3.3)              |
| AnyTreatment-RelatedTEAE                                       | 82 (86.3)                    | 8 (66.7)                    | 61 (76.3)                  | 62 (76.5)                  | 193 (75.7)                    | 29 (64.4)                            | 435 (76.6)            |
| Any treatment-relatedTEAEofGrade3to5                           | 17 (17.9)                    | 1 (8.3)                     | 13 (16.3)                  | 10 (12.3)                  | 26 (10.2)                     | 5 (11.1)                             | 72 (12.7)             |
| Any treatment-related seriousTEAE                              | 10 (10.5)                    | 1 (8.3)                     | 5 (6.3)                    | 5 (6.2)                    | 38 (14.9)                     | 4 (8.9)                              | 63 (11.1)             |
| Any treatment-related TEAEleading to infusion interruption     | 0                            | 0                           | 4 (5.0)                    | 0                          | 1 (0.4)                       | 0                                    | 5 (0.9)               |
| Anytreatment-relatedTEAEleadingtotreatmentcycle delayed        | 13 (13.7)                    | 0                           | 9 (11.3)                   | 9 (11.1)                   | 49 (19.2)                     | 4 (8.9)                              | 84 (14.8)             |
| Any treatment-related TEAEleading to treatment discontinuation | 7 (7.4)                      | 1 (8.3)                     | 4 (5.0)                    | 5 (6.2)                    | 24 (9.4)                      | 1 (2.2)                              | 42 (7.4)              |
| Anytreatment-relatedTEAEleadingtodeath                         | 1 (1.1)                      | 1 (8.3)                     | 0                          | 0                          | 4 (1.6)                       | 1 (2.2)                              | 7 (1.2)               |
| AnyInfusion-Related ReactionTEAE                               | 1 (1.1)                      | 0                           | 4 (5.0)                    | 13 (16.0)                  | 1 (0.4)                       | 0                                    | 19 (3.3)              |
| Immune-RelatedAEsbyInvestigatorAssessmenta                     | 39 (41.1)                    | 0                           | 22 (27.5)                  | 32 (39.5)                  | 137 (53.7)                    | 8 (17.8)                             | 238 (41.9)            |

MedDRA version 24.1.

Immune-related AEs by Sponsor assessment are provided in the individual CSRs.

AE=adverse event;CSR=clinical studyreport;MedDRA=Medical Dictionary forRegulatory Activities;TEAE=treatment-emergent adverse event

Sources: Module 5.3.5.3,Table 3.1.1 andTable 3.2.11.1

## Adverse events by system organ class and preferred term

Table 50: Most commonly reported treatment-emergent adverse events (&gt; 10% of participants overall) by system organ class and preferred term, sugemalimab monotherapy pool (safety analysis set)

| System Organ Class Preferred Term                 | CS1001-101a/b (N = 95) n (%)   | CS1001-102 (N =12) n (%)   | CS1001-201 (N = 80) n (%)   | CS1001-202 (N =81) n (%)   | CS1001-301 (N = 255) n (%)   | CS1001-302 Crossover (N = 45) n (%)   | Total (N = 568) n (%)   |
|---------------------------------------------------|--------------------------------|----------------------------|-----------------------------|----------------------------|------------------------------|---------------------------------------|-------------------------|
| Number ofParticipants With at Least One Event     | 93 (97.9)                      | 12 (100.0)                 | 77 (96.3)                   | 73 (90.1)                  | 246 (96.5)                   | 40 (88.9)                             | 541 (95.2)              |
| Investigations                                    | 78 (82.1)                      | 6 (50.0)                   | 57 (71.3)                   | 46 (56.8)                  | 163 (63.9)                   | 28 (62.2)                             | 378 (66.5)              |
| Aspartate aminotransferase increased              | 39 (41.1)                      | 1 (8.3)                    | 19 (23.8)                   | 9 (11.1)                   | 46 (18.0)                    | 6 (13.3)                              | 120 (21.1)              |
| Alanine aminotransferaseincreased                 | 34 (35.8)                      | 1 (8.3)                    | 13 (16.3)                   | 14 (17.3)                  | 51 (20.0)                    | 4 (8.9)                               | 117 (20.6)              |
| White blood cell count decreased                  | 13 (13.7)                      | 0                          | 24 (30.0)                   | 5 (6.2)                    | 19 (7.5)                     | 4 (8.9)                               | 65 (11.4)               |
| Bloodbilirubin increased                          | 31 (32.6)                      | 2 (16.7)                   | 5 (6.3)                     | 2 (2.5)                    | 16 (6.3)                     | 3 (6.7)                               | 59 (10.4)               |
| Respiratory,Thoracic andMediastinal Disorders     | 23 (24.2)                      | 1 (8.3)                    | 18 (22.5)                   | 13 (16.0)                  | 133 (52.2)                   | 7 (15.6)                              | 195 (34.3)              |
| Cough                                             | 14 (14.7)                      | 0                          | 5 (6.3)                     | 7 (8.6)                    | 47 (18.4)                    | 1 (2.2)                               | 74 (13.0)               |
| Infections andInfestations                        | 18 (18.9)                      | 3 (25.0)                   | 30 (37.5)                   | 35 (43.2)                  | 78 (30.6)                    | 11 (24.4)                             | 175 (30.8)              |
| Upper respiratory tract infection                 | 5 (5.3)                        | 0                          | 10 (12.5)                   | 22 (27.2)                  | 22 (8.6)                     | 1 (2.2)                               | 60 (10.6)               |
| Pneumonia                                         | 1 (1.1)                        | 1 (8.3)                    | 9 (11.3)                    | 8 (9.9)                    | 33 (12.9)                    | 7 (15.6)                              | 59 (10.4)               |
| GeneralDisordersandAdministration Site Conditions | 33 (34.7)                      | 4 (33.3)                   | 33 (41.3)                   | 33 (40.7)                  | 58 (22.7)                    | 9 (20.0)                              | 170 (29.9)              |
| Pyrexia                                           | 15 (15.8)                      | 1 (8.3)                    | 24 (30.0)                   | 28 (34.6)                  | 15 (5.9)                     | 4 (8.9)                               | 87 (15.3)               |
| Bloodand LymphaticSystemDisorders                 | 37 (38.9)                      | 1 (8.3)                    | 20 (25.0)                   | 16 (19.8)                  | 69 (27.1)                    | 15 (33.3)                             | 158 (27.8)              |
| Anaemia                                           | 34 (35.8)                      | 0                          | 13 (16.3)                   | 12 (14.8)                  | 56 (22.0)                    | 15 (33.3)                             | 130 (22.9)              |
| EndocrineDisorders                                | 12 (12.6)                      | 1(8.3)                     | 19 (23.8)                   | 20 (24.7)                  | 65 (25.5)                    | 5 (11.1)                              | 122 (21.5)              |
| Hypothyroidism                                    | 8 (8.4)                        | 1 (8.3)                    | 17 (21.3)                   | 15 (18.5)                  | 44 (17.3)                    | 4 (8.9)                               | 89 (15.7)               |
| Injury，Poisoning and Procedural Complications     | 3 (3.2)                        | 0                          | 2 (2.5)                     | 0                          | 72 (28.2)                    | 1 (2.2)                               | 78 (13.7)               |
| Radiation pneumonitis                             | 0                              | 0                          | 0                           | 0                          | 61 (23.9)                    | 0                                     | 61 (10.7)               |

MedDRA version 24.1.

MedDRA =MedicalDictionary forRegulatory Activities;PT=preferred term; SOC= system organ class

Source: Module 5.3.5.3,Table 3.2.1

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The incidence of IRRs in the sugemalimab monotherapy pool was 3.3%.

Overall, the incidences of treatment-related TEAEs by PT, adverse events grade 3-5, and treatment-related adverse events grade 3-5 in the sugemalimab arm of study 301 were consistent with the findings in the sugemalimab monotherapy pool.

## Adverse events of special interest

Table 51: Overall summary of immune-related adverse events from investigator assessment, sugemalimab monotherapy pool (safety analysis set)

|                                                                                 | CS1001- 101a/b (N =95) n (%)   |   CS1001- 102 (N =12) n (%) | CS1001- 201 (N =80) n (%)   | CS1001- 202 (N=81) n (%)   | CS1001- 301 (N=255) (%)u   | CS1001- 302 Crossover (N = 45) n (%)   | Total (N = 568) n (%)   |
|---------------------------------------------------------------------------------|--------------------------------|-----------------------------|-----------------------------|----------------------------|----------------------------|----------------------------------------|-------------------------|
| Number of Participants With at Least OneEvent                                   | 39 (41.1)                      |                           0 | 22 (27.5)                   | 32 (39.5)                  | 137 (53.7)                 | 8 (17.8)                               | 238 (41.9)              |
| Grade3to5event                                                                  | 7(7.4)                         |                           0 | 3 (3.8)                     | 5 (6.2)                    | 14 (5.5)                   | 1 (2.2)                                | 30 (5.3)                |
| Serious event                                                                   | 6 (6.3)                        |                           0 | 1 (1.3)                     | 4 (4.9)                    | 29 (11.4)                  | 1 (2.2)                                | 41 (7.2)                |
| Event leading to sugemalimabpermanently discontinued                            | 4 (4.2)                        |                           0 | 0                           | 3 (3.7)                    | 19 (7.5)                   | 1 (2.2)                                | 27 (4.8)                |
| Event leading to sugemalimabinterruption (cycle delayed/ infusion interruption) | 8 (8.4)                        |                           0 | 4 (5.0)                     | 3 (3.7)                    | 35 (13.7)                  | 0                                      | 50 (8.8)                |
| Event leading to death                                                          | 0                              |                           0 | 0                           | 0                          | 2 (0.8)                    | 1 (2.2)                                | 3 (0.5)                 |
| Event treated with systemiccorticosteroid                                       | 0                              |                           0 | 1 (1.3)                     | 1 (1.2)                    | 44 (17.3)                  | 1 (2.2)                                | 47 (8.3)                |
| Eventtreatedwith high-dose systemic corticosteroid                              | 0                              |                           0 | 1 (1.3)                     | 1 (1.2)                    | 38 (14.9)                  | 1 (2.2)                                | 41 (7.2)                |

MedDRAversion24.1.

MedDRA=MedicalDictionaryforRegulatoryActivities

Source:Module 5.3.5.3,Table3.2.11.1

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 52: Immune-related adverse events from investigator assessment by category, sugemalimab monotherapy pool (safety analysis set)

| Category                                                | CS1001- 101a/b (N =95) n (%)   |   CS1001- 102 (N =12) n (%) | CS1001- 201 (N=80) n(%)   | CS1001- 202 (N=81) n (%)   | CS1001- 301 (N =255) n (%)   | CS1001- 302 Crossover (N=45) n (%)   | Total (N = 568) n (%)   |
|---------------------------------------------------------|--------------------------------|-----------------------------|---------------------------|----------------------------|------------------------------|--------------------------------------|-------------------------|
| Number of Participants With at Least OneEvent           | 39 (41.1)                      |                           0 | 22 (27.5)                 | 32 (39.5)                  | 137 (53.7)                   | 8 (17.8)                             | 238 (41.9)              |
| Immune-related hypothyroidism                           | 15 (15.8)                      |                           0 | 13 (16.3)                 | 14 (17.3)                  | 49 (19.2)                    | 4 (8.9)                              | 95 (16.7)               |
| Immune-related hyperthyroidism                          | 8 (8.4)                        |                           0 | 5 (6.3)                   | 3 (3.7)                    | 45 (17.6)                    | 3 (6.7)                              | 64 (11.3)               |
| Immune-related pneumonitis                              | 2 (2.1)                        |                           0 | 1 (1.3)                   | 0                          | 49 (19.2)                    | 1 (2.2)                              | 53 (9.3)                |
| Immune-relatedskin adverse reactions (excluding severe) | 4 (4.2)                        |                           0 | 7 (8.8)                   | 8 (9.9)                    | 32 (12.5)                    | 1 (2.2)                              | 52 (9.2)                |
| Immune-related hepatitis                                | 13 (13.7)                      |                           0 | 2 (2.5)                   | 9 (11.1)                   | 20 (7.8)                     | 2 (4.4)                              | 46 (8.1)                |
| Immune-related myocarditis                              | 6 (6.3)                        |                           0 | 1 (1.3)                   | 3 (3.7)                    | 5 (2.0)                      | 1 (2.2)                              | 16 (2.8)                |
| Immune-relateddiabetes mellitus                         | 2 (2.1)                        |                           0 | 1 (1.3)                   | 2 (2.5)                    | 8 (3.1)                      | 0                                    | 13 (2.3)                |
| Immune-relatedmyositis                                  | 3 (3.2)                        |                           0 | 2 (2.5)                   | 1 (1.2)                    | 5 (2.0)                      | 2 (4.4)                              | 13 (2.3)                |
| Immune-related colitis                                  | 2 (2.1)                        |                           0 | 2 (2.5)                   | 0                          | 4 (1.6)                      | 0                                    | 8 (1.4)                 |
| Immune-related nephritis (including renal failure)      | 1(1.1)                         |                           0 | 0                         | 1 (1.2)                    | 5 (2.0)                      | 0                                    | 7 (1.2)                 |
| Immune-related pancreatitis                             | 7 (7.4)                        |                           0 | 0                         | 0                          | 0                            | 0                                    | 7 (1.2)                 |
| Immune-relatedsevere skin adversefeactions              | 0                              |                           0 | 1 (1.3)                   | 1 (1.2)                    | 4 (1.6)                      | 0                                    | 6 (1.1)                 |
| Immune-related upper gastrointestinal disorders         | 1 (1.1)                        |                           0 | 0                         | 0                          | 2 (0.8)                      | 0                                    | 3 (0.5)                 |
| Immune-related thyroiditis                              | 0                              |                           0 | 0                         | 2 (2.5)                    | 1 (0.4)                      | 0                                    | 3 (0.5)                 |
| Immune-related hypophysitis                             | 2 (2.1)                        |                           0 | 0                         | 0                          | 0                            | 0                                    | 2 (0.4)                 |
| Immune-related pancytopenia/bicytopenia                 | 1 (1.1)                        |                           0 | 0                         | 1 (1.2)                    | 0                            | 0                                    | 2 (0.4)                 |
| Immune-related adrenal insufficiency                    | 1 (1.1)                        |                           0 | 0                         | 0                          | 0                            | 0                                    | 1 (0.2)                 |
| Immune-related arthritis                                | 0                              |                           0 | 0                         | 0                          | 1 (0.4)                      | 0                                    | 1 (0.2)                 |
| Immune-related haemolytic anaemia                       | 0                              |                           0 | 0                         | 1 (1.2)                    | 0                            | 0                                    | 1 (0.2)                 |
| Immune-relatedocular toxicities                         | 0                              |                           0 | 1 (1.3)                   | 0                          | 0                            | 0                                    | 1 (0.2)                 |
| Immune-related rhabdomyolysis/myopathy                  | 0                              |                           0 | 0                         | 0                          | 0                            | 1 (2.2)                              | 1 (0.2)                 |
| Immune-relatedvasculitis                                | 0                              |                           0 | 0                         | 1 (1.2)                    | 0                            | 0                                    | 1 (0.2)                 |

MedDRAversion 24.1.

MedDRA=Medical DictionaryforRegulatoryActivities

Source:Module5.3.5.3,Table 3.2.12.3

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Serious adverse events

Table 53: Serious treatment-emergent adverse events (&gt; 2% of participants overall by preferred term) by system organ class and preferred term, sugemalimab monotherapy pool (safety analysis set)

| SystemOrgan Class Preferred Term               | CS1001- 10la/b (N =95) n (%)   | CS1001- 102 (N =12) n (%)   | CS1001- 201 (N =80) n (%)   | CS1001- 202 (N =81) n (%)   | CS1001- 301 (N =255) n (%)   | CS1001- 302 Crossover (N = 45) (%) u   | Total (N= 568) n (%)   |
|------------------------------------------------|--------------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------------|----------------------------------------|------------------------|
| Number of Participants With at Least One Event | 26 (27.4)                      | 6 (50.0)                    | 18 (22.5)                   | 15 (18.5)                   | 72 (28.2)                    | 7 (15.6)                               | 144 (25.4)             |
| Infections and Infestations                    | 5 (5.3)                        | 2 (16.7)                    | 8 (10.0)                    | 9 (11.1)                    | 24 (9.4)                     | 3 (6.7)                                | 51 (9.0)               |
| Pneumonia                                      | 1 (1.1)                        | 0                           | 4 (5.0)                     | 6 (7.4)                     | 20 (7.8)                     | 3 (6.7)                                | 34 (6.0)               |
| Respiratory,Thoracic and MediastinalDisorders  | 2 (2.1)                        | 0                           | 0                           | 3 (3.7)                     | 34 (13.3)                    | 1 (2.2)                                | 40 (7.0)               |
| Immune-mediated lung disease                   | 0                              | 0                           | 0                           | 0                           | 14 (5.5)                     | 1 (2.2)                                | 15 (2.6)               |
| Pneumonitis                                    | 1 (1.1)                        | 0                           | 0                           | 0                           | 11 (4.3)                     | 0                                      | 12 (2.1)               |
| Injury,Poisoning and ProceduralComplications   | 0                              | 0                           | 0                           | 0                           | 17 (6.7)                     | 0                                      | 17 (3.0)               |
| Radiationpneumonitis                           | 0                              | 0                           | 0                           | 0                           | 15 (5.9)                     | 0                                      | 15 (2.6)               |

MedDRA version 24.1.

MedDRA=MedicalDictionaryforRegulatoryActivities;PT=preferred term;SOC=system organ class

Source:Module 5.3.5.3,Table3.2.4.1

## Post marketing experience

At DCO for the current applicant, sugemalimab was only authorised for marketing in China. As of 24 July 2024, sugemalimab is authorised for marketing in the EU.

Cumulatively, as of 19 December 2024, the estimated patient exposure for the cumulative period is based on worldwide sales of 4,210 Standard Units while the patient exposure is approximately 121 patient-years.

## 2.5.1. Discussion on clinical safety

The safety assessment is focused on data from the pivotal study CS1001-301 (study 301) in patients with unresectable stage III NSCLC without sensitising EGFR mutations, or ALK or ROS1 genomic aberrations whose disease had not progressed following concurrent or sequential platinum-based chemoradiotherapy.

Data are presented as of DCO date 03 April 2023, when all patients in study 301 had discontinued sugemalimab or placebo treatment and discontinued from the study.

In study 301, 255 patients were exposed to sugemalimab monotherapy and 126 to placebo.The size of the safety database is considered acceptable. As expected in a placebo-controlled study, the median duration of treatment exposure in the active sugemalimab arm was longer (9.0 months) than in the placebo arm (7.6 months). The patient exposure is acceptable and evokes no concern. Safety data from study 301 is the focus of this assessment, however the full safety database for sugemalimab monotherapy encompasses 568 patients exposed to the recommended sugemalimab dose of 1,200 mg/kg Q3W as presented in section 4.8 of the SmPC.

Almost all patients in study 301 experienced TEAEs of any grade (97.3% sugemalimab vs. 96.0% placebo). Overall, the incidences of the most commonly occurring TEAEs by SOC and PT were comparable between the sugemalimab and placebo arm in study 301.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

TEAEs by PT with &gt; 5.0% higher incidence in the sugemalimab vs. the placebo arm were `ALT´ and `AST increased´ (24.7% and 20.4% sugemalimab vs. 15.9% and 10.3% placebo, respectively), `weight increased´(16.6% vs. 11.1%), and `hypo-´ and `hyperthyroidism´ (20.8% and 15.7% vs. 11.9% and 4.8%, respectively).

Infusion-related reactions (IRRs) were rare and occurred in one (0.4%) patient in the sugemalimab arm. This patient experienced a total of two events of vomiting and dizziness. In the placebo arm, two (1.6%) patients experienced IRRs.

IRR is an established adverse reaction pertaining to sugemalimab and cases of e.g., anaphylactic reactions have been reported in clinical studies. This is reflected in the SmPC sections 4.2, 4.4. and 4.8.

It is noted that different terms for reporting TEAE pneumonitis are used. In the SmPC 4.8 the terms pneumonitis (not otherwise specified), immune-mediated lung disease and interstitial lung disease, which are listed separately in the CSR, are grouped together as ADR pneumonitis. This is outlined with a footnote under the ADR table, which was introduced at the time of approval. According to the Applicant, merging of these terms is made because they are difficult to clinically differentiate. This is acknowledged. Radiation pneumonitis, however, is not included in the ADR term pneumonitis due to its different aetiology and is not considered an ADR pertaining to sugemalimab. Although it may be clinically difficult to distinguish between radiation pneumonitis and `other´ cases of pneumonitis, this is considered acceptable.

Dose modification recommendations for radiation pneumonitis and a warning for radiation pneumonitis, in addition to the existing warning pertaining to immune-mediated pneumonitis, are included in the SmPC 4.2 and 4.4. Patients should be monitored for signs and symptoms of radiation pneumonitis. Suspected radiation pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded. In case of grade 2 and 3 radiation pneumonitis, treatment should be withheld until radiation pneumonitis recovers to Grade 0 to 1. In case of grade 4 radiation pneumonitis, treatment should be permanently discontinued. This is acknowledged.

In the table of ADRs of SmPC section 4.8, some ADRs are presented as immune-mediated, but for some ADRs this association is only indicated with a footnote. It was clarified that this is because some MedDRA PT terms have `immune-related/mediated´ in the name. For those without this specification, the immune-mediated relationship is clarified in a footnote. This is acknowledged.

Grade 3-5 TEAE incidences were comparable between the sugemalimab arm (34.1%) and the placebo arm (30.2%) of study 301. The majority of AEs by PT occurred in &lt; 1% of participants. In both study arms, the most common grade 3 and 4 TEAEs respectively were pneumonia and hyperuricaemia. Grade 5 TEAEs were twice as common in the sugemalimab arm (n=12 [4.7%]) than in the placebo arm (n=3 [2.4%]).

TEAEs leading to study treatment interruption were equally uncommon in the sugemalimab and placebo arms of study 301 (one patient each). TEAEs leading to study cycle delay were reported for 39.6% of the patients in the sugemalimab arm and 28.6% in the placebo arm, respectively.

In the sugemalimab arm, the most common reasons for study cycle delay were related to pulmonary events, e.g., radiation pneumonitis (8.6%), pneumonitis (6.3%), pneumonia (5.9%), and immune-mediated and interstitial lung disease (3.5% each). This is acknowledged considering the primary disease location and previous irradiation of the lungs. Treatment cycle delays in the placebo arm were mainly due to pneumonitis (11.1%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

In line with the reasons for treatment cycle delay, all but two of the in total 36.9% SAEs in the sugemalimab arm were pulmonary events: pneumonia (9.4%), immune-mediated lung disease (6.7%), radiation pneumonitis (6.3%), pneumonitis (4.3%), and interstitial lung disease (3.5%). As expected, SAEs occurred less frequently in the placebo arm (29.4%).

A total of 116 (45.5%) of the patients in the sugemalimab arm and 66 (52.4%) of the patients in the placebo arm died while on study. Of these deaths, 12 (4.7%) and three (2.4%), respectively, were due to TEAEs. The only deaths due to TEAEs occurring in &gt; 1 patient in the sugemalimab arm were pneumonia (n=4 patients) and haemoptysis (n=2 patients). The Investigator assessed three cases of deaths due to TEAEs as related to sugemalimab (pneumonia n=2 and immune-mediated lung disease n=1).

Immune-related AEs (irAEs) were considered AESIs in all sugemalimab clinical studies. As expected, the incidence of irAEs was higher in the sugemalimab than in the placebo arm (58.8% vs. 38.9%) of study 301, although the incidence of supposedly irAEs reported in the placebo arm was surprisingly high. The most frequently reported Investigator-assessed irAE categories were irhypothyroidism (sugemalimab 24.7% vs. placebo 12.7%), ir-pneumonitis (21.6% vs. 15.9%), irhyperthyroidism (21.2% vs. 9.5%), ir-skin adverse reaction (excluding severe) (14.1% vs. 4.0%) and ir-hepatitis (8.6% vs. 4.8%, respectively). All other irAE categories were reported in &lt; 5% of participants in each treatment arm.

In the sugemalimab arm, the majority of all irAEs were grade 1-2. There was a total of 18 (7.1%) grade 3 irAEs in the sugemalimab arm, of which pneumonitis and severe skin adverse reactions were the most common (six cases [2.4%] each). There were two grade 4 (0.8%) and one grade 5 irAE (0.4%), all pertaining to pneumonitis. At the time of DCO, most of the irAEs (67.3%) had resolved completely.

Novel dose modifications for immune-related ADRs are outlined in the SmPC 4.2 and extensive warnings are presented in 4.4.  Moreover, a novel dose modification recommendation for nonimmune mediated adverse reactions is introduced. This is endorsed.

The most commonly reported abnormal clinical chemistry parameters in the sugemalimab arm were ALT and AST high (32.2% and 32.9%, respectively), cholesterol high (38.0%), creatinine high (87.8%), and fasting glucose high (49.4%), as well as albumin low (39.2%), phosphate low (34.9%), potassium low (23.1%), and sodium low (31.4%). The majority of the laboratory changes were grade 1-2.

There were no case reports meeting the criteria for Hy's law. Hepatic enzyme increased, hepatic function abnormal, and hepatitis are established ADRs pertaining to sugemalimab and dose modification and warnings are for immune-related hepatitis were already included in the SmPC 4.2 and 4.4.

Thyroid function tests were regularly performed, with baseline values representing the patients' last observations prior to initiation of study drug. The majority of patients (&gt; 90%)  had normal thyrotropin, free triiodothyronine, and free thyroxine values at baseline.

In line with the higher incidence of immune-related thyroid disorders in the sugemalimab arm (please refer to irAEs above), the shifts in thyroid parameters were overall greater in patients exposed to sugemalimab compared to placebo.

According to the Applicant there were no clinically meaningful changes in vital signs (blood pressure, pulse rate, respiratory rate, body temperature) and weight from baseline and across treatments. Most patients (93.7%) maintained an ECOG performance status of 0-1 post-baseline.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

At baseline, 12 (4.7%) patients in the sugemalimab arm had an abnormal, clinically significant ECG and post-baseline the number of patients had increased to 18 (7.1%). It is not outlined what kind of clinically significant ECG findings that were reported. It is also noted that post-baseline ECGs were missing for 132 (51.8%) of the patients and that no information on potential cases with QTcF &gt; 500 msec at baseline and post-baseline or cases with a maximum change in QTcF &gt; 60 msec were provided. Since QTcF prolongation has not been identified as a problem for other PD-L1 inhibitors, though, this issue is not pursued further.

The TEAE incidences (TEAEs all grade, TEAEs grade &gt; 3, SAEs, irTEAEs, TEAEs leading to death, and TEAEs leading to treatment discontinuation) by special populations sex, age groups, weight groups, ECOG performance status, PD-L1 status, and ADA status were overall comparable between subgroups.

A total of 47 (18.4%) of the patients in the study 301 sugemalimab arm and six (4.8) in the placebo arm discontinued study treatment due to TEAEs. In line with the SAEs and TEAEs leading to dose modifications, the most common TEAEs leading to discontinuation in the sugemalimab arm were pulmonary events (immune-mediated lung disease 5.1%, pneumonitis 2.7%, pneumonia 2.0%, interstitial lung disease 1.2%, and haemoptysis and radiation pneumonitis 0.8% each).

Generally, the TEAE incidence in the placebo arm of study 301 was surprisingly high. Except for lung related side effects and symptoms, which may be explained by the tumour location and prior lung irradiation, the incidences of e.g., hypothyroidism (11.9%), and ALT and AST increased (15.9% and 10.3%, respectively), in the placebo arm were intriguing. The worldwide annual incidence of hypothyroidism is estimated to be 1-1.5% (prevalence approximately 3-4%) and, thus, the incidence in the placebo arm was 8-10 times higher than expected. It is noted that almost all patients in both the sugemalimab arm and the placebo arm used concomitant medications, with 51.85% in the sugemalimab arm vs. 53.2% in the placebo arm using preparations against cough and cold (including herbal medicines) and 35.7% vs. 40.5%, respectively, using unspecified herbal and traditional medicines. This may possibly contribute to the high TEAE incidences. However, since the TEAE incidence, as expected, was consistently higher in the sugemalimab arm than in the placebo arm of study 301 and the safety profile overall appeared manageable, this issue is not pursued further.

A sugemalimab monotherapy pool was provided as support for the overall sugemalimab safety profile. This comparison was limited by the fact that a) the monotherapy pool consisted of various advanced tumours with different pre-treatments and toxicity and b) approximately half of the monotherapy pool was based on the study 301 sugemalimab arm. Overall, though, the findings in the sugemalimab arm of study 301 were consistent with known findings in other sugemalimab monotherapy studies, apart from irAEs which were more commonly reported in the study 301 sugemalimab arm. This pool consisting of 568 patients has been used for the ADR table in section 4.8 of the SmPC.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile is considered acceptable and as anticipated for a compound of this wellknown class.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.0 is acceptable.

The CHMP endorsed the Risk Management Plan version 2.0 with the following content:

## Safety concerns

| Important identified risks   | Immune-mediated adverse reactions       |
|------------------------------|-----------------------------------------|
| Important potential risks    | Reproductive and developmental toxicity |
| Missing information          | None                                    |

No changes to the list of safety concerns were needed as a result of this extension of indication.

The list of safety concerns remains unchanged.

## Pharmacovigilance plan

None.

## Risk minimisation measures

| Safety concern                          | Risk minimisation measures                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                                           |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-mediated adverse reactions       | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.5 SmPC Section 4.8 PL Section 2 PL Section 4 Restricted medical prescription. Additional risk minimisation measures: Patient card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None proposed. Additional pharmacovigilance activities : None proposed. |
| Reproductive and developmental toxicity | Routine risk minimisation measures: SmPC Section 4.6 PL Section 2 Restricted medical prescription. Additional risk minimisation measures: None proposed.                                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None proposed. Additional pharmacovigilance activities : None proposed. |

No changes to risk minimisations measures were needed as a result of this extension of indication.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. Particularly, a new warning with regard to radiation pneumonitis has been added to the product information. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

1. The proposed indication extension is for the medicinal product of same route of administration, targeting the same patient population - NSCLC just at different stage of disease.
2. The overall design, layout and style of writing in PIL will not be changed.
3. The proposed PIL will only introduce the changes below to the approved PIL:
- Section 1 What Cejemly is and what it is used for:
5. o In subsection 'What CEJEMLY is used for' the sentence CEJEMLY is used in combination with platinum-based chemotherapy will be updated to include the proposed indication. CEJEMLY is used in combination with platinum-based chemotherapy or as monotherapy.
- Section 3: How you are given CEJEMLY
7. o The subsection 'How much is given' is updated to reflect the dosage recommendation of stage III NSCLC patients.
- Section 4: Possible side effects
9. o The subsections 'Side effects' may trigger immediate medications and other side effects will be updated to reflect the overall side effects when used as monotherapy for stage III NSCLC patients.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed indication for sugemalimab, revised during the procedure is, as monotherapy for the treatment of unresectable stage III NSCLC with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy.

## 3.1.2. Available therapies and unmet medical need

Platinum-based chemotherapy concurrent with radiotherapy is standard of care for patients with unresectable stage III NSCLC. If concurrent chemoradiotherapy is not possible-for any reason sequential approaches of induction chemotherapy followed by definitive radiotherapy represent a valid and effective alternative. In this treatment niche, durvalumab is approved as maintenance for patients whose disease did not progress after chemoradiotherapy and whose tumours express PD-

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

L1 on ≥ 1% of tumour cells. Moreover, for patients expressing relevant EGFR driver mutations, osimertinib is approved.

## 3.1.3. Main clinical studies

The pivotal study CS1001-301 was a randomised, double-blind, placebo-controlled, multicentre Phase III study conducted in China, to evaluate the efficacy and safety of sugemalimab or placebo as consolidation therapy, in patients with locally advanced or unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy.

Patients had to have confirmed locally advanced, unresectable stage III-NSCLC and both squamous and non-squamous patients were included. Patients with known mutation/translocation status of EGFR, ALK and ROS1 were excluded. Importantly, testing for PD-L1 expression status was not mandatory.

## 3.2. Favourable effects

At the pre-planned PFS interim analysis and at the final PFS analysis sugemalimab showed a statistically significant improvement in PFS compared to placebo. At the final PFS analysis a total of 154 PFS events were observed in the sugemalimab group, compared to 90 in the placebo group, with a median follow-up of 27.1 months and 23.5 months for the sugemalimab group and placebo group, respectively. The median PFS was 10.5 months in the sugemalimab group versus 6.2 months in the placebo group (stratified HR 0.65 [95% CI: 0.50, 0.84], two-sided p = 0.0012).

OS did not reach statistical significance at the OS interim analysis (DCO: 03 April 2023). A total of 114 OS events were observed in the sugemalimab group, compared to 66 in the placebo group. The median OS was 47.4 months (95% CI: 34.3, NR [not reached]) in the sugemalimab group and 32.4 months (95% CI: 24.1, NR) in the placebo group (stratified HR 0.78 [95% CI: 0.57, 1.05], two-sided P = 0.1036) and the actual statistical superiority boundary of 0.0392 was not reached.

The study was terminated and all patients discontinued the study on DCO of 03 April 2023.

## 3.3. Uncertainties and limitations about favourable effects

The study was closed after the abovementioned OS interim analysis. This was due to futility with respect to the likelihood of a statistically significant read-out. Notably, 41% (n=52) of patients in the control arm were treated with a PD-L1 targeting agent after progression.

For more than 50% of patients in both study arms, PD-L1 expression status was not determined. For patients with reported PD-L1 status there was no trend for efficacy as a function of PD-L1 expression. Hence, no conclusions regarding PD-L1 status as an effect modifier can be drawn based on the pivotal study. This is reflected in section 5.1 of the SmPC.

## 3.4. Unfavourable effects

The safety database in the sought indication consists of 381 participants included in study CS1001301 (study 301). Participants were randomised 2:1 to either sugemalimab monotherapy (n=255) or placebo (n=126). The full safety database for sugemalimab monotherapy comprises 568 treated patients.

The median duration of treatment in the sugemalimab arm was 9.0 months (range: 0.2, 50.7) compared to 7.6 months (range: 0.7, 42.2) in the placebo arm. The median duration of follow-up

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

had then reached 40.4 months (range: 38.67, 45.47) and 35.4 months (range: 32.59, 39.92) in the sugemalimab and placebo arms, respectively.

Overall, the reported TEAEs in the sugemalimab arm were in line with the established safety profile pertaining to sugemalimab + platinum-based chemotherapy. The most common TEAEs in the sugemalimab arm which are also proposed ADRs were ALT and AST increased (24.7% and 20.4%, respectively), anaemia (24.3%), radiation pneumonitis (24.7%), and hypothyroidism (20.8%).

Grade &gt; 3 TEAEs were reported for 34.1% and 30.2% of the patients in study 301, respectively. In the sugemalimab arm, the most commonly occurring TEAE grade &gt; 3 which is also an ADR pertaining to sugemalimab was immune-mediated lung disease (3.1%).

SAEs were reported for 36.9% of the patients in the sugemalimab arm vs. 29.4% in the placebo arm. The vast majority were lung related (immune-mediated lung disease, pneumonitis and radiation pneumonitis, interstitial lung disease, and pneumonia). A warning on radiation pneumonitis has been added to section 4.4 of the SmPC to include recommendations on how to monitor and manage it.

TEAEs leading to treatment infusion interruption was uncommon (one patient in each study arm), whereas treatment cycle delay was reported for 39.6% vs. 28.6% of participants, respectively. As for SAEs, the most common reasons were lung related.

A total of 18.4% of patients in the sugemalimab arm discontinued treatment due to TEAEs vs. 4.8% in the placebo arm. The most common TEAEs leading to treatment discontinuation were lung related.

Of the in total 12 (4.7%) deaths due to TEAEs reported in the sugemalimab arm, three were considered related to sugemalimab treatment by the investigator. These were pneumonia (n=2) and immune-meditated lung disease (n=1). In all three cases, onset of symptom occurred shortly after initiation of sugemalimab treatment.

The key safety issues for sugemalimab treatment were immune-related (ir) adverse reactions. Several such reactions are established ADRs pertaining to sugemalimab + chemotherapy and were also confirmed to pertain to sugemalimab monotherapy. The most frequently reported irADRs in the sugemalimab arm were ir-hypothyroidism (24.7%), ir-pneumonitis (21.6%), and irhyperhyroidism (21.2%).

Overall, the safety profile of sugemalimab monotherapy was in line with that pertaining to sugemalimab + platinum-based chemotherapy, as well as other PD-L1 targeting agents. No new safety concerns were identified.

## 3.5. Uncertainties and limitations about unfavourable effects

None.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 54: Effects Table for study CS1001-301, DCO 03 April 2023

| Effect               | Short description                                            | Unit                 | Treatment              | Control              | Uncertainties / Strength of evidence                                                       | References           |
|----------------------|--------------------------------------------------------------|----------------------|------------------------|----------------------|--------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                           | Favourable Effects   | Favourable Effects     | Favourable Effects   | Favourable Effects                                                                         | Favourable Effects   |
|                      |                                                              |                      | Sugemalimab N=255      | Placebo N=126        |                                                                                            |                      |
| PFS, median          | Time from randomisation to first tumour progression or death | months HR, 95% CI    | 10.6 0.73 (0.56, 0.95) | 6.2                  |                                                                                            | CSR                  |
| OS, median           | Time from randomisation until death                          | months HR, 95% CI    | 47.4 0.78 (0.57, 1.05) | 32.4                 | Not statistically significant. p=0.1036 (actual statistical superiority boundary=0.0392)   |                      |
| Unfavourable Effects | Unfavourable Effects                                         | Unfavourable Effects | Unfavourable Effects   | Unfavourable Effects | Unfavourable Effects                                                                       | Unfavourable Effects |
| AEs                  | Grade 3-4 Grade 5 SAEs Leading to treatment discontinuation  | %                    | 29.4 4.7 36.9 18.4     | 27.8 2.4 29.4 4.8    | Asia-only study, limited follow-up time, unexpectedly high AE incidence in the placebo arm |                      |
| Immune- related AEs  | Any Grade 3-4 Grade 5 SAEs Leading to                        | %                    | 58.8 7.8 0.4 15.7 10.2 | 38.9 0 0 5.6 0.8     |                                                                                            |                      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The pivotal study for this application was performed exclusively in China. As has been the case for several previous applications conducted exclusively in China, there is a notable dominance of men in the study population, who are also quite young. However, given the extensive experience of products in the class, sharing the same mechanism of action, with several products showing similar results in China only studies, as was seen in the rest of the world, extrapolation of effects is considered possible provided similar exposure.

The study met the primary endpoint with a statistically significant improvement in PFS assessed by BICR at the PFS analyses (DCO: 08 March 2021 and 01 April 2022). OS did not reach statistical significance at the OS interim analysis (DCO: 03 April 2023). The study was subsequently terminated, hence there will not be any more OS updates from this study. Notably, given the extent of use of PD-L1 targeting agents on progression in the placebo control arm, the sensitivity of the study to show an OS gain was limited.

Given available knowledge, a prolongation of PFS of the present magnitude after chemoradiotherapy for unresectable stage III NSCLC after chemoradiotherapy is considered to isolate clinical benefit, in the absence of any signal of a detrimental effect on OS.

PD-L1 expression status is unknown for over 50% of patients in both study arms. For patients with reported PD-L1 status there was no trend for efficacy as a function of PD-L1 expression. Hence, no conclusions regarding PD-L1 status as an effect modifier can be drawn based on the pivotal study. In light of the relevant precedent (Imfinzi) where the indication has been restricted to patients expressing PDL1 ≥1%, specific data would be required to support an inference of efficacy also in patients expressing PD-L1 &lt;1%. Thus, the indication has been restricted to patients expressing PDL1 ≥ 1%. The key risks identified for sugemalimab monotherapy were immune-related adverse reactions, especially hypo- and hyperthyroidism, and pneumonitis. These are all established ADRs pertaining to sugemalimab + platinum-based chemotherapy, as well as for PD-L1 targeting agents in general, and included as important identified risks in the EU RMP. Overall, the safety profile of sugemalimab monotherapy was manageable and no new safety concerns were identified.

## 3.7.2. Balance of benefits and risks

A prolongation of PFS has been demonstrated, with a trend towards increased overall survival. Tolerability is acceptable. However, in view of the missing PD-L1 expression status in a majority of the patients randomised in the pivotal study, and the precedent of Imfinzi in the same setting, the indication is restricted to patients expressing PD-L1 ≥ 1% as efficacy in patients with PD-L1 expression (&lt;1%) could not be demonstrated.

## 3.8. Conclusions

The overall B/R of Cejemly is positive.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following changes:

| Variation accepted   | Variation accepted                                                                  | Type              | Annexes affected   |
|----------------------|-------------------------------------------------------------------------------------|-------------------|--------------------|
| C.I.6.a              | C.I.6.a Addition of a new therapeutic indication or modification of an approved one | Variation type II | I and IIIB         |

Extension of indication to include the treatment of unresectable stage III non -small -cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy for CEJEMLY, based on final results from study CS1001-301; this is a Phase III, multicentre, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of sugemalimab as consolidation therapy versus placebo in participants with locally advanced or unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been agreed.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## · Additional risk minimisation measures

The MAH shall ensure that in each Member State where Cejemly is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use Cejemly have access to/are provided with the patient card.

The patient card shall contain the following key elements:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- -Description of the main signs and symptoms of the irARs and the importance of notifying their treating physician immediately when symptoms occur.
- -Reminder to carry the patient card at all times.
- -Contact details of the Cejemly prescriber.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_